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ABSTRACT OF DISSERTATION

ANALYSIS OF THE ROLE OF TWO AUTOPHAGY PATHWAY RELATED GENES, BECN1 AND
TSC1, IN MURINE MAMMARY GLAND DEVELOPMENT AND DIFFERENTIATION
The mammary gland is a dynamic organ that undergoes the majority of its
development in the postnatal period in four stages; mature virgin, pregnancy, lactation,
and involution. Every stage relies on tightly regulated cellular proliferation, programmed
cell death, and tissue remodeling mechanisms. Misregulation of autophagy, an
intracellular catabolic process to maintain energy stores, has long been associated with
mammary tumorigenesis and other pathologies. We hypothesize that appropriate
regulation and execution of autophagy are necessary for proper development of the
mammary ductal tree and maintenance of the secretory epithelia during late pregnancy
and lactation. To test this hypothesis we examined the role of two genes during
development of the mammary gland.
Beclin1 (Becn1) is an essential autophagy gene. Since the Becn1 knockout model
is embryonic lethal, we have generated a Becn1 conditional knockout (cKO). We used
two discrete mammary gland-specific Cre transgenic lines to interrogate the role of
BECN1 during development. We report that MMTV-CreD; Becn1fl/fl mice have a hyperbranching phenotype and WAP-Cre; Becn1fl/- mice are unable to sustain a lactation
phase. Becn1 mutants exhibit abnormal glandular morphology during pregnancy and
after parturition. Moreover, when autophagy is chemically inhibited in vitro, mammary
epithelial cells have an increased mean number of lipid droplets per cell.
MTOR inhibits autophagy upstream of BECN1; we looked higher in the regulatory
pathway for regulatory candidates. It has been well characterized that Tuberous
sclerosis complex 1 (TSC1), in a heterodimer with its primary binding partner TSC2,
inhibits MTOR signaling via inhibition of RHEB. Using the Tsc1 floxed model we
generated a mammary gland specific Tsc1 cKO and found that these mice phenocopy
the Becn1 cKO mice, including a gross lactation failure. Tsc1 cKO glands have altered
morphology, retained lipid droplets in secretory epithelia, and an overall increase in

MTOR signaling. We show that TSC1 and BECN1 are interacting partners, and that the
interaction is nutrient responsive.
These results suggest that Becn1 and Tsc1 are necessary for proper mammary
gland development and differentiation. Furthermore, we have demonstrated a novel
murine protein-protein interaction and an important link between regulation of MTOR
pathway and regulation of autophagy in a developmental context.
KEYWORDS: Autophagy, Bax, Beclin1, mammary gland, Tuberous Sclerosis Complex 1
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Chapter One: Autophagy: Regulation and Role in Development
Overview
This chapter has been published and is included here for completeness of the
dissertation.1
Mammalian autophagy refers to three cellular processes: chaperone-mediated
autophagy, microautophagy, and macroautophagy. This review will focus on the latter,
macroautophagy, hereafter referred to simply as “autophagy.” Autophagy proceeds in
successive stages to form a mature autophagosome, which include: 1) de novo
formation of a double membrane bound structure or phagophore, 2) elongation of
these lipid-based membranes, and 3) encapsulation of intracellular cargo to form the
mature autophagosome. Autolysosomes, formed from the fusion of autophagosomes
and lysosomes, then degrade and recycle the macromolecule components in order to
maintain energetic homeostasis in the cell. Autophagy is an ancient process that is
highly conserved among eukaryotes. The initial characterization of the autophagy
pathway was worked out in yeast 2-4 with the identification of approximately 30
autophagy-related (ATG) genes, and many mammalian genetic homologs have been
identified. Autophagy has been implicated in longevity/lifespan extension, disease
prevention and promotion, as well as mammalian development (reviewed in: Autophagy
and longevity: lessons from C. elegans,5 Autophagy in the pathogenesis of disease,6
Autophagy and disease: always two sides to a problem,7 The Role of Autophagy in
Mammalian Development: Cell Makeover Rather than Cell Death.8) This review will
concentrate on the process and regulation of autophagy, as well as the role for
autophagy in murine development.
1

Core machinery involved in autophagosome formation
Mechanistic (mammalian) target of rapamycin (MTOR), upstream of autophagy
induction, senses cellular nutritional levels and regulates cell growth and survival and
directly inhibits autophagy. MTOR is a cellular survival pathway that is the crux of many
interconnected cellular pathways and integrates information to modulate cellular
growth, metabolism and survival. MTOR is active in nutrient rich conditions, inhibiting
autophagy and protein degradation. While in nutrient poor conditions MTOR is inactive
and autophagy is induced by alleviating MTOR phosphorylation on unc-51 like kinase 1
(ULK1) and ATG13. When MTOR is inactivated by starvation conditions,
dephosphorylated ULK1 dissociates from the MTOR complex and phosphorylates ATG13
and RB1CC1 (RB1-inducible coiled-coil 1, also known as FIP200) to induce the nucleation
phase (Figure 1.1A).9 Autophagosome nucleation is a highly orchestrated process
relying on the PtdIns3K/VPS34 (phosphoinositide-3-kinase, class 3) complex that serves
to phosphorylate phosphatidylinositol to phosphatidylinositol 3-phosphate (PtdIns3P)
(Figure 1.1B). This modified lipid targets membranes to be recruited into the
autophagosome. The PIK3 complex, anchored by the interaction between core
members PtdIns3K and Beclin1 (BECN1), exhibits different functions depending upon
the composition of ancillary proteins in the complex. UVRAG (UV irradiation resistanceassociated gene) and ATG14 are found in BECN1 complexes in a mutually exclusive
manner. For example, the complex of ATG14 (proposed mammalian homolog of yeast
Atg14, or Barkor), PIK3R4/VPS15, PtdIns3K and BECN1 positively regulate
2

autophagosome formation at the nucleation step. In contrast, a complex including
UVRAG, BIF1, PtdIns3K, PIK3R4, and BECN1 reportedly controls autophagosome
maturation and RAB7 (GTPase)-dependent lysosomal fusion.10 Autophagy regulation
may be influenced through additional protein-protein interactions to either promote or
inhibit autophagy. BIF1 directly associates with UVRAG and is a positive regulator of
autophagy; similarly, AMBRA1 (autophagy/Beclin1 regulator 1) directly binds BECN1 to
stimulate autophagy. In contrast, Rubicon (RUN domain and cysteine-rich domain
containing, Beclin1-interacting protein) also directly binds BECN1 but acts as a negative
regulator of autophagy.11
Elongation of the autophagosome membranes is accomplished by two ubiquitin
like conjugation systems (Figure 1.1C). An ATG12–ATG5-ATG16L1 complex associates
on the forming membrane. ATG12 is first activated by an ATP dependent reaction with
ATG7, an E1-like enzyme. ATG12 is then conjugated to ATG5 by ATG10, an E2-like
enzyme. ATG16L1 then interacts with the ATG12–ATG5 conjugate, forming a multimeric
complex. Components of the complex dissociate from the autophagosome and return
to the cytoplasm when elongation is complete. The second ubiquitin like conjugation
that contributes to membrane elongation modifies MAP1 LC3, the mammalian homolog
of yeast protein Atg8. ATG4B, one of the four mammalian ATG4 homologs, cleaves the
C-terminal 22 residues of precursor LC3 (proLC3) producing LC3-I. Cytoplasmic LC3-I is
then conjugated with phosphatidylethanolamine (PE) by ATG7 and ATG3, an E2-like
enzyme. Lipidated LC3 (LC3-II) is selectively incorporated into the forming
autophagosomal membrane. LC3-II remains associated with the autophagosome until
3

fusion with the lysosome, when LC3-II associated with the outer membrane dissociates
and LC3-II associated with the inner membrane is degraded by lysosomal proteases
along with the autophagosomal cargo (Figure 1.1D). This specific association of LC3-II
makes it an attractive autophagy marker and will be discussed in further detail in later
sections. The autophagosome fuses with a lysosome, forming the autolysosome (or
autophagolysosome). Fusion with the lysosome results in breakdown of the inner
autophagosomal membrane and cargo by lysosomal proteases and recycling of
macromolecules. Soluble NSF attachment protein receptors (SNAREs), RAB7 and the
homotypic vacuole fusion protein sorting (HOPS) complex likely are primary regulators
of autophagosome/lysosome fusion.12, 13

Sources of Autophagosomal Membranes
The main lipid sources that are recruited in the formation of autophagosomes
are thought to emanate from the endoplasmic reticulum (ER), mitochondria, Golgi
apparatus, or the plasma membrane (PM). Integral membrane proteins normally found
in the rough ER have been localized to the inner and outer autophagosome membranes
by immunostaining.14 This was also supported by electron microscopy (EM)-3D
tomograms that identified points of contact between the rough ER and the nascent
phagophore, which indicated that the growing isolation membrane might be a
subdomain of the rough ER.15, 16 Moreover, ER regions enriched in PtdIns3P have also
shown to be the sites of emerging omegasomes. The ER protein ZFYVE1 can be found in
omegasomes extending out from the ER by EM-3D tomography, and the PI3K-complex
protein ATG14 is localized at the ER surface.17 Contrary to the ER-based models, Hailey
4

et al18 have proposed a novel model suggesting that the mitochondrial outer membrane
may provide a membrane source for the biogenesis of autophagosomes. Following
amino acid starvation, investigators observed by fluorescence microscopy that
fluorescently labeled LC3 and ATG5 transiently localized to the outer mitochondrial
membrane (OMM) and NBD–PE (7-nitro-2-1,3-benzoxadiazol-4-yl-phosphoserine;
loaded into cells as NBD–PS and converted to NBD–PE in the mitochondria) could be
detected in autophagosomes. Further, loss of the mitochondrial protein Mitofusin2
caused a dramatic depletion in starvation-induced autophagy. Other recent
observations have suggested that cytoplasmic vesicles derived from the Golgi apparatus
may act as a membrane source for forming autophagosomes in an ATG9-dependent
manner. In yeast overexpressing Atg9, EM confirmed that under starvation conditions,
post-Golgi ATG9-positive vesicles were transported to the vacuole and could be seen
forming large tubulo-vesicular structures.19, 20 Recent reports have described findings
indicating that exocytic and endosomal SNARE proteins may mediate fusion of postGolgi Atg9-positive vesicles and remodeling of tubulo-vesicle clusters in phagophore
assembly.21 Exocytic Q/t-SNAREs Sso1/2 and Sec9 were shown to be essential for
homotypic fusion of Atg9-positive vesicles in starvation-induced autophagy in yeast. As
well, endosomal Q/t-SNARE Tlg2 and R/v-SNAREs Ykt6 and Sec22 were found to interact
with Q/t-SNAREs Sso1/2 and Sec9 and are essential for trafficking of post-Golgi Atg9positive vesicles to the vacuole and during phagophore assembly. Finally, a number of
studies have also indicated that the PM is capable of directly contributing membrane to
forming isolation membranes. An analysis by Ravikumar et al22 described interaction of
5

the clathrin heavy chain (associated with endocytic vesicles) with ATG16L1 at the
extending phagophore and later confirmed that disruption of the interaction resulted in
decreased autophagosome formation.23 Recently, experimental data has also suggested
that the action of PM SNAREs in complexes with tethering proteins may be essential for
fusion of membranes in the phagophore. In HeLa cells, it was shown that the
membrane protein LC3 is sufficient to tether PM-integral PE, potentially facilitating the
activity of PM SNAREs.24

Cellular Stress Responses
Although the core machinery for autophagy was initially identified in yeast,
seminal experiments defining the induction of autophagy were performed in a
mammalian cell- the hepatocyte. These studies defined the importance of hormonal
regulation, energy status, and nutrient levels as key modulators of autophagy. Initially,
the presence of double-membrane organelles were found to be induced in rat
hepatocytes exposed to glucagon;25 these organelles were eventually demonstrated to
be autophagosomes years later.26 Conversely, treatment of hepatocytes with insulin
gave the opposite result, which invariably defined autophagy as a catabolic, energygenerating mechanism for the cell.27 The dependence of the cell on autophagy for
energy homeostasis was confirmed the same year by showing that amino acid
supplementation inhibited autophagy in the rat liver.27 A final, important mechanistic
link between autophagy and nutrient-energy sensing was established when rapamycin,
an inhibitor of the energy sensor MTOR, was found to induce autophagy in

6

hepatocytes.28 Thus, cellular stress became a focal point upon which to understand how
autophagy could be regulated.
In addition to nutrient status and hormonal regulation, environmental stressors
such as: hypoxia,29 heat stress,30 and reactive oxygen species (ROS) accumulation can
also induce autophagy (Reviewed in: Autophagy signaling through reactive oxygen
species ).31 Additionally, ER stress is also a potent inducer. The ER is a highly active and
tightly regulated organelle responsible for protein folding fidelity, biogenesis of
membrane structures, metabolism and a veritable menagerie of cellular processes. If
the delicate microenvironment of the ER is disrupted, for instance by accumulation of
unfolded (or misfolded) proteins, then the unfolded protein response (UPR) will be
activated. There are three main pathways activated by the UPR: ATF6 (activating
transcription factor-6), IRE1 (inositol requiring enzyme 1), and PERK (PKR-like eIF2α
kinase, also known as EIF2AK3). All of these proteins are typically bound to an
inactivating chaperone molecule, BIP/Grp78, and released/activated in response to
unfolded proteins. It has been reported that autophagy is activated in response to ER
stress and UPR by both PERK and ATF6 pathways, perhaps in an effort to ameliorate the
accumulation and aggregation of misfolded proteins. Interestingly, IRE1 activation
inhibits autophagy in some systems and is required for autophagy induction in others;
however, more systematic work is needed to define these pathways in mammalian
systems.32 Although evidence is supportive of ER stress inhibiting MTOR- and Aktmediated cell survival pathways, which would alleviate autophagy inhibition
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independently of the UPR, additional studies are needed to elucidate this process.
(Reviewed in: Autophagy and the Integrated Stress Response).33
Autophagy may also be induced as a survival mechanism in response to hypoxic
conditions in normal and tumor cells.34 Induction of autophagy can proceed through
different pathways depending on the severity of hypoxia and cell type. 35 The best
characterized means of hypoxia-induced autophagy is by activation of the transcription
factor HIF1 (Hypoxia-inducible factor 1).36 HIF1 is capable of transcriptional activation of
a variety of target genes involved in offsetting the damaging effects of hypoxia including
erythropoiesis, angiogenesis, and autophagy. The HIF1-target gene Bnip3
(BCL2/adenovirus E1B 19kDa interacting protein 3) encodes a putative BH3-only (Bcl2
homology domain-only) protein that is necessary and sufficient to induce autophagy by
competitively binding BCL2 (B cell leukemia/lymphoma 2) and disrupting the BCL2BECN1 interaction.37, 38 Bnip3 has also been identified as a target gene of the
transcription factor E2F, which can be activated by inhibition of the RB1 (retinoblastoma
1) protein via severe hypoxia.39 This suggests that BNIP3 can trigger autophagy by HIF1dependent and HIF1-independent mechanisms. Severe hypoxia/anoxia (<0.1% oxygen)
can also induce autophagy by AMP-activated protein kinase (AMPK)-mediated MTOR
inhibition as well as protein kinase C activation of MAPK8 (mitogen-activated protein
kinase 8) and BECN1.40 41 42
The ubiquitin proteasome system (UPS) and autophagy act as the major
pathways for cellular catabolism and were initially thought to function independently of
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one another. However, new observations suggest that the two degradation pathways
function in a highly coordinated manner to maintain cellular homeostasis. The UPS
pathway specifically targets soluble proteins in the nucleus or cytoplasm, which are
labeled for proteasomal degradation by the addition of the small peptide ubiquitin at
various lysine residues. Through the action of three classes of enzymes, E1 ubiquitinactivating, E2 ubiquitin-conjugating, and E3 ubiquitin-ligases, the UPS pathway can
ensure high levels of specificity in labeling protein targets for degradation. The most
well-known limitations of the UPS pathway result from the small size and cylindrical
structure of the 26S proteasome to which poly-ubiquitinated-proteins must enter for
degradation by a series of peptidases. It appears that proteins may need to be partially
denatured and monomeric in order to be degraded within the proteasome, greatly
limiting the UPS pathway for clearance of aggregated proteins or large multimeric
complexes.43 In contrast, autophagy is limited in its activity to the cytoplasm and can
efficiently degrade soluble proteins, protein aggregates, and organelles by engulfment
by the isolation membrane followed by lysosomal fusion. Previously, autophagy was
viewed as a non-specific degradation pathway for cellular recycling; however, it is clear
that several proteins and common aggregates are selectively degraded in the
autolysosome, rather than the proteasome.44, 45 46 It has been observed that
ubiquitinated proteins could be selectively degraded by autophagy.45 Suppression of
the UPS pathway by siRNA is offset by an increase in autophagy.47 However, inhibition
of autophagy results in inhibited degradation of UPS substrates. 48, 49 As a result, current
models for the autophagy and UPS pathways suggest not only overlapping roles for the
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two systems, but a more dynamic and coordinated approach than previously
described.(Reviewed in: Mechanisms of crosstalk between the ubiquitin-proteasome
and autophagy-lysosome systems).50
SQSTM1 (Sequestosome 1, also known at p62) is a scaffolding protein with
several known functions in various tissues and is the most well-known target of selective
autophagy.44 As SQSTM1 is constitutively expressed, it shows a consistent turnover and
normally forms aggregates in the cytoplasm, which are selectively degraded by
autophagy. These characteristics are easily observed by immunohistochemistry and
have been used to monitor successful autophagy in vitro. Tissue-specific ablation of
autophagy results in accumulation of SQSTM1 aggregates and proteins carrying polyubiquitinated Lys-63 residues.51 The SQSTM1 protein contains both an ubiquitin-binding
domain as well as an LC3-interacting domain, which has led to its implication as a central
link between autophagy and the UPS pathway. Current models describe SQSTM1 as a
cargo receptor for autophagic degradation of various proteins.52, 53
Autophagy can also be pharmacologically stimulated or inhibited in a number of
ways; each method is accompanied by its own set of advantages and disadvantages
(Table 1.1). Autophagy can be stimulated indirectly through inhibiting the UPS pathway,
inducing an ER stress response, reducing intracellular calcium levels, or modifying the
acetyl proteome. Use of proteasomal inhibitors MG132 or bortezomib in human cancer
cell lines induces both the accumulation of the lipidated form of LC3B and the
localization of a green fluorescent protein (GFP) tagged reporter (GFP-LC3) to
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autophagosomes.54 Tunicamycin, an inhibitor of N-acetylglucosamine
phosphotransferase, is used widely in the literature to induce ER stress. 55 Tunicamycin
treatment in vitro increases autophagosomes and autolysosomes as detected by EM and
GFP-LC3 puncta formation, a fluorescent marker of autophagy. Although thapsigargin
acts as an ER stressor to inhibit the sarco/endoplasmic reticulum Ca2+ ATPase
(ATP2A1/SERCA1), it can also act directly by blocking the fusion of autophagosomes with
lysosomes by preventing recruitment of RAB7.56 Intracellular calcium can activate
CAPN-1 (calpain 1), a protease that targets ATG5 for degradation, thus inhibiting
autophagy.57 Fluspirilene induces autophagy through reducing calcium stores, which
leads to a deactivation of CAPN-1 and stabilization of the ATG5–ATG12 conjugate.
Lastly, resveratrol and spermidine are being studied for their ability to induce autophagy
in vivo in order to promote longevity.58, 59 The apparent mechanism though which they
act is through modification of the acetylproteome, principally through cytoplasmic
deacetylation reactions mediated by the sirtuins.60
Rapamycin is a highly specific inhibitor of MTOR and is commonly used both in
vitro and in vivo.61-63 In contrast, lithium chloride is an MTOR-independent inducer of
autophagy that inhibits inositol monophosphatase, leading to a decrease in inositol
availability. Inositol monophosphatase inhibition results in increasing cellular levels of
PtdIns3P, thus inducing autophagy.64 L-690,330 also inhibits inositol monophosphatase
and is more potent, but has a reduced ability to permeate the PM and blood-brain
barrier.65 Carbamazepine also works by a similar mechanism to lithium, and has been
used in vivo to ameliorate proteinopathies in mice either suffering from mutant
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SERPINA1 (α1-antitrypsin) Z or TAR DNA binding protein (TARDBP) accumulations.66, 67 A
broader range of pharmacological agents used to induce autophagy in the treatment of
proteinopathies has been previously reported.68 The xestospongin family of natural
compounds purified from marine sponges, xestospongin B (XeB) and xestospongin C
(XeC), are inducers of autophagy. XeC inhibits both the inositol 1,4,5-trisphosphate
receptor 1 (ITPR1) and ER Ca2+ receptors indiscriminately, thus altering Ca2+ flux.69 XeB
was originally identified as an inhibitor of inositol 1,4,5-trisphosphate-mediated Ca2+
signaling70 and has more recently been shown to act as an antagonist of ITPR1 on the ER
membrane. Evidence supports a mechanism wherein ITPR1 facilitates BCL2-mediated
sequestration of BECN1 to inhibit autophagy. XeB would rapidly induce autophagy by
interfering with these protein-protein interactions, freeing BECN1 in an organellespecific manner.71 The induction of autophagy by XeB appears to be independent of
steady state Ca2+ levels in the ER or cytoplasm.72
For autophagy inhibition, 3-methyladenine (3-MA) inhibits autophagy in nutrient
poor conditions by inhibiting PI3K and autophagosome formation. However, 3-MA
inhibits both PIK3C1 and PI3CK3 indiscriminately which could lead to pleiotropic cellular
effects. Interestingly, in complete media 3-MA is pro-autophagic, leading to an
accumulation of autophagic markers and increased conversion of LC3-I to LC3-II. Wu
and colleagues were able to show that the increase in autophagic markers is a result of
increased autophagic flux rather than an effect of autophagosome accumulation and
seems to be cell line independent. Therefore, use of 3-MA as an autophagic inhibitor is
well supported and substantiated when used in starvation conditions and at relevant
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concentrations.73 Another PI3K inhibitor, wortmannin, functions in a similar way but
does not show pro-autophagic effects in complete media. This difference is attributed
to wortmannin more stably inhibiting PtdIns3K compared to 3-MA, which has a
transient effect on PtdIns3K but a stable effect on PIK3C1.74 The second group of
inhibitors either target PI3K stabilization or autophagosome-lysosome interaction. A
recently identified inhibitor, spautin-1 (specific and potent autophagy inhibitor-1),
blocks the deubiquitinase activities of USP10 and USP13, leading to the UPS-mediated
degradation of the PtdIns3K component of the PI3K complex.75 Vacuolar ATPase is an
enzyme that resides on the lysosomal membrane and regulates the lysosomal
acidification. Bafilomycin A1 (BafA1) is a vacuolar ATPase inhibitor. BafA1 inhibits fusion
of autophagosomes with lysosomes and leads to an accumulation of autophagosomes in
the cell as well as a reduction of protein degradation, another indication that autophagy
is impaired.76 The fusion blockage seems to be an effect secondary to the reduced
acidification of the lysosome.77 Conflicting reports in the literature imply that both cell
type and length of drug treatment affect the degree of inhibition as well as more
general effects. It is important to note here that interpretation of commonly used
autophagic activity and flux assays may be altered when using drugs affecting lysosomal
acidification. In a short communication, Klionsky et al78 discuss the complications that
may arise such as reduced LC3-II degradation at early time points and the difficulty in
discriminating autophagosomes from autolysosomes in this system due to GFP
persistence in the less acidified lysosomes.
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Types of Autophagy
Aggrephagy
Aggrephagy refers to the autophagic process of degrading proteins that are
assembled into large protein aggregates, which are less toxic to the cell than more
numerous small protein aggregates. Although this is seen as a companion system to the
UPS to promote protein degradation, there are subtle distinctions as to the intertwining
of these pathways. For example, proteins targeted for degradation by this means can
be ubiquitinated but do not necessarily have to be. Histone deacetylase 6- (HDAC6)
mediated dynein transport of proteins along microtubules occurs preferentially with
proteins that have K-63 linked polyubiquitin chains. Conversely, BAG3-mediated
aggresome formation, which also uses dynein transport along microtubules, does not
require such protein modifications. The forming aggresome requires K-63 linked
polyubiquitination to recruit autophagy receptors SQSTM1, NBR1, and WDFY3. These
receptors provide a physical link to ATG8, found in the developing phagophore, to
ultimately envelope the aggresomes.79
Allophagy, crinophagy, and zymophagy

Allophagy refers to the autophagic degradation of paternally derived
mitochondria upon fertilization in the zygote. As such, this mechanism is a
developmental-specific form of mitophagy. Sperm mitochondria, located in the midpiece region, are initially tagged with K63-linked ubiquitin prior to fertilization. This
labeling increases immediately after fertilization, presumably to insure their quick and
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successful degradation prior to fusion of the male and female pronuclei.80 Historically,
crinophagy refers to the process by which secretory granules containing hormones are
directly routed to lysosomes without contribution from autophagy. However, a parallel
mechanism involving encapsulating these granules within autophagosomes does occur,
as demonstrated within Paneth cells and pancreatic β-cells.81, 82 This provides a
turnover mechanism to regulate appropriate granule numbers in these cells. Autophagy
is also responsible for the regulation of neurotransmitter vesicle levels, as dopamine
responses are substantially increased in the dorsal striatum of Atg7-deficient mice.83
Conversely, induction of autophagy through rapamycin administration attenuates
dopamine responses. Although it has not been demonstrated, these processes are most
likely ubiquitin-dependent. For example, the closely related process of zymophagy
allows for the autophagic degradation of activated zymogen granules, 84 which is
dependent on VMP1 (vacuole membrane protein 1), SQSTM1 and the ubiquitin protease
USP9X.85 This mechanism prevents acute pancreatitis from occurring by removing
potentially harmful activated zymogen granules.
Exophagy
Autophagy is also associated with non-degradative processes involved in protein
secretion known as exophagy. Deretic et al86 review the roles of autophagy in
conventional (regulated and constitutive) and unconventional secretion. Conventional
secretion pathways normally route through the Golgi complex or occasionally directly
from the ER; however, the TOR-autophagy spatial coupling compartment87 is a newly
identified region that is responsible for constitutive secretion of IL-6 and IL-8. Regulated
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secretion examples include lysozyme release by Paneth cells and cathepsin K by
osteoclasts. Autophagy-based unconventional secretion, or autosecretion, involves
omegasome formation at the ER to secrete proinflammatory factors IL-1β and HMGB1
in mammalian cells.
Heterophagy and endosomal microautophagy
Heterophagy is distinguished from autophagy in the sense that it is a process
devoted to degrade extracellular material that has been internalized within the cell, in
contrast to the degradation of pre-existing intracellular material. Upon endocytosis,
proteins are routed into early endosomes and late endosomes/multivesicular bodies
(MVBs) for fusion with lysosomes. However, there is synergy with the endosomal
system and autophagy, as early endosomes and MVBs can both fuse with
autophagosomes to form amphisomes, which in turn fuse with lysosomes. These
amphisomes have been shown to carry protein markers early endosome antigen 1
(EEA1) and mannose 6-phosphate receptor (M6PR), present in early and late
endosomes, respectively.88 These fusion events are driven by GTPases, as MVBautophagosome fusion is RAB11-dependent and amphisome-lysosome fusion is RAB7dependent.89 In contrast to internalized materials, cytosolic proteins can be routed into
MVBs through endosomal microautophagy either hsc70-mediated or through a nonspecific mechanism. This process occurs during MVB formation and requires the ESCRT I
and ESCRT III protein machinery.90
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Immunophagy
More broadly, autophagy plays a larger role in both innate and adaptive
immunity in a process termed immunophagy.91 As recently reviewed, immunophagy is
subdivided into three types: Type I, Type II, and Type III.92, 93 Type I immunophagy
involves the processing of foreign or endogenous immunologically active molecules. This
would include: xenophagy, the autophagic activation of macrophages, pattern
recognition receptor activation, MHC II endogenous antigen presentation, and thymic
selection. Type II immunophagy regulates cell viability and immune cell function.
Specific roles for this type include: T/B cell homeostasis, T cell maturation, and Paneth
cell maintenance. Type III immunophagy utilizes specific ATG proteins but doesn't
require the entire process of autophagy to occur. Examples in this class include:
inhibition of RIG-I-like receptor signaling by ATG5–ATG12, and the negative regulation of
TBK1 signaling for type I interferon secretion by ATG9.
Lipophagy
Lipophagy involves the metabolic regulation of lipids through degradation of
lipid droplets (LDs) by autophagy. Ultimately, fusion with lysosomes contributes to
lipolysis of LDs, or the breakdown of triglycerides into free fatty acids. In addition to
lipophagy, cytosolic lipases promote free fatty acids from lipolysis in an autophagyindependent fashion. Although these cytosolic lipases are well characterized, the
autophagy proteins involved in the detection and mobilization of LDs are not known.
This field has recently expanded due to the pathologies associated with autophagydeficient mice. Liver-specific ablation of Atg7 results in LD accumulation known as liver
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steatosis (fatty liver).94 Similar studies have shown that lipophagy is a sensor for
appetite regulation in hypothalamic cells,95 whereas reduced lipolysis in macrophages
causes their premature conversion into foam cells to promote atherosclerosis.96
Mitophagy
Mitophagy is the selective degradation of mitochondria through autophagy,
although the process may be cell specific within mammals. For example, reticulocytes
lose their mitochondria as they mature into red blood cells, an interaction-dependent
process driven by BNIP3L (BCl2/adenovirus E1B 19kDa interacting protein 3-like) located
on mitochondria and LC3 found on phagophores.97 Within other cells, a PINK1 (PTENinduced putative kinase protein 1)-Parkin system seems to regulate mitophagy.98, 99
PINK1 localization at the OMM of damaged mitochondria recruits the E3 ubiquitin ligase
Parkin to cause K63-ubiquitination of three known mammalian proteins: mitofusin1,
mitofusin2 and voltage-dependent anion selective channel protein 1 (VDAC1).
Autophagy can subsequently be directed by SQSTM1- and HDAC6-dependent
mechanisms. Given the enrichment of Parkin within skeletal muscle, brain, heart, and
liver, it is possible that other tissues may use distinct E3 ubiquitin ligases for selective
removal of mitochondria. A recent genomic mammalian screen revealed 96 proteins
required for Parkin-mediated mitophagy, underscoring the complexity and uncertainty
of this mechanism.100
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Nucleophagy
Although yeast undergo piecemeal microautophagy of the nucleus, where
portions of the yeast nuclear membrane and nucleoplasm are invaginated into a vacuole
for degradation,101 mammalian cells can exhibit complete encapsulation of the nucleus
known as nucleophagy. This was initially demonstrated in murine models that exhibit
nuclear envelopathies from mutations in nuclear membrane associated proteins such as
lamin A and emerin.102 Murine embryonic fibroblasts (MEFs) isolated from these
mutant mice demonstrated decreased cell viability and increased nuclear abnormalities
when pharmacological inhibitors of autophagy were used. Wild-type MEFs also
exhibited signs of nucleophagy, although at lower levels than mutant MEFs, suggesting a
control mechanism when nuclear damage occurs. This notion is strengthened by
findings that anti-cancer drugs that elicit DNA damage can trigger nucleophagy.103
Topoisomerase inhibitors (e.g. camptothecin, etoposide), DNA intercalating agents (e.g.
cisplatin), and oxidative stress damage (e.g. vanadyl (IV)) can induce nucleophagy in
cancer cells. It is possible that basal piecemeal nucleophagy occurs to maintain nuclear
architecture, energy production, and nucleotide stores for DNA repair enzymes.
Pexophagy
Pexophagy, or degradation of peroxisomes through autophagy, is probably the
most utilized of the three known mechanisms to eliminate superfluous peroxisomes.
Analysis of liver-specific Atg7-deficient mice showed pexophagy contributed to about
70-80% of the turnover, compared to the remainder linked to both a LON proteasemediated mechanism and 15-LOX-mediated autolysis.104 The only known mammalian
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peroxisome receptor involved in pexophagy is PEX14, which can associate with LC3 on
the phagophore membrane.105 An LC3-RAB7-FYCO1-kinesin complex is responsible for
the transport of engulfed peroxisomes along microtubules to the lysosome. Although
ubiquitination of a distinct membrane protein of the peroxisome allows for SQSTM1mediated autophagy to occur, the identity of this protein is currently not known. 106
Reticulophagy and Ribophagy
Degradation of the ER through reticulophagy occurs in response to ER stress, and
is seen as an additional stress coping mechanism like the UPR and ER-associated
degradation.107, 108 The trigger for all three mechanisms lies in the accumulation of
unfolded protein aggregates within the ER lumen. Activation of the resident ER
membrane protein PERK occurs when chaperones dissociate from the luminal side of
PERK to assist in protein folding. This causes dimerization of PERK, phosphorylation of
EIF2A, and activation of ATG12, thus triggering the autophagic response via ATG12–
ATG5-ATG16L1 complex formation. Ribophagy, the selective elimination of free
ribosomes in the cytosol, is also linked to the ER stress response similar to
reticulophagy. ER stress leads to reduced translation levels, via phosphorylated EIF2A,
to avoid the additional burdening of chaperone recruitment to nascent peptides. 109 In
modeling neurodegenerative disorders in Purkinje cells, polyribosomes were
disassembled into non-translational monosomes, which became associated with
autophagosomes.110 However, it is not known which ATG proteins mediate the
recognition and sequestration of ribosomes and ER fragments into autophagosomes.
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Xenophagy
Viruses, bacteria, and parasites can be eliminated in an autophagic process
involved in innate immunity defense termed xenophagy, which has been previously
reviewed.93, 111 Invading bacteria can generally be classified as vacuolar (e.g.
Salmonella) or cytosolic (e.g. Listeria, Shigella). Cytosolic bacteria can undergo
ubiquitin-dependent and ubiquitin-independent mechanisms for autophagosomal
envelopment followed by translocation to lysosomes. Vacuolar bacteria can be routed
into autophagosomes, or in the instance of Mycobacteria, autophagy proteins can
resume the maturation of the vacuole and promote fusion with the lysosome.112 The
main recognition receptors that link detection and autophagy induction include the
membrane TLRs (Toll-like receptors) and the cytoplasmic nucleotide-binding
oligomerization domains (NOD)-like receptors (NLRs). The receptors can recognize the
lipopolysaccharides and peptidylglycans of Gram-negative bacteria. Microbial
interference with autophagy can occur due to the adaptive nature of bacteria. For
example, Shigella flexneri secretes the protein lcsB, which prevents ATG5-induced
autophagy at the bacterial surface.113 Yersinia pseudotuberculosis resides within
arrested autophagosomes in macrophages, since it can inhibit the fusion process with
lysosomes.114

Transcriptional Regulation
A multitude of studies have focused on discovering the transcription factors
responsible for controlling ATG genes. Thus far these studies have culminated in nine
transcription factors that orchestrate the expression of autophagy-related genes in
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mammals. We have learned that autophagy is under the regulatory control of circadian,
metabolic, inflammatory and cell death factors.
Circadian Regulation
As might be expected, autophagy genes are transcribed with a circadian rhythm
under control of the biological clock due to metabolic demands. A circadian rhythm
refers to the oscillation of a biochemical process (e.g. transcription, translation,
phosphorylation, etc.) that goes through a cycle roughly every 24 hours. The circadian
clock is a transcription/translation feedback loop between the positive transcription
factors CLOCK and ARNTL/BMAL1 and the negative transcription factors PER1 and PER2.
These signals originate in two clusters of hypothalamic neurons of the suprachaismatic
nucleus (SCN), which is reset by a light-dark cycle. The oscillation in the SCN is
considered the “master pacemaker” and is responsible for coordinating “subordinate
pacemakers” throughout an organism, giving rise to circadian rhythms in every tissue.
Autophagy is under circadian control likely because metabolism demands change
throughout the day, an idea recently reviewed.115 While only ~10% of transcripts are
globally rhythmically expressed,116-119 research using mice has shown that the mRNA
expression of many autophagy genes such as Becn1, and Map1lc3b are rhythmic in the
distal colon,120 liver, kidney, heart and skeletal muscle.121 In addition, the conversion of
LC3-I to LC3-II is rhythmic in the liver of mice.121 The expression of the transcription
factor CEBPβ, known to be controlled by the clock, was found to coordinate autophagy
gene rhythms by directly binding to the promoters of autophagy genes, such as, Bnip3,
Ctsl and gamma-aminobutyric acid receptor-associated protein (Gabarap). Additionally,
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CEBPβ has been identified as the transcription factor responsible for rhythmic
autophagy gene expression in the mouse liver.121 Furthermore, this rhythm was
abolished in Arntl knockout livers, proving that autophagy rhythms from CEBPβ are
dependent on the clock and thus, are circadian.121 It remains untested if CEBPβ or
another component of the clock controls autophagy rhythmicity in other tissues such as
the distal colon, but logic would dictate this to be the case. While there have not been
any direct links to disease caused by interrupting the link between autophagy and the
circadian clock, there are several lines of research suggesting this link exists. Metabolic
disorders like diabetes have been shown to be similarly exasperated independently by
both autophagy and CLOCK deficiencies.122, 123 It is surely to be found that the link
between autophagy and the biological clock is stronger than we currently understand.
FoxO Family
The FoxO (forkhead box, class O) family is comprised of four proteins in
mammals: FOXO1, FOXO3, FOXO4 and FOXO6. FOXO proteins are transcription factors
known to be involved in metabolism, longevity, oxidative-stress resistance, apoptosis
and autophagy. Once FOXO proteins are activated in the cytosol, FOXO proteins are
shuttled into the nucleus where they bind to promoters to initiate transcription. Their
role in controlling autophagy gene transcription comes from studies on skeletal
muscle,124-126 neurons,127 ischemic insults on the heart128 and human cancer cell lines.129
Upon starvation or denervation of skeletal or heart muscles, both autophagy and FOXO
activity are increased suggesting a transcriptional control link. These studies have
shown that FOXO1 and FOXO3 can induce the expression of Gabarapl1 (GABARAP-like
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1), LC3b, Atg12l, Atg4B, PtdIns3K, Ulk2, Becn1, Bnip3, and Bnip3l. Further analysis by
ChIP has found FOXO proteins bound to the consensus sequence (T/C/G) (G/A/T) AAA
(C/A) A found in the promoters of several autophagy genes including Becn1, Gabarapl1,
LC3b, Atg12 and Bnip3.128 The activation of autophagy by FOXO is one major arm of
autophagy activation as FOXO is independent of MTORC1 signaling. FOXO1 can be
activated in neurons through loss of Mapk8.127 Studying Mapk8-/- mouse brains and
neurons it is clear that MAPK8 is a negative regulator of autophagy by inhibiting FOXO1.
Mapk8-/- neurons have increased levels of dephosphorylated, nuclear-localized,
activated FOXO1 and greater autophagic flux. In cardiomyocytes, Sirtuin 1 (SIRT1) and
nuclear protein transcription regulator 1 (NUPR1 also known as P8) play crucial roles in
regulating autophagy through modification of FOXO1 and FOXO3.130, 131 SIRT1 regulates
the activation of autophagy by directly deacetylating and activating FOXO1 during
glucose deprivation (GD).132 Knockdown of either Sirt1 or Foxo1 leads to no increase in
expression of ATG genes and failure of autophagy induction during GD.131 Utilizing a
mutated FOXO1 (3A/LXXAA), which cannot be recognized by SIRT1, leads to increased
acetylation of FOXO1 and failure to induce of autophagy after GD.131 Additionally, Foxo1
conditional KO or Foxo1 (3A/LXXAA) overexpression in cardiomyocytes of mice
significantly deteriorates cardiac function after GD proposed to be a direct cause of the
significant decrease in autophagic flux. Knockdown of Nupr1, a transcriptional
corepressor of Foxo3, leads to activation and nuclear localization of FOXO3 where it
associates more with target gene promoters such as Bnip3, which in turn have increased
mRNA and protein expression. Subsequently, Nupr1 knockout mice have increased
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Bnip3 expression and increased autophagic flux in cardiac tissue, likely due to the
increased FOXO3 activity.130 In primary skeletal muscle myotubules, AMPK is a potent
activator of autophagy through both activation of FOXO3 and inhibition of MTORC1. 126
While more regulators of FOXO proteins are likely to be found, this research shows a
clear link between FOXO activation and autophagy induction, through the increased
expression of ATG-genes in several cell types.
Trp53
Transformation related protein 53 (TRP53 or TP53/p53) is a tumor-suppressor
protein with well-known roles in regulating both cell cycle progression and the cell
survival/death axis. Recently, it has also been shown to provide both positive and
negative regulation of autophagy. In normal cells, TRP53 remains in the cytoplasm at
low levels, which are maintained by the E3-Ubiquitin ligase MDM2 and the UPS. Upon
activation by post-translational modifications, TRP53 translocates to the nucleus where
it functions to transactivate a number of target genes involved in cell survival, death,
and cell cycle regulation. Initial observations that TRP53 inhibition resulted in increased
autophagy were complicated by the discovery that nuclear TRP53 was able to induce
autophagy by transactivation of specific target genes.133 The current model for TRP53
regulation of autophagy describes distinct, independent roles for cytoplasmic TRP53 and
nuclear TRP53. Analysis in vitro in a variety of cell types and in vivo in various organisms
has shown that cytoplasmic TRP53 functions as a repressor of autophagy. Trp53
knockout (in enucleated cells) as well as inhibition or inactivation of cytoplasmic TRP53
results in increased levels of autophagy, similar to that of cells following induction by
25

starvation or treatment with rapamycin.134 As well, induction of autophagy by
starvation or rapamycin results in rapid depletion of cytoplasmic TRP53 by UPS
degradation. Mutant TRP53, lacking an ubiquitylation site, has been shown to strongly
inhibit the induction of autophagy in vitro.134, 135 In contrast, nuclear TRP53 has shown
to transactivate several genes known to stimulate autophagy following genotoxic stress.
The TRP53 target gene, Dram1, encodes a highly conserved lysosomal protein whose
function is unclear but has shown to strongly induce autophagy in a variety of cell
types.133 Other nuclear TRP53 transactivation targets include Sesn2, Tsc2, and genes
encoding AMPK α/β subunits, which function together to stimulate autophagy during
nutrient deprivation. AMPK can activate the TSC1/2 complex, which functions as a
potent and sensitive inhibitor of MTOR, thereby de-repressing autophagy. The AMPK
activator SESN2 functions to amplify the TRP53-directed autophagic response.136, 137
While it is widely accepted that TRP53 levels in normal cells are maintained by
MDM2 ubiquitylation and proteasomal degradation,138 it is also well demonstrated that
tumor cells commonly carry various TRP53 mutants capable of escaping the regulation
by MDM2 and proteolytic degradation.139-141 Accumulation of mutant TRP53/TP53 in
tumor cells is associated with metastases and resistance to chemotherapeutic agents. It
has also previously been shown that various post-translational modifications can
stabilize and destabilize cytoplasmic TRP53.142 Recent analyses have shown that glucose
restriction of tumor cells results in deacetylation and subsequent autophagy-dependent
degradation of mutant TRP53, followed by apoptotic cell death. Inhibition of autophagy
prevented degradation of the mutant TRP53 and promoted tumor cell survival during
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glucose restriction.143 This finding presents an interesting link in regulation of TRP53
and the cell death/survival axis by selective autophagy because cytoplasmic TRP53 has
classically been characterized as a negative regulator of autophagy.
RB1-E2F1
The Rb1 – E2F pathway is a well-characterized regulator of the G1/S cell cycle
transition. Under normal conditions, RB1 directly inhibits E2F so that the cell remains in
G1. When RB1 is phosphorylated by CCND1−CDK4, RB1 disassociates from E2F proteins,
which allows them to bind to promoters of several genes including Ccne1 and virtually
all initiators of the pre-replication complex necessary for entrance into S-phase. As this
pathway is the major pathway augmented to increase proliferation in many cancer
models, Rb1 and E2F have become targets of many therapies. E2F1, a member of the
E2F family of eukaryotic transcription factors, is unique in that when DNA damage is
sensed E2F1 can directly promote apoptosis through expression of TRP73 and indirectly
through TRP53 accumulation by expression of CDKN2A/p19arf (Reviewed in p53 and E2f:
partners in life and death.144) Evidence for how RB1-E2F regulates autophagy is
confusing, as both RB1 and E2F1 can induce autophagy separately and often in an
inverse relationship to each other. E2F1 indirectly increases the expression of
autophagy related genes after E2F activation in U2-OS cells.145 A comprehensive
analysis of ATG-gene promoters in the presence of E2F1 reveals that E2F1 promotes the
expression of Ulk2, Atg4B, Atg4D, Atg7, Gabarap2, LC3a, LC3b, Atg9, Atg10, Atg12 and
Dram1.146 More recently, E2F1 overexpression in SK-MEL2 and MEFs induces
autophagic flux by LC3-II conversion and GFP-LC3, irrespective of a functional
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transactivation domain.147 While the E2F2 transactivation domain contains the RB1
binding site, autophagy induction cannot be linked to E2F1-RB1 interaction since the
expression of RB1 compared to E2F1 was not investigated. This data also does not
address whether E2F1tr (deletion of transactivation domain) can still induce expression
of ATG genes. As might be expected, removal of RB1 a negative regulator of E2F1,
increases autophagic flux and expression of ATG genes in myoblasts.148 Together these
data suggest that regulation of autophagy by RB1-E2F is dependent on active E2F to
promote transcription. However, when Rb1 is overexpressed in several human cancer
cell lines (U2-O2, Saos-2, Hep3b and U-87MG) autophagic flux is dramatically increased
by detection through LC3-II conversion, GFP-LC3 localization and transmission EM.149
Furthermore, when mutant RB1 that cannot bind to E2F family members is
overexpressed in these same cell lines, autophagy is not induced which suggests that
the repression of E2F by RB1 is necessary for autophagy induction. To corroborate
these findings, knockdown of E2F1 in the same cells increases autophagy, suggesting
that the regulation of autophagy by RB1-E2F is dependent on RB1 inhibiting E2F. To
best determine if the control of autophagy by RB1-E2F is physiological, more studies
conducted in non-cancer cell lines are needed since discrepancies could be due to the
models used. Either way, RB1-E2F is clearly a transcriptional regulator of ATG-genes and
could be involved in post-transcriptional regulation.
TFEB
The transcription factor EB (TFEB) is a well-characterized master regulator of
lysosome biogenesis. TFEB directly promotes the transcription of several lysosomal
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specific genes. Recent work in several labs has shown that when TFEB is phosphorylated
it remains inactive at the lysosome membrane and does not translocate to the nucleus.
Along these lines, it has been elucidated that MTORC1 at the lysosomal membrane is
responsible for the inhibiting phosphorylation at Ser142 of TFEB. 150-152 Further, the
inhibiting activity of MTORC1 is blocked during nutrient starvation, which is strikingly
similar to MTORC1’s inhibition of ULK1. When TFEB is overexpressed in HeLa cells, ATG
genes UVRAG, WIPI1, LC3b, SQSTM1, VPS11, VPS18, and ATG9b are upregulated along
with lysosomal genes.153 Analysis of these same cells showed that autophagic flux is
increased as well, indicating a parallel pathway to induce autophagic flux due to
starvation. It is interesting that TFEB, a lysosomal master switch, is implicated in the
induction of ATG genes post-starvation and that it is regulated through the starvation
sensor MTORC1.

Autophagy-Apoptosis Crosstalk
Beclin 1-Bcl2/XL Interaction
Classically, crosstalk between autophagy and apoptosis has focused primarily on
the interaction of the pro-autophagic protein BECN1 and the anti-apoptotic protein
BCL2.154, 155 While the mechanisms behind the regulation of autophagy remain elusive
and highly debated, the most widely accepted theory describes BCL2 as a BECN1
antagonist, through direct interaction with the BH3 domain found on BECN1, preventing
activation of the PI3K complex and induction of autophagy.156-158 Further analyses have
identified additional components of regulation in that only ER-localized BCL2 or BCL2L1
(BCL2-like 1/BCL X) in complex with the ITPR1 complex and the NAF1 protein can
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sufficiently inhibit the induction of autophagy under starvation conditions. 159 It has
been stated that BCL2 and BCL2L1 in complex with BECN1 retain their anti-apoptotic
capabilities; however, this data can be misleading as the interaction with BECN1 is
dependent upon ER-localization of BCL2 and BCL2L1 while the regulation of intrinsic
apoptosis occurs primarily at the mitochondria.160 This may suggest multiple
independent roles of the BCL2 and BCL2L1 proteins, dependent upon sub-cellular
localization; however, it is unknown what drives the specific distribution of ER- and
mitochondrial-BCL2/BCL2L1 proteins and whether or not redistribution may occur under
starvation conditions as a functional link between apoptosis and autophagy. Recent
data suggests that BCL2 may indirectly regulate BECN1 by interaction with AMBRA1, a
positive regulator of BECN1 and autophagy. BCL2 interaction with AMBRA1 is disrupted
upon autophagic stimuli, at which point AMBRA1 competes with ER-localized BCL2 for
interaction with BECN1. Interestingly, AMBRA1 is preferentially bound by the
mitochondrial fraction of cellular BCL2, rather than ER-localized BCL2, further linking the
regulation of apoptosis and autophagy.161
Becn1- BCL2L11 Interaction
In contrast to the previous model, a novel interaction has been observed that
suggests that the pro-apoptotic protein BCL2L11 (also known as BIM) can inhibit
autophagy by recruitment of BECN1. BCL2L11 is a BH3-only Bcl2 family protein that has
been previously shown to function in an active, phosphorylated state or an inactive,
dephosphorylated state. Phosphorylated BCL2L11 induces mitochondrial pore
formation and apoptosis by activating pro-apoptotic BAX/BAK1 proteins, while the
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dephosphorylated BCL2L11 is found in complex with the dynein light chain 1/LC8
protein. Luo et al162 recently described the complex formed by BCL2L11 bridging the
BECN1-LC8 interaction, which appears to sequester and inhibit BECN1 at the dynein
motor complex. Upon knockdown or knockout of Bcl2l11, cells in culture exhibit an
increase in autophagosome formation, which is reversible by overexpression of Bcl2l11
(mutants unable to induce apoptosis). While this interaction appears sufficient to
reduce levels of autophagy in nutrient-rich conditions, starvation-induced
phosphorylation of BCL2L11 eliminates its interaction with BECN1, suggesting that
inactive BCL2L11 may act to repress BECN1 until autophagy is induced by nutrient
deprivation. This model also proposes an interesting link between autophagy and
apoptosis in that BCL2L11 phosphorylation potentially enables BECN1-dependent
autophagosome formation and also activates pro-apoptotic BAX/BAK1 proteins,
inducing mitochondrial apoptosis.
Extrinsic apoptosis and autophagosomes
While the models mentioned above primarily involve interactions between
BECN1 and the BCL2 family proteins, a recent study has described autophagosomes as
potential platforms for formation of the death-inducing signaling complex (DISC) for the
activation of caspase 8 (CASP8). Classically, the DISC forms near the PM off of adapter
proteins bound to the cytoplasmic domain of various death receptors, activated by
extracellular apoptotic signaling. CASP8 is recruited to the DISC as a monomer, which
then self-associates and cross activates by cleavage of the pro domain. Active CASP8
cleaves and activates caspase 3 (CASP3) triggering the apoptotic cascade. It has been
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previously reported that CASP8 requires SQSTM1 for efficient self-association; however,
Young et al has described complex formation between ATG5 and CASP8, as well as ATG5
and the adapter protein FADD at the autophagosomal membrane. Atg5 knockdown is
associated with reduced CASP8 activation upon induction of apoptosis.163 While other
amplification mechanisms have been described in the apoptotic machinery, this appears
to be the first that is dependent upon autophagy/autophagosome formation.

Transgenic Models for Autophagy Detection
GFP-LC3
The best characterized and most widely used detection model is the GFP-LC3
transgenic mouse generated by Mizushima and colleagues. This robustly expressing
transgenic mouse, in which LC3 is driven by a constitutive CAG promoter, displays
punctate GFP fluorescence that corresponds to LC3 positive phagophores and
autophagosomes.164 With this transgenic model quantitation of autophagosomes and
phagophores is feasible using a high-resolution fluorescent microscope. This reporter
line has been crossed into many of the knockout and floxed autophagy models
generated in the field. For example, Atg5-/- mice are autophagy deficient and Atg5-/-;
GFP-LC3 mice do not exhibit the punctate fluorescence indicative of autophagosome
formation.165 (Protocols for use are widely available and published references are
helpful, for detailed information see Deretic, V, Autophagosome and phagosome,
Methods in Molecular Biology, 2008).166 This model is limited in that only phagophore
and autophagosome number, not autophagic flux can be evaluated. In basal conditions,
lysosomal degradation clears the autophagosome and contents from the cell, to
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maintain a “balance” of autophagosome formation and degradation. An accumulation
of LC3 positive structures may represent either an increase in formation or a decrease in
fusion events. Ferreting out these differences is relevant for proper data interpretation,
especially when using chemical autophagy inhibitors and inducers. Measuring
autophagic flux in vivo has been problematic to date and the field is in need of an
appropriate reporter model; currently, tandem fluorescent-tagged autophagy proteins
are a valuable in vitro tool.167 Due to its chemical nature, GFP is quenched by the low pH
of the autolysosome; however, red fluorescent proteins are more pH-stable, thus will
retain their fluorescence in the lower pH of the autolysosome. The need for better
detection mechanisms with regard to cardiac autophagy has led to the generation of a
double transgenic reporter. A cardiac muscle specific alpha myosin heavy chain
(αMyHC) promoter was used to drive expression of a mCherry-LC3 construct. These
mice were crossed with the GFP-LC3 model previously described to produce a double
label, which allows for the detection and evaluation of autophagic flux. 165 GFP-LC3 will
still function for visualization of LC3 positive phagophores and autophagosomes, while
mCherry-LC3 puncta will mark phagophores, autophagosomes and autolysosomes. Any
double-labeled puncta are indicative of phagophores or autophagosomes, while redonly puncta correspond to autolysosomes. The comparison of double labeled structures
to red fluorescent only labeled structures is informative to distinguish an increase in
formation and a decrease of fusion events. Although this model is cardiac-specific, a
similar strategy could be used to target other tissues or to generate a global transgenic
model.
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GFP-GABARAP
GFP-GABARAP transgenic mice were originally generated to address the question
of the role of GABARAP in podocytes. Since GABARAP was reported to be highly
expressed in podocytes, a pCAG-GFP-GABARAP transgenic mouse was produced in order
to examine subcellular localization in this specialized cell type.168 The expression level
of GFP-GABARAP is low, yet visible, ameliorating many of the potential effects of highly
expressing fluorescent proteins. In podocytes, GFP-GABARAP merged with SQSTM1
aggregates but not LC3-II. Though it was shown that GABARAP was not the preferred
Atg8 ortholog for conjugation in podocytes this is a valuable reporter model for use
across the field as differences in Atg8 orthologs are ferreted out.

Autophagy and development
Since the seminal genetic studies conducted in yeast, there has been an
explosion in global and tissue-specific mouse knockout models produced to ascertain
the role of autophagy in mammalian development and disease. Although this section
stresses development over disease, the pathologies that arise from induced mutations
frequently lead to diseased states. More commonly, mouse models are generated to
profile and to uncover treatment regimens to address human diseases. The models that
we present are segregated into 1 of 4 distinct complexes that the encoded protein
primarily functions in rather than by resultant phenotype, these being the: 1) ULK1
complex, 2) PI3K complex, 3) ATG9 complex, and 4) ATG12 conjugation/LC3-lipidation
system. Lastly, we include a section on induced mutations that impact autophagy more
indirectly beyond these complexes.
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ULK1 complex
ULK1 is the namesake member of the ULK kinase complex, and was initially
identified as the mammalian homolog of yeast Atg1. ULK1 kinase complex functions
early in the autophagy pathway, during the induction phase, and consists of ULK1,
ATG13, RB1CC1 and ATG101/C12orf44. ULK1 and ATG13 are phosphorylated by
activated MTORC1 in nutrient rich conditions; however, during stress MTORC1 is
inactivated and the ULK1 complex is liberated to induce autophagy. In this sense, ULK1
is a direct link to nutrient sensing in the cell. Contrary to expectations based on other
autophagy component knockouts, the ULK1 conventional knockout mice are viable and
have no overt developmental defects. It is noted by the authors that Ulk1 knockout
mice exhibit LC3 conversion at the same rate as wild-type controls, indicating that
starvation-induced autophagy is not impaired in these mutants. Under closer inspection
Ulk1 knockout mice exhibit specific red blood cell lineage populations retaining
mitochondria and ribosomes, as well as delayed mitochondria elimination in
reticulocytes and increased reticulocyte numbers.169 It is evident from these initial
studies that ULK1 is important for organelle clearance during erythrocyte maturation
but not necessarily for starvation-induced autophagy. Ulk2 knockout mice, like Ulk1
knockouts, are phenotypically normal and viable, which is not surprising since there is
most likely some degree of functional redundancy in the mammalian system.170 To
investigate this possibility, the authors generated Ulk1/Ulk2 double knockout mice,
which die shortly after birth. This result suggests that elimination of ULK function yields
a similar phenotype to the other autophagy deficient models. Ulk1-/-/Ulk2-/- MEFs are
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specifically impaired in response to amino acid deprivation, though they have a similar
response to glucose deprivation as wild type MEFs.170
RB1CC1, the mammalian functional counterpart of yeast Atg17, is a direct
interacting partner of ULK1 and a member of the ULK kinase induction phase
complex.171, 172 Rb1cc1 knockout mice die in utero at approximately E14.5-E15.5, with
the lethality attributed to massive liver and cardiac cell death from increased levels of
apoptosis. At E14.5, Rb1cc1 knockout embryos exhibit ventricular abnormalities: the
left ventricular wall is lacking in trabeculation, contains fewer cells, and is thinner that
control littermates.173 Autophagy may also impact the differentiation of hematopoietic
stem cells (HSCs) as revealed in the conditional knockout of Rb1cc1. Tie2-Cre; Rb1cc1 fl/fl
mice die perinatally from severe erythroblastic anemia and have 6-fold fewer HSCs than
control mice. There is not a proliferation defect, as apoptosis rates are similar between
groups and proliferation is actually slightly higher in the conditional knockout (35%
compared to 25%). However, a 4-fold increase in myeloid cells is found in the livers of
CKO fetuses at E14.5, possibly explaining the depletion of fetal HSCs.174, 175 Eight
proteins have been identified as binding partners of RB1CC1, including TSC1, a tumor
suppressor gene, which is also a negative regulator of MTOR. This interaction has been
shown to mediate cell size and growth. As a compliment to the Rb1cc1 KO studies, Tsc1
knockout embryos also show defects in the heart and liver; however, the heart defects
consist of thickened, rather than thinned, ventricular walls.176
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As part of the ULK1 kinase complex ATG13 functions during the induction phase.
ATG13, the mammalian homolog of yeast Atg13, is directly phosphorylated by both
MTORC1 and ULK1/2 and has been characterized as an adapter protein. At this time
there is not an Atg13 knockout mouse, though intriguing in vitro studies indicate that
Atg13 is essential for autophagy induction. Interestingly, when researchers
simultaneously knockout both Ulk1 and Ulk2, RB1CC1 and ATG13 are able to induce
autophagy, suggesting that ATG13 and RB1CC1 are functioning independently of
MTORC1 input to ULK1/2.177 This higher order autophagy regulation network is
deserving of further attention.
PI3K complex
AMBRA1 promotes the positive association of PtdIns3K and BECN1 to form the
core multi-protein autophagy induction complex. Cecconi and colleagues initially
reported that Ambra1 knockout mice, generated by using a gene trap strategy, are nonviable.178 The majority of Ambra1 null embryos exhibit severe neural tube defects and
spina bifida at E10 through E14.5. Additionally, a myriad of autophagy-deficient effects
are seen including cell cycle abnormalities, accumulation of ubiquitinated proteins and
increased apoptotic cell death. AMBRA1 is expressed specifically in the developing
nervous system and appears to serve a role in controlling neuron survival. Like the
Becn1 knockout model, the phenotype of the Ambra1 knockout is particularly severe
and strongly affects the developing embryo. Interestingly, new evidence suggests that
AMBRA1, like its binding partner BECN1, is a regulator of the autophagy-apoptosis
crosstalk. Pagliarini et al. report that AMBRA1 is selectively and irreversibly degraded by
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caspases and calpains.179 This would help shift the cell from a survival program into an
apoptotic program by destabilizing the autophagy promotion complex
(BECN1/AMBRA1/PtdIns3K). To support this hypothesis, a non-cleavable mutant of
Ambra1 introduced into a 2F cell line shows a delay and partial prevention of apoptosis
by extending the pro-survival effect of activated autophagy.178 It has been widely
reported in the literature that Parkin, an E3 ubiquitin ligase involved in the
pathogenicity of Parkinson’s disease, translocates from the cytosol preferentially to
depolarized mitochondria and prompts their selective degradation via mitophagy.180
Emerging evidence shows that AMBRA1 directly interacts with Parkin, although it is not
a target for ubiquination. Additionally, Ambra1 overexpression leads to an increase of
mitophagy but only in the presence of Parkin. These findings suggest a novel
mechanism whereby recruitment of AMBRA1, by Parkin, to the area of depolarized
mitochondria elicits the nucleation of a phagophore.
BECN1 is a core protein component of the PI3K complex needed for the
nucleation phase of autophagy, and serves as a scaffolding protein whereby a dynamic
grouping of autophagy-related proteins hub. BECN1 is unique among the autophagy
related proteins in that it contains an N-terminal BH3, which can be bound and inhibited
by BCL2 and family member BCL2L1. 181 This inhibition is primarily disrupted by
phosphorylation of BCL2/BCL2L1.182 BECN1 contains a central coiled-coil interaction
domain, which affords it the ability to oligomerize.183 Interestingly, the other domains
of BECN1 are non-essential for self-oligomerization, and self-oligomerization is not
affected by starvation, rapamycin or overexpression of Bcl2l1, Uvrag, or PtdIns3K.
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Higher-level understanding of this property has yet to be elucidated. The evolutionary
conserved domain is responsible for autophagic function. BECN1 interacts with
PtdIns3K directly to induce autophagosome nucleation and promote elongation.
Perhaps attributed to its unique juxtaposition between two programmed cell death
pathways or autophagy-independent functions, Becn1 knockout mice have a more
severe phenotype than other autophagy-related genes. Becn1-/- mice die in utero
around E7.5 days, with the embryonic lethality ascribed to a developmental failure to
close the pro-amniotic canal.184 As a classical tumor suppressor, heterozygous
disruption of Becn1 results in an increase in tumor incidence.184, 185 Additional induced
mutant models for Becn1 demonstrate a developmental-specific role for autophagy in
blood cell lineages. Becn1-deficient Rag1-/- chimeras have a dramatic reduction in early
marrow-derived thymocytes and B cells, while displaying normal levels of peripheral B
and T cells. Thus, autophagy is required for undifferentiated lymphocyte progenitor
maintenance and is not needed for the peripheral T and B cell compartments.186 Naive
T-cell homoeostasis is crucial for protective immunity against infection and it appears
that autophagy is necessary for this process. A T-cell specific deletion of PtdIns3K shows
that T-cell development does not require autophagy; however, naïve T cell survival is
contingent upon autophagy to effectively remove damaged mitochondria via
mitophagy.187
PtdIns3K is a highly conserved ancient kinase, and the only PI3K identified in
yeast. PtdIns3K phosphorylates phosphatidylinositol to generate phosphatidylinositol 3phosphate, which is used in the elongating autophagosomal membrane. A global
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knockout of PtdIns3K was generated by crossing a conditional PtdIns3K allele with a
Meox-Cre transgenic strain, for conversion to a null allele early in development. As with
several other autophagy knockout models, the hemizygous mouse is viable and exhibits
no obvious phenotype. In stark contrast to the hemizygous state, the homozygous
PtdIns3K knockout is lethal in the early embryonic stages (E7.5). The embryos fail to
form a recognizable mesoderm and both the endosomal trafficking and
autophagosomal pathways are disrupted.188 In a liver-specific knockout of PtdIns3K
(Alb-Cre; PtdIns3K fl/fl), mice are smaller and have enlarged, pale livers. At the molecular
level, hepatocytes have reduced levels of autophagy nucleation complex and an
increase in intracellular lipid droplet formation. Mitochondria are smaller, despite fed
conditions, indicating a potential mitochondrial fusion defect. Additionally, when
challenged with a 24-hour starvation, there are no observable GFP-LC3 puncta formed in
the mutants, indicating a cessation of autophagic flux in the PtdIns3K liver-specific
knockout mice.189 A cardiomyocyte-specific knockout (Mck-Cre; PtdIns3K fl/fl) results in
mice with cardiomegaly, with an increased left ventricular wall thickness, decreased
cardiac contractility and reduced cardiac output.189 Although these mutants appear to
be healthy at birth, they die between 5 and 13 weeks of age. Consistent with the liverspecific knockout, small and deformed mitochondria are observed, and autophagic flux
is disrupted. It is evident that PtdIns3K is essential for autophagy regulation as well as
autophagy-independent functions such as endosomal trafficking.
UVRAG is a coiled-coil, BECN1 interacting protein. It has been characterized as a
positive regulator of autophagy acting in a complex with requisite autophagy proteins
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BECN1 and PtdIns3K. UVRAG has tumor suppressor activity and a negative effect on
tumor cell proliferation, as UVRAG is recurrently monoallelically mutated in human
colon cancers.190 Although Becn1 serves a host of autophagy-independent functions,
UVRAG may have autophagy-independent roles as well. Liang et al. elegantly showed
that a UVRAG- PtdIns3K complex coordinates both late endosome fusion and trafficking,
independently of its BECN1-dependent role in mediating autophagosomal formation
and maturation.10 Although neither UVRAG knockout nor conditional knockout mice
currently exist, the generation of a model would be of great value to the field, aiding in
ascribing autophagy-dependent and independent functions to each member of the
induction complex.
Atg9 complex
ATG9 is the only multi membrane spanning autophagy related protein identified
to date. Proposed to function in membrane trafficking, it dynamically shuttles between
organelles during starvation conditions. There are 2 mammalian homologs: Atg9a, with
a global expression profile, and Atg9b, with a restricted expression in the placenta and
pituitary gland.191 Not surprisingly, Atg9a-/- mice, like Atg5-/- and Atg7-/- mice, die as
neonates. Thus, several autophagy-deficient mouse strains are unable to survive the
transition from placenta-derived nutrition without an intact autophagic response.
ATG9a is necessary for LC3 to conjugate PE, which is essential for autophagy function.
This study reveals that Atg9a is an essential autophagy gene. In addition to autophagy
related functions, Saitoh and colleagues show that Atg9a regulates double stranded
DNA innate immune response.192
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Atg12-conjugation and LC3-lipidation
ATG3 functions as the E2-like enzyme acting with LC3 in the LC3 ubiquitin-like
conjugation system. Similar to Atg5-/-, Atg7-/-, and Atg9a-/- mice, Atg3-/- neonates die
within one day of parturition, as amino acid levels are reduced and the overall energy
homeostasis is disrupted after termination of the placental nutrient supply. The Atg12–
Atg5 conjugate system is affected as well as the ATG8 conjugation system,193 suggesting
cooperation between the two distinct conjugation complexes during elongation. Atg3-/cells contained small autophagosome-like, ATG16L1 positive structures, disorganized
isolation membranes, and altered levels of GABARAP and GABARAPL2/GATE-16.
In yeast, a single Atg4 cysteine protease is responsible for cleaving Atg8 to
expose an essential, terminal glycine residue. In humans and mice, four Atg4 homologs
(also referred to as autophagins) have been identified: Atg4a, Atg4b, Atg4c, and Atg4d.
Of the Atg4 homologs, Atg4b and Atg4c knockout mouse models have been generated
to date. Atg4c is the most widely expressed Atg4 homolog in human tissues, although
Atg4b is the most efficient and broadly active family member in vitro.194 Atg4b-/- mice
are viable but have a depletion of ATG8-like proteins in normal and nutrient poor
conditions. These mice have balance and coordination deficits resulting from defective
development in the vestibular system. The otoconia within the inner ear do not develop
normally, resulting in abnormal, giant, or missing otoconia, a phenotype recapitulated in
the Atg5-/- model.195 In contrast, Atg4c-/- mice have normal levels of basal autophagy,
but are less responsive to starvation-induced autophagy in the diaphragm. This role in
ameliorating cell stress is highlighted in this model’s increased susceptible to methyl
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cholanthrene (MCA)-induced fibrosarcoma formation.195 Given the functional
redundancy of Atg4 homologs, double knockout models should be highly informative.
Atg16L1 binds to ATG5 to regulate the localization of the Atg12–Atg5 conjugate
to the nascent autophagosomal membrane. Atg16L1-/- neonates do not survive the
perinatal starvation period and have a disruption of LC3-PE conjugation.196 Crohn’s
disease, a chronic inflammatory bowel disease, is strongly linked genetically to the
autophagy gene ATG16L1 in humans,197 and hypomorphic Atg16l1 mice show altered
Paneth cell morphology and decreased intestinal antimicrobial protein secretion. 198
Immunological synapse dynamics between dendritic cells (DCs) and T cells seems to be
autophagy-dependent, as RNAi knockdown of ATG16L1 in DCs stabilizes DC-T cell
interaction and hyperstimulates the T cell response.199 This “hyperstability” is also
found in DCs from Crohn’s disease patients with an ATG16L1 risk allele, which suggests
that normally autophagy is activated at the synapse to negatively regulate T-cell
activation. In addition, Atg16l1-/- mice may help to model an autophagy-inflammasome
connection, since they have an induced expression of inflammatory cytokines including
IL-1β.196
Atg5-/- mice die perinatally, suggesting that autophagy is not essential for
embryonic development;200 however, maternal mRNAs and proteins persist in the early
embryo and may permit autophagic activity during the preimplantation period. Recent
studies demonstrate that autophagy is essential for the oocyte-to-embryo transition.
Analysis of GFP-LC3 embryos and oocytes show that autophagy is selectively
upregulated in fertilized embryos from the one cell to the four cell stage. 201 Very little
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evidence of autophagy is detectable in mature oocytes or ovulated, unfertilized oocytes,
indicating that fertilization stimulates the induction of autophagy. Mating of oocytespecific Atg5-deficient females (Zp3-Cre; Atg5fl/fl) with Atg5+/- males, leads to embryos
devoid of maternally inherited autophagic protein that fail to develop.202 Autophagy
may function to eliminate maternally inherited proteins or to catabolize cellular
components for energy homeostasis. Since Atg5-/- neonates die from starvationinduced amino acid deprivation,200 conditional gene deletion models have been
developed to characterize autophagy later in development. From these models,
autophagy has been shown to play a pivotal role in the prevention of
neurodegeneration and the onset of age-related neurological diseases and
cardiomyopathies. Nestin-Cre; Atg5fl/fl mice are viable and do not exhibit the suckling
defect comparable found with Atg5- or Atg7-deficient neonates.203 After three weeks of
age, progressive motor and behavioral defects become apparent including: growth
retardation, ataxia, poor motor coordination, and failed clasping reflex. High levels of
neurodegeneration are found in the cerebellar Purkinje cells, and ubiquinated protein
accumulations are observed across several anatomical regions of the brain.203 A
Purkinje-cell specific deletion strategy (pcp-Cre; Atg5fl/fl model) shows a later onset of
motor defect around 10 months of age compared to the more regional nestin-Cre.204
Autophagy-dependent cardiomyopathies may have a developmental component, as
cardiac-specific Atg5 deletions in young and adult mice have different pathologies.205
Inducible deletion of Atg5 in adult mice leads to cardiac myopathy, contractile
dysfunction, altered sarcomere structure, and aberrant mitochondrial organization.
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Conversely, cardiac-specific Atg5 deletion during gestation does not result in these
abnormalities, which points to adaptability of cardiomyocytes during early
development.
Similar to Atg5, Atg7 is necessary for the survival of neonates through amino
acid pool maintenance as shown in the traditional knockout model. 200 Neuronal-specific
Atg7-/- mice share many of the Atg5 knockout phenotypes including: abnormal behavior,
altered limb-clasping response and reduced motor coordination. The nestin-Cre; Atg7fl/fl
model shows high levels of neurodegeneration in the cerebellar and cerebral cortex
with death occurring by 28 weeks of age.206 Remaining neurons, which demonstrate
normal proteasome function, accumulate poly-ubiquinated proteins and harbor
inclusion bodies that increase with age. The nestin-Cre; Vps18fl/fl model exhibits a more
severe neurodegeneration phenotype and results in lethality by postnatal day 12,207
perhaps due to VPS18 being part of a protein tethering complex at the lysosome needed
for its fusion with autophagosomes or endosomes. Ablation of Atg7 within
dopaminergic neurons of the substantia nigra has been performed to model Parkinson’s
disease.208 Dopamine transporter (DAT)-Cre; Atg7fl/fl and engrailed-1-Cre; Atg7fl/fl adult
mice have ubiquitinated protein aggregates and show a 40% to 60% reduction in
dopaminergic neurons, respectively, and a corresponding decline in dopamine by 55%
to 65%. Although DAT-Cre; Atg7fl/fl mice do not display locomotive deficits, engrailed-1Cre; Atg7fl/fl mice exhibit an ataxic gait, presumably from additional Atg7 ablation within
the hindbrain, cerebellum, and midbrain. Using a tyrosine hydroxylase-specific Cre
mouse (TH-IRES-Cre) with the Atg7fl/fl model, there is a 40% reduction in dopaminergic
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neurons compared to controls and an accumulation of α-synuclein protein.209 Seizure
activity, in human TSC patients, is believed to occur due to a hyperstimulated MTOR
pathway.210 Inhibition of autophagy is demonstrated in CaMKIIα-Cre; Ptenfl/fl mice,
CaMKIIα-Cre; Tsc1fl/fl mice, and brains of TSC patients.211 Moreover, CaMKIIα-Cre;
Atg7fl/fl mice are prone to spontaneous tremors, as 75% of the mice develop symptoms
by 6-7 weeks of age. A liver-specific Atg7 deletion results in hepatomegaly and an
increase in hepatocyte size due to an accumulation of peroxisomes and deformed
mitochondria.212 Insulin-producing pancreatic β-cells use autophagy to maintain
homeostasis, as β-cell-specific RIP-Cre; Atg7fl/fl mice show β-cell mass reduction and
exhibit hypoinsulinemia and hyperglycemia.213 Atg7-deficient islet cells have reduced
numbers of insulin granules, increased mitochondrial swelling, and distended rough ER
and Golgi complex. Interestingly, these mice do not become diabetic until bred with
ob/ob mice to trigger an obesity-induced ER stress response. Obesity induces the UPR
in β-cells, which in the absence of autophagy leads to an increase in β-cell death from an
increase in reactive oxygen species.213, 214
Since there are several Atg8 mammalian homologs (e.g. GABARAP, LC3s,
GABARAPL1, and GABARAPL2), it is not surprising to find that Lc3b-/- and Gabarap-/- mice
are viable, have normal lifespans, and exhibit normal autophagy levels in fed and
starved conditions.215, 216 While the subcellular re-localization of LC3 is useful in
monitoring autophagy, LC3 has been recently implicated in mitophagy. BNIP3L, an
outer mitochondrial membrane spanning protein, has a cytoplasmic LC3 interaction
region (LIR) domain through which it can recruit mitochondria to the autophagosome;
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ablation of this interaction severely affects mitochondrial clearance.97 Although
SQSTM1 interacts with all of the LC3 orthologs, recent studies have revealed that only
lipidated LC3 selectively binds to SQSTM1 and directs it to the autophagosome. 164 Thus,
closer examination of the Lc3b-/- model may reveal defects in mitophagy or aggresome
clearance in a cell-specific fashion.
Autophagy-modifying models
Activation of autophagy, through the ectopic overexpression of peroxisome
proliferative activated receptor gamma, coactivator 1 α (PPARGC1A, also known as PGC1α), results in the degradation of HTT/huntingtin protein aggregates and ameliorates
the phenotype of Huntington’s disease mice.217 This PPARGC1A-mediated proteolysis
occurs by activation of TFEB, a known master regulator of autophagy. Induction of
autophagy through rapamycin administration can reverse protein plaque formation in a
murine model for Gerstmann–Sträussler–Scheinker disease, a prion disease that results
in ataxia from extracellular PrP amyloid plaques.218 Rapamycin treatment eliminates
amyloid plaque formation, reduces symptoms, and extends the survival time of these
mice.219 Within the hippocampus, the region devoted to learning and memory, an
increase in autophagosomes in aged mice has been correlated with short-term memory
deficits.220 This suggests an impairment of productive autophagosome-lysosome fusion
in aged hippocampal cells. A genetic affirmation of this mechanism is shown in a rescue
of the TgCRND8 mouse model for Alzheimer’s disease.221 Ablation of cystatin B, a
lysosomal cysteine protease inhibitor, reverses this defect through an increase in
productive autophagy and reduction of amyloid protein deposition. The Sqstm1
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knockout mouse displays an Alzheimer’s-like phenotype, characterized by
accumulations of cytotoxic aggregates of ubiquitinated proteins in neurons and other
tissues.222 Autophagy mitigates ROS-mediated cellular damage through productive
mitophagy. The E3 ubiquitin ligase PARKIN initially was found to be necessary for
mitophagy in neurons,223 and Parkin mutations are associated with juvenile
Parkinsonism.224
However, PARKIN-mediated mitophagy is also important for increased
myocardial survival after induced infarction. Fatalities from myocardial infarction
increase from 20% in control mice to 60% in Parkin-/- mice during the first week after
insult.225 Mitophagy may be a necessary process after injury to eliminate damaged
mitochondria to avoid an inflammatory response. Lysosomal DNase II functions to
degrade mitochondrial DNA upon autophagy-mediated trafficking of mitochondria to
the lysosome. Upon pressure overload, mice with DNase II-deficient hearts exhibit
myocarditis from an inflammatory response and dilated cardiomyopathy.226 Autophagy
could impact cell differentiation by restructuring the cell through the elimination of
organelles, proteins, and structures while providing necessary ‘building block’
metabolites. FGF signaling inhibits the transition from cardiac precursor cells to
differentiated cardiomyocytes. Abrogation of FGF signaling through the conditional
deletion of floxed FGFR1/2 or FRS2α causes premature cardiomyocyte differentiation
through precocious autophagy activation.227 A potential regulatory mechanism for
autophagy induction comes from a recent study that examined potent miRNAs that are
expressed upon hypertrophic stimuli.228 miRNA-212/132-/- mice are protected from
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transaortic constriction-induced hypertrophy and exhibit increased basal levels of
autophagy. Transgenic overexpression of miRNA-212/132 causes a decrease in the proautophagic transcription factor FOXO3, impairment of starvation-induce autophagy, and
leads to hypertrophy and heart failure. Lastly, blocking the fusion of autophagosomes
and lysosomes in cardiomyocytes through a cardiac-specific deletion of Mitofusin 2
(Mfn2) leads to increased sensitivity to ischemia and late onset cardiac dysfunction.229
Sonic hedgehog (SHH) is a crucial morphogen that promotes angiogenesis during
development230 and after ischemia in adults.231 Ligation of mouse common carotid
arteries induces neointimal lesion formation due to SHH-mediated, autophagydependent smooth muscle cell proliferation.232 Inhibition of autophagy with 3-MA or
BafA1 inhibits cell proliferation and neointima formation. This potentially signifies an
angiogenic role for autophagy in SHH-mediated smooth muscle cell proliferation during
development as well. A reduced level of autophagy is associated with arterial
endothelial cell ageing and dysfunction in older humans, as autophagy markers are
decreased by 50% and endothelium-dependent dilatation (EDD) is lowered by 30%.233
In addition, aged mice have a 40% decrease in autophagy markers and a 25% reduction
in EDD due to suppressed nitric oxide generation and an increased inflammatory
response. Induction of autophagy with trehalose reverses the EDD through normalizing
both nitric oxide levels and inflammatory cytokine expression. The dependence of cell
differentiation on autophagy is probably cell specific, since autophagy may inhibit
skeletal muscle differentiation from myoblasts. TGF-β1, an inhibitor of muscle
differentiation, induces autophagy through phosphoprotein enriched in
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diabetes/phosphoprotein enriched in astrocytes (PED/PEA-15) activation.234 Ectopic
overexpression of PED/PEA-15 in transgenic mice activates autophagy leading to
atrophic fibers accumulation in skeletal muscle.

Summary
Autophagy is a complex process with many constituent players and is highly
regulated. Autophagic degradation of cellular contents and turnover of organelles is
crucial for cell vitality and for the fidelity of organismal development. The concerted
effort of specific types of autophagy is essential for cellular homeostasis and immune
function. Transgenic mouse models of autophagic deficiency, both global and
tissue/temporal specific, have revealed the importance of autophagy in the oocyte-toembryo transition, post-natal survival, development, differentiation, and aging. A
synopsis of the induced genetic models discussed in this review is provided in Table 1.2.
From the collection of phenotypes of these models, a common thread emerges to assert
that autophagy may not be essential for embryogenesis. Six models (Atg3-/-; Atg5-/-;
Atg7-/-; Atg9a-/-; Atg16L1-/-; Ulk1-/-Ulk2-/-) exhibit a perinatal lethality partly based on an
inability for the neonates to maintain a pool of amino acids after parturition. In
contrast, a separate cluster of mutations, three within the PI3K complex (Ambra1-/-;
Becn1-/-; PtdIns3K-/-) and one in the ULK complex (Rbc1cc1-/-), demonstrate early to midgestation lethality in the respective knockout models. Reconciliation of these
phenotypic differences may be argued by functional redundancies or alternative
mechanisms (e.g. cell-specific Atg5/7-independent autophagy) found within the former
group, or additional autophagy-independent roles for members of the latter group.
50

With regards to the ULK complex, a recent study showed that both Atg13- and Rbc1cc1deficient avian DT40 cells had impaired autophagy, which was independent of
Ulk1/Ulk2.177 Generation of an Atg13-deficient mouse model should help in discerning
the developmental consequences of ULK1/2-independent autophagy. In addition to this
ULK1/2-independent activation, ULK3 can also contribute to the induction of autophagy
as well.235 This affirms Einstein’s notion that a problem, when looked at in the right
context, becomes increasingly more complicated. It also illustrates that there is
considerable work to be done in this area, especially as our methods of detection
improve.
Our understanding of autophagy has increased tremendously in the past decade
and continues to do so as the research effort in this area continues to accelerate. A
more productive growth will be greatly benefitted with the advent of more specific
pharmacological agents to induce or inhibit autophagy both in vitro and in vivo, as well
as the generation of a global reporter model to monitor autophagic flux in currently
existing induced mutant strains. The interconnectedness of many cell regulation
pathways (e.g. Akt, MTOR, apoptosis regulation) and autophagy implicitly underscore
the importance of these processes to cellular function. It is conservative to predict that
as the field continues to mature the tenuous nature of each of these interactions will
become clearer.
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Figure 1.1 The core machinery of autophagy. Autophagy is a complex degradation
process in which general cytoplasm or organelles are engulfed by a double membrane
bound structure and degraded and recycled following fusion with a lysosome. (A)
Dephosphorylated ULK1 dissociates from the MTOR complex and phosphorylates itself,
ATG13 and RB1CC1 to induce the nucleation phase. (B) The PI3K complex is assembled
at the site of the nascent autophagosomal membrane. UVRAG and ATG14 are found in
BECN1 complexes in a mutually exclusive manner. BECN1 is inhibited when bound by
anti-apoptotic BCL2, which results in downregulated autophagy. (C) The two ubiquitinlike conjugation systems essential for membrane elongation are outlined schematically.
(D) The autophagosomal membrane (orange crescent) is studded with ATG8 (stylized in
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black). The membrane elongation is dependent on the ATG12–ATG5-ATG16L1
conjugation system. During fusion with the lysosome (blue oval) ATG8 associated with
the outer membrane is cleaved and recycled by ATG4 while ATG8 associated with the
inner-membrane is degraded by lysosomal proteases along with the cargo of the
autophagosome.
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Table 1.1 Pharmacological inducers and inhibitors of autophagy
Autophagy
Inducer
MG132
Bortezomib
Tunicamycin
Thapsigargin

Fluspirilene
Resveratrol
Spermidine

Action

Reference

Inhibit 26S Proteasome
Inhibit 26S Proteasome
Induce ER stress by inhibiting N-acetylglucosamine
phosphotransferase
Induce ER stress via SERCA inhibition
Prevent autophagosome/lysosomal fusion by
inhibiting Rab7 recruitment
Stabilize ATG5–ATG12 by preventing Ca2+-mediated
CALPAIN-1 activation
Sirtuin-mediated deacetylation of cytoplasmic
proteins
Sirtuin-mediated deacetylation of cytoplasmic
proteins
Inhibit MTOR
Increase PI3P levels by inhibition of IMPase

54
54
55
56

57
58, 60
59, 60

Rapamycin
Lithium
chloride
L-690,330
Increase PI3P levels by inhibition of IMPase
Carbamazepine Increase PI3P levels by inhibition of IMPase
Xestospongin B Antagonize IP3R (and IP3R-mediated BCL2-BECN1
interaction)
Xestospongin C Inhibit IP3R and ER Ca2+ receptors
Autophagy
Action
Inhibitor

61-63
64

3Methyladenine

Inhibit PI3K (PI3KC1 and PI3KC3)

73

Wortmannin

Inhibit PI3K (PI3KC1 only)

74

Bafilomycin-A1

Inhibit vacuolar ATPase

76

Spautin-1

Inhibit USP10 and USP13 deubiquitinase activity

75

54

65
66, 67
70-72

Reference

Table 1.2 Atg knockout and conditional knockout mouse phenotypes
Gene
Genotype
Phenotype
-/Ulk1
Ulk1
Viable; No developmental defects or
impairment to starvation-induced
autophagy; Delayed mitochondria
elimination from reticulocytes
-/Ulk2
Ulk2
Viable; No overt phenotype/fertility defects
Ulk1-/-; Ulk2-/Neonatal lethal; impaired response to amino
acid deprivation
-/Rb1cc1
Rb1cc1
Embryonic lethal at E14.5-15.5; Excessive
liver and cardiac apoptosis; Thin left
ventricular wall, lacking trabeculation
Tie2-Cre;
Perinatal lethal; Severe erythroblastic
Rb1cc1fl/fl
anemia; 6-fold decrease in HSCs; Increased
number of myeloid cells in liver
Atg13
Currently no KO mouse
Atg101
Currently no KO mouse
Ambra1 Ambra1-/Non-viable; Embryos show neural tube
defects, spina bifida at E10-E14.5,
accumulation of ubiquitinated proteins, and
increased apoptosis in various tissues
-/Becn1
Becn1
Embryonic lethal at E7.5; Failure to close proamniotic canal
+/Becn1
Increased tumor incidence in various tissues
-/-/Becn1 ; Rag1
Reduced levels of early marrow-derived
thymocytes and B cells
PtdIns3k Meox-Cre;
Embryonic lethal at E7.5; Embryos fail to
fl/fl
PtdIns3k
form recognizable mesoderm
Alb-Cre;
Smaller adult mice; Enlarged, pale liver. In
fl/fl
PtdIns3k
hepatocytes: Reduced levels of autophagy
nucleation complex; Arrested autophagic
flux; Increased intracellular lipid droplet
formation; Reduced size of mitochondria
Mck-Cre;
Lethal between 5-13 weeks; Cardiomegaly
PtdIns3kfl/fl
with increased thickness of left ventricular
wall, decreased cardiac contractility/reduced
cardiac output; Arrested autophagic flux;
Reduced size of mitochondria
Uvrag
Currently no KO mouse
Atg9a
Atg9a-/Neonatal lethal during perinatal starvation
Atg9b
Currently no KO mouse
Atg3
Atg3-/Neonatal lethal at P1; Many cells contain
small ATG16L1-positive structures and
scattered isolation membranes
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Reference
169

170
170
171-173

174, 175

178

184
185
186
188
189

189

192
193

Table 1.2 Continued
Gene
Genotype
Phenotype
Atg4a
Currently no KO mouse
Atg4b
Atg4b-/Viable; Inner ear developmental defects
and associated defects in
balance/coordination
-/Atg4c
Atg4c
Viable; No overt phenotype/fertility
defects; Decreased starvation-induced
autophagy in diaphragm
Atg4d
Currently no KO mouse
Atg16l1 Atg16l1-/Neonatal lethal during perinatal
starvation; Induced expression of IL-1β
-/Atg5
Atg5
Neonatal lethal during perinatal starvation
Nestin-Cre; Atg5fl/fl Viable; Neurological defects appear after 3
weeks of age: growth retardation, ataxia,
poor motor coordination, failed clasping
response; Increased accumulations of
ubiquinated proteins; Abundant
neurodegeneration of cerebellar Purkinje
cells
fl/fl
Pcp-Cre; Atg5
Viable; Neurological defects appear after
10 months of age
-/Atg7
Atg7
Viable; Neurological defects appear after
10 months of age
Nestin-Cre; Atg7fl/fl Lethal by 28 weeks of age; Abundant
neurodegeneration/neuron death in
cerebrum and cerebellum, ubiquitinated
protein accumulations in remaining
neurons; Motor and clasping defects
fl/fl
DAT-Cre; Atg7
Viable; 40% reduction of dopaminergic
neurons and 55% reduction in dopamine;
ubiquitinated protein accumulations in
remaining neurons
En1-Cre; Atg7fl/fl
Viable; 60% reduction of dopaminergic
neurons and 65% reduction in dopamine;
ubiquitinated protein accumulations in
remaining neurons; Ataxic gait
TH-IRES-Cre;
Viable; 40% reduction of dopaminergic
fl/fl
Atg7
neurons; accumulation of α-synuclein
protein
fl/fl
CaMKIIαCre;Atg7
Viable; Spontaneous tremors in 75% of
mice by 6-7 weeks of age
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Reference
195

195

196
236
203

204
237
206

208

208

209

211

Table 1.2 Continued
Gene
Genotype
Alb-Cre; Atg7fl/fl
RIP-Cre; Atg7fl/fl

Lc3b
Lc3b-/Gabarap Gabarap-/Sqstm1
Sqstm1-/-

Parkin

Parkin-/-

Mfn2

Mfn2-/- (cardiac
sp.)

Phenotype
Viable; Enlarged hepatocytes;
Hepatomegaly; Accumulation of
peroxisomes and mitochondria
Viable; Hypoinsulinemia and hyperglycemia;
Reduced number of insulin granules;
Swelling of mitochondria, rough ER, and
Golgi
Viable; No overt phenotype/fertility defects
Viable; No overt phenotype/fertility defects
Alzheimer’s-like phenotype; Accumulation
of ubiquitinated proteins in neurons and
various tissues
40% increase in fatalities from induced
myocardial infarction due to mitophagy
defect
Increased sensitivity to ischemia and late
onset cardiac dysfunction
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Reference
212

213

215
216
222

225

229

Chapter Two: Altering Autophagy: Mouse Models of Human Disease
Introduction
This chapter has been published and is included here for completeness of the
dissertation.238
Since the advent of knockout technologies using mouse embryonic stem cells in
the late 1980s, there has been an explosion of murine models to profile human
diseases. The understanding of the genetic contribution to these diseases has been
further enhanced with the incorporation of tissue-specific gene deletion strategies
through the use of the Cre-lox and FLP-FRT site-specific recombination systems.
Autophagy, a crucial regulator of cell energy homeostasis, is also a companion process
to the ubiquitin-proteasome system to assist in the turnover of proteins. Two distinct
types of mouse models have been engineered to characterize autophagy. The first type
is based on the reporter model system to both detect and quantitate the in vivo levels of
autophagy in all tissues and organs. The second type is based on genomic modification
to perform global or tissue-specific gene deletions for generation of pathological disease
conditions. A wide array of human diseases and conditions have been shown to be
intimately linked to alterations in autophagy and include: 1) cancer, 2) heart disease, 3)
neurodegenerative diseases (e.g. Alzheimer’s and Parkinson’s disease), 4) aging, 5)
lysosomal storage disorders, 6) infectious disease and immunity (e.g. Crohn’s disease),
7) muscle atrophy, 8) stroke, 9) type 2 diabetes, and 10) reproductive infertility. This
article will address the role of autophagy in human disease progression by reviewing the
strengths and weaknesses of current murine models, as well as discussing their utility as
therapeutic models for disease prevention and amelioration.
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Transgenic models for autophagy detection
GFP-LC3
The best characterized and most widely used detection model is the GFP-LC3
transgenic mouse generated by Mizushima and colleagues.164 This robustly expressing
transgenic mouse, in which LC3 is driven by a constitutive CAG promoter, displays
punctate GFP fluorescence that corresponds to autophagosomes. With this transgenic
model, quantitation of autophagosomes is feasible using a high resolution fluorescence
microscopy. This reporter has been crossed into many of the knockout and floxed
autophagy models generated in the field. For example, Atg5 -/- mice are autophagy
deficient and Atg5 -/-; GFP-LC3 mice do not exhibit the punctate fluorescence indicative
of autophagosomes. Protocols for use are widely available and published references are
helpful, for detailed information see reference.239 This model is limited in that only
autophagosome numbers, not autophagic flux, can be evaluated.
In basal conditions, lysosomal degradation clears the autophagosome and
contents from the cell, thus maintaining a “balance” of autophagosome formation and
degradation. An accumulation of autophagosomes could either represent an increase in
formation or a decrease in fusion events. Ferreting out these differences is relevant for
proper data interpretation especially when using chemical autophagy inhibitors and
inducers. Measuring autophagic flux in vivo has been problematic to date and the field is
in need of an appropriate reporter model; currently, tandem fluorescent-tagged
autophagy proteins are a valuable in vitro tool. An increase in GFP puncta (denoting
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labeled autophagosomes) could indicate an increase in autophagosome formation or a
decrease in vesicular fusion with the lysosome. Due to its chemical nature, GFP is
quenched by the low pH of the autolysosome. Since red fluorescent proteins are more
pH stable, they have been utilized in assays designed to monitor autophagic flux. The
need for better detection mechanisms with regard to cardiac autophagy has led to the
generation of a double transgenic reporter. A cardiac muscle specific alpha myosin
heavy chain (αMyHC) promoter was used to drive expression of a mCherry-LC3
construct. These mice were crossed with the GFP-LC3 model previously described to
produce a double reporter which allowed for the monitoring of autophagic flux;
autophagosomes were identified by GFP and mCherry co-localized puncta, while
autolysosomes were tracked by mCherry-only puncta.165 Although this model is cardiacspecific, a similar strategy could be used to target other tissues. Additionally, a dual
labeled RFP-GFP-LC3 construct could be used to generate a ubiquitous transgenic model
to quantitate autophagic flux.
GFP-GABARAP
GFP-GABARAP transgenic mice were originally generated to address the
question of the role of GABARAP in podocytes. Since GABARAP was reported to be
highly expressed in podocytes, a pCAG-GFP-GABARAP transgenic mouse was produced
in order to examine subcellular localization in this specialized cell type. The expression
level of GFPGABARAP is low, yet visible, ameliorating many of the potential effects of
highly expressing fluorescent proteins. In podocytes, GFP-GABARAP co-localized with
SQSTM1 aggregates but not LC3II. Although it was shown that GABARAP was not the
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preferred Atg8 ortholog for conjugation in podocytes, this may prove to be a valuable
reporter model in other tissues.168
Cancer
As we will see as a common thread in many of the disease models featured in
this chapter, there is no consensus in the literature as to whether autophagy is
protective or maladaptive. The contribution of autophagy to cancer development is the
most demonstrable example of the Janus-like role of autophagy in disease pathogenesis,
and perhaps the most thoroughly investigated. Autophagy is hypothecated to
contribute to tumor progression through two distinct mechanisms. Tumor growth is
initially restricted when the centrally-located cells undergo nutrient deprivation,
hypoxia, and if prolonged, subsequently undergo necrosis. This metabolic stress induces
autophagy to maintain energy homeostasis and prevent necrosis until neovascularization occurs. Angiogenesis is potentially able to restore a nutrient supply
throughout the tumor, promoting tumor survival and facilitating growth and metastasis.
Additionally, transformed cells that harbor defects in apoptosis and autophagy
pathways tumor cells undergo chronic necrosis, which foments vascularization of the
necrotic area, thus promoting tumorigenesis. Conversely, intact autophagy can be
cytoprotective by eliminating damaged or aged organelles and degrading aggregated or
misfolded proteins, thus preventing accumulation of tumorigenic and/or cytotoxic
cellular inclusions.
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These two scenarios are manifested in mouse models of autophagy disruption.
When Beclin1 (Becn1) was heterozygously disrupted (Becn1+/-), these mice exhibited an
increase in tumor formation when compared to control littermates.185 Disruptions in
pro-autophagy genes Becn1 184, UVRAG 240, and Bif-1241resulted in increased frequencies
of lymphomas and mammary neoplasia through an increase in genetic instability.
TSC1/TSC2-deficient mice, which were unable to effectively suppress MTOR, had
reduced autophagy and a subsequent increase in tumor occurrence.242, 243 These models
all bolster the stance that autophagy is tumor suppressive. The embryonic or neonatal
lethality of many autophagy knockout models is prohibitive for studying diseases, such
as cancer, that are associated with age. Tissue-specific knockout studies will provide
more insights in elucidating gene-specific mechanisms for tumor suppression. Evidence
is forthcoming from cancer cell lines and primary tumor profiling that autophagy is
permissive for tumor growth and enhanced in primary tumors. In a pancreatic cancer
cell line (8988T cells), inhibition of autophagy by Atg5 siRNA resulted in an inhibition of
soft agar growth, a measure of tumorigenic potential.244 In cell lines with activated Ras,
a strong oncogene, autophagy was necessary for the quick growth and high metabolic
needs of tumor cells. These cancer cells were described as “addicted to autophagy,” and
the phenomenon was consistent amongst several Ras-activated cell lines (e.g. T14,
H1299, and CHT116). These data suggest that in quickly growing tumors, autophagy
inhibition may sensitize the cells to death thus enhancing available treatment
options.245 This study provides primarily in vitro evidence of a role for autophagy
induction in supporting tumor growth.
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Heart disease
Coronary heart disease (CHD) is the leading cause of death of men and women in
the United States. CHD is caused by narrowing of the arteries that supply the heart. In
mouse models a standard treatment is to induce an ischemic event by surgically
occluding one or more coronary artery. This occlusion may be relieved at a later time
(ischemia/reperfusion) or remain (permanent occlusion). Interestingly, autophagy is
induced in both ischemia/reperfusion (I/R) events and permanent occlusion events but
the outcomes are differential. During I/R events autophagy is activated, however in
Becn1+/- mice damage was reduced indicating that induction of autophagy was
maladaptive during reperfusion.246 Conversely, autophagy appears to be protective
during permanent occlusion events. Long term ischemia causes relief of mechanistic
target of rapamycin (MTOR) inhibition of autophagy, thus leading to autophagy
induction. In concordance with this, expression of a dominant negative MTOR regulator
resulted in a reduction of autophagy and subsequent increase in cardiac damage.247 Two
recent mouse models of heart disease provide evidence supporting a protective role of
autophagy for the prevention of CHD.248 Razani et al provided evidence that autophagy
prevented cholesterol crystal-induced inflammation that normally can lead to
atherosclerosis. Since high fat diets have been shown to inhibit autophagic flux,
competent autophagic flux may be necessary for the prevention of CHD. 249
In addition to CAD, congenital mutations and other pathological conditions (e.g.
type 2 diabetes) my result in cardiomyopathies. In a recent study, Choi et al showed that
in a cardiomyopathy model resulting from a mutation in A-type lamins (A/C) resulted in
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active MTOR in cardiomyocytes, which inhibited autophagy activation.250 This lack of
autophagy activation was proposed to lead to an energy deficit and was detrimental to
the survival of the cardiomyocytes and resulted in disease progression. Further evidence
of the protective role of autophagy was obtained when autophagy was reactivated by
the MTOR-inhibiting drug rapamycin. In mice mutant for A-type lamins, rapamycin
treatment attenuated the cardiomyopathy phenotype. In another approach, a mouse
model of diabetic cardiomyopathy, generated by diet alteration to include a surplus of
saturated fatty acids, has revealed that autophagy was activated in response to pressure
increase resultant from cardiac hypertrophy. Autophagy induction was measured by
increased Becn1 and LC3B mRNA, as well as increased GFP-LC3 puncta in the diabetic
hypertrophy model. In this system, isolated cardiomyocytes that were autophagy
impaired did not develop hypertrophy, indicating that increased autophagy was
required for hypertrophy. Furthermore, isolated cardiomyocytes treated with myristate
led to an increase in BECN1 and ATG7 expression through a ceramide-dependent
mechanism.251 The role of autophagy is complex and seems to be highly context specific
with regard to heart disease. It is apparent that the method by which autophagy is
inhibited or induced and in which type of model differentially dictates whether
autophagy will result in a positive or negative outcome.
Neurodegenerative diseases (e.g. Alzheimer’s and Parkinson’s disease)
Post-mitotic neurons rely heavily on basal autophagy to clear old, damaged
organelles and potentially harmful protein aggregates. Several neurodegenerative
disorders result from expansions of poly-glutamine or poly-alanine stretches, including
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Huntington’s disease, Parkinson’s disease, spinocerebral ataxias, and fronto-temporal
dementia. Mutant proteins involved in these diseases have an increased propensity to
aggregate and poison the cell; accordingly, the disease progression is directly related to
the amount of protein aggregates formed in these patients. In normal physiology,
neurons rely on both the proteasomal degradation system and autophagy to maintain
protein and energy homeostasis. It has been shown that autophagy is used
preferentially to remove large aggregated proteins or multiprotein plaques. In a rat
model of Machado-Joseph disease (spinocerebral ataxia type 3) overexpression of
BECN1 reduced both mutant ataxin-3 accumulation and ubiquitin-positive inclusions.252
It seems that autophagy is used as a compensatory mechanism to relieve the toxic
effects of these mutant protein aggregates in the cell, serving a protective role.
Neuronal-specific conditional deletion of Rb1cc1 (Rb1cc1fl/fl; nestin-Cre) resulted in
dystrophy (axonal swelling), neurodegeneration, accumulation of polyubiquitinated
proteins, damaged mitochondria, and neuronal death. When compared to Atg5/Atg7
neuronal conditional deletion models, the Rb1cc1-/- phenotypes were more severe,
present at an earlier age, and resulted in premature death. Unique to the Rb1cc1-/conditional knockout mice is the development of diffuse brain spongiosis, observed as
early as 2 weeks of age, and associated with ubiquitin positive inclusions, indicative of
impaired clearance of cytotoxic proteins by autophagy.253 Targeted deletions of either
Atg5 or Atg7 resulted in the accumulation of polyubiquitinated proteins and sensitized
neurons to degeneration; supporting the hypothesis that autophagy is
neuroprotective.203, 206 Purkinje cells (PC) reside within the gray matter at the interface
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between the molecular and the granular layers of the cerebellar cortex and are
important for signal integration, balance, and motor coordination. PC-specific
conditional deletion models of Atg7 (Atg7fl/fl; pcp2-Cre) resulted in PC dystrophy and
subsequent axon terminal degeneration. PC degeneration was followed by PC death and
behavioral changes in the mutant mice.237 In a similar experiment, deletion of Atg5 in
PCs (Atg5 fl/fl; pcp2-Cre) also resulted in axonal swelling and neurodegeneration.204
Although both the nestin-Cre and pcp2-Cre have been employed as useful tools to
investigate the result of tissue-specific autophagy loss, one important difference is that
nestin-Cre is also expressed in some astrocyte populations as well as other CNS
structures, while pcp2-Cre is restricted to PCs. This difference may alter the
experimental designs, as nestin-Cre is more appropriate for diffuse CNS ablation studies
and pcp2-Cre is more Purkinje cell-specific.
Aging
Autophagy and its association with aging have been explored in two distinct
contexts: 1) the impact of autophagy on increasing lifespan or longevity, and 2) the role
of autophagy in age-related disease states. Longevity‑promoting regimens, including
caloric restriction (CR) and inhibition of TOR with rapamycin, resveratrol or the natural
polyamine spermidine, have been associated with autophagy induction.254 CR can
improve heart function through autophagy, as long-term CR preserved cardiac
contractile function with improved cardiomyocyte function and lessened cardiac
remodeling.255 Rapamycin prolonged median and maximal lifespan of both male and
female mice when fed beginning at 600 days of age; this supplementation led to a life
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span increase of 14% for females and 9% for males. In addition, rapamycin-treated mice
beginning at 270 days of age also increased survival in both males and females.256
Lifelong administration of rapamycin extended the lifespan of female 129/Sv mice, as
22.9% of rapamycin-treated mice survived the age of death of the last control mouse.
Rapamycin also inhibited age-related weight gain, decreased aging rate, and delayed
spontaneous cancer formation.257 Although rapamycin and caloric restriction both
increase the life span of mice, they probably do not occur through similar mechanisms.
Dietary restricted mice (40% food restriction) and rapamycin-treated mice both
exhibited increased levels of autophagy.258 The fat mass was similar between control
and rapamycin-treated mice, but lower for the caloric restricted mice. There were also
striking differences in insulin sensitivity and expression of cell cycle and sirtuin genes in
mice fed rapamycin compared with dietary restriction. Spermidine, a natural polyamine
whose intracellular concentration declines during human aging, extended the lifespan of
yeast, flies and worms, and human immune cells. In addition, spermidine administration
potently inhibited oxidative stress in aging mice.58
Basal autophagy helps to reduce the deleterious effects from oxidative stress,
heat stress and cytoplasmic protein aggregates. During the aging process, basal
autophagy levels gradually decline so that the cell is not equipped to deal with these
stressors. Since many age-related diseases correlate with a decline in basal autophagy, a
targeted therapeutic strategy would be to increase the levels of productive autophagy
to reduce the severity of the disease. However, it is important to keep in mind that a
tight regulation of basal autophagy levels is important, as too much autophagy could
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have a negative outcome. For example, in the Zmpste24-null progeroid mice, which
model the human laminopathy Hutchinson-Gilford Progeria Syndrome (HPGS), there
was an increase in autophagy instead of the anticipated reduction that occurs during
normal aging. Although autophagy levels were similar to those found associated with
caloric restriction and prolonged lifespan, in this instance autophagy was linked to
having a potential role in the premature aging phenotype. However, these mice also
have several metabolic alterations including changes in circulating hormones (e.g.
leptin, insulin, adiponectin) and glucose levels that probably impact additional
contributing cellular processes.259 Progerin, the truncated form of lamin A protein, was
found to co-localize with the autophagic adapter protein SQSTM1 and the autophagy
linked FYVE protein, ALFY.260 Moreover, rapamycin decreased Progerin protein levels
through autophagy induction, which rescued the Progeria phenotype in HGPS
fibroblasts.261 Rapamycin-induced autophagy has therapeutic implications for other
types of laminopathies as well. For example, Lmna-null (lamin A-deficient) mice
exhibited skeletal muscle dystrophy and cardiac hypertrophy; these pathologies were
improved through rapamycin administration.262 An oxidative environment potentially
plays a crucial role in the aging process, as Sqstm1-/- mice exhibited accelerated aging
phenotypes and tissues displayed elevated oxidative stress due to defective
mitochondrial electron transport.263 Likewise, Cisd2-null mice exhibited nerve and
muscle degeneration and a premature aging phenotype.264 CISD2, the gene responsible
for Wolfram syndrome 2 (WFS2), encodes for a mitochondrial protein involved in
mammalian life-span control. Although mitochondrial degeneration was exacerbated
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with age with a concomitant elevation of autophagy, this elevation was most likely due
to a cellular response of mitophagy to clear damaged mitochondria. In addition to
induced-mutation mouse models, there have been several different naturally occurring
strains of senescence-prone (9 lines) and senescence-resistant (3 lines) mice that have
been developed since the 1970s at Kyoto University in Japan.265 These mice have been
important to model aging, senile dementia, and Alzheimer’s disease. By 12 months of
age, the senescence accelerated mouse prone 8 (SAMP8) mice demonstrated a decline
in cognitive ability that corresponded to increased levels of ubiquitinated proteins and
autophagic vacuoles (AV) in hippocampal neurons, and decreased expression levels of
Becn1.266 In contract, the senescence-resistant strain did not show an accumulation of
these autophagic vacuoles. In the future, it would be interesting to examine whether
calorie restriction or rapamycin administration could reduce the accumulation of
ubiquitinated proteins and improve learning and memory in the senescence-prone
model.
Lysosomal storage disorders
The group of degenerative disorders included in umbrella term lysosomal
storage disorders (LSDs) is a heterogeneous and emerging list of diseases that
commonly present with an inability to metabolize a normal cellular substrate. The
metabolic defect may reside with the ability of the lysosome to degrade the substrate,
or a blockade of autophagic flux, most often inhibiting fusion of the autophagosome and
lysosome. A reduction in autophagic flux may result in an increase in autophagosome
like structures in the cytoplasm as well as uncharacteristically large autophagosome like
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structures being formed. Consequently, failure to eliminate/recycle the autophagosomal
contents induces cellular stress and may result in death.
Pompe disease, the first LSD to be characterized, is caused by an inability to
synthesize acid α-glucosidase (GAA), a lysosomal enzyme needed to breakdown
glycogen. Pompe mice (GAA KO) phenocopied the human condition, and abnormal
autophagosomal and autolysosomal structures were seen intracellularly. When Pompe
mice were crossed with Atg5/7 muscle-specific conditional knockouts to inhibit
autophagy, mice metabolized glycogen more efficiently than the Pompe mice and had a
more positive prognosis. In this model system, autophagy was contributing to the
pathology of the disease and inhibition of autophagy was been shown to be a useful
therapeutic intervention. A side effect of muscle-specific autophagy inhibition, i.e.
muscular atrophy, will be discussed in a later section.
Multiple sulfatase deficiency (MSD) is a disease where affected individuals have
a reduction in the activity of all sulfatases due to mutations in Sulfatase Modifying
Factor 1 (SUMF1), an enzyme responsible for post-translational modification of all
sulfatases. A sumf1 knockout mouse model shared characteristic manifestations of MSD
including: skeletal abnormalities, kyphosis, and growth retardation. Impaired
autophagosome-lysosome fusion was implicated, as a build-up of undigested material
was detrimental to cellular homeostasis and led to death. Though models have
exhibited that MSD is accompanied by defective autophagic flux, whether autophagy is
protective or detrimental to the pathogenesis of the disease is unclear.
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Mucopolysaccharidosis type VI (MPS VI) is caused by a specific sulfatase
deficiency (N-acetylgalactosamine-4-sulfate) and patients may be short in stature and
suffer from joint stiffness and destruction, cardiac valve abnormalities and corneal
clouding. In a rat model of MPS VI, an increased number of autophagic structures were
identified by electron microscopy.267
Niemann Pick type C disease is a metabolic disorder characterized by the
accumulation of lipids in late endosomes/lysosomes. The vast majority of cases are due
to mutations in the NPC1 gene. Npc1-/- mice had higher levels of autophagy proteins
(LC3II) than controls, and PCs were preferentially affected exhibiting an increase in
autophagic vesicles by electron microscopy. Npc-/- mice had the ability to form
autophagosomes but were defective in autophagosome- lysosome fusion, which
resulted in a functional autophagic block and inability to metabolize cargo.268
Mucolipidosis type IV disease (MLIV) is caused by mutations in the MCOLN1 gene
which encodes a lysosomal cation channel. Affected patients suffer from psychomotor
delays and multiple ophthalmic pathologies. The Mcoln1-/- mouse model recapitulated
most of the symptoms observed in patients with the exception of corneal clouding. In
Mcoln1-/- brains, lysosomal inclusions were observed in several anatomical areas and
cell types.269 Neurons had increased LC3-II expression and failed to clear LC3-II, once
again indicating a functional autophagic block that led to the pathogenesis.270
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Infectious disease and immunity (e.g. Crohn’s disease)
The innate immune system is the first line of defense against pathogens; it is
evolutionarily more ancient than the adaptive immune system and is deployed quickly
and effectively despite its lack of pathogen specificity or memory. Viruses, bacteria, and
parasites can be eliminated in an autophagic process involved in innate immunity
defense termed ‘xenophagy.’ Invading bacteria can generally be classified as vacuolar
(e.g. Salmonella) or cytosolic (e.g. Listeria, Shigella). Cytosolic bacteria can undergo
ubiquitin-dependent and ubiquitin-independent mechanisms for autophagosomal
envelopment followed by translocation to lysosomes. Vacuolar bacteria can be routed
into autophagosomes, or in the instance of Mycobacteria, autophagy proteins can
resume the maturation of the vacuole and promoter fusion with the lysosome. The main
recognition receptors that link detection and autophagy induction include the
membrane TLRs (Toll-like receptors) and the cytoplasmic nucleotide-binding
oligomerization domains (NOD)-like receptors (NLRs). The receptors can recognize the
lipopolysaccharides (LPS) and peptidylglycans of Gram-negative bacteria. Microbial
interference with autophagy can occur due to the adaptive nature of bacteria. For
example, Shigella flexneri secretes the protein lcsB, which prevented ATG5-induced
autophagy at the bacterial surface. Yersinia pseudotuberculosis resides within arrested
autophagosomes in macrophages, since it can inhibit the fusion process with
lysosomes.92, 111
The more complicated adaptive immune system also relies on autophagy in
many capacities. Studies inducing ablation of autophagy proteins have revealed an
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essential role for autophagy in maintaining normal numbers of B cells, T cells and
hematopoietic stem cell survival and function. Atg5- and Atg7- deficient models have
shown that autophagy was important for T cell survival and maintenance of
mitochondria. An increase in mitochondrial mass has been correlated with T cell death
in circulating T cells, indicating a potential mechanism of action.271 Thymic epithelial
cells have a high rate of basal autophagy compared to other cell types. During T cell
selection thymic epithelial cells display decorations of “self” and “non-self” antigens,
aiding in this process autophagy is proposed to facilitate ligand (MHC-II molecule)
loading. When autophagy was depleted specifically in thymic epithelial cells, the mature
T cell repertoire was diminished due to alterations in positive and negative T cell
selection processes. Interestingly, severe colitis, patches of flakey skin, atrophy of
uterus, absence of fat pads and enlargement of lymph nodes were observed in many
cases. Inflammation was observed in the colon, uterus, lung and Harderian gland of
recipient mice. These manifestations are indicative of autoimmune diseases and this
model provides a clear linkage between autophagy and autoimmune/inflammatory
diseases.272 A B cell-specific ablation of Atg5 was achieved by either a Cre-LoxP
approach (Atg5fl/fl; CD19-Cre) or by repopulating irradiated mice with progenitor cells
derived from an Atg5-/- fetal liver. In these experiments, autophagy was found to be
essential for the survival of pre-B cells (after the pro-B cell to pre-B cell transition).
Additionally, in peripheral circulation Atg5 was required to maintain normal numbers of
B-1a B cell populations but not B-2 B cells.273
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Genome wide association studies of Crohn’s Disease identified two autophagy
associated genes, Atg16L and IRGM. A naturally occurring insertion/deletion mutation
was identified in the 5’UTR (untranslated region) of IRGM (immunity-related GTPase
family, M) which disrupted a transcription factor binding site.274 In another study, a SNP
in the coding region of IRGM was identified that affected a microRNA binding site.275
These identified mutations suggested that IRGM expression level changes were
associated with Crohn’s disease in humans. A mouse knockout model of Irgm1 (a.k.a.
LRG-47) has been developed and does not display any overt phenotype, including
development of the immune system. However, when challenged with infection, Irgm-/mice were unable to control the replication of intracellular pathogens.276 Unfortunately,
the Irgm1-knockout mice have not been investigated specifically in the context of
autophagy function in immunity to date. However in parallel with in vitro data, IRGM1
has recently been shown to induce autophagy in a mouse model of stroke. The
promotion of autophagy, most likely at the level of LC3I to LC3II conversion, was
generally protective.277
The relationship between Crohn’s disease and the autophagic process is more
developed in terms of investigating the Atg16L risk allele association by using two
Atg16L gene trap models and an intestinal epithelium-specific Atg5 knockout (Atg5fl/fl;
villin-Cre). Both Atg16L gene trap models (HM1 and HM2) result in a hypomorphic
expression of Atg16L protein. Interestingly, in the Atg16L mutants Paneth cells exhibited
abnormal morphology including decreased granule number and disorganization of
granules. Researchers concluded that autophagy was required to maintain fidelity of the
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Paneth cell granule exocytosis pathway. When challenged with infection, the Atg16L
hypomorphs performed similarly to controls. In Atg5fl/fl; villin-Cre ileum, abnormal
Paneth cells were identified which paralleled to those identified in the ATG16L mutants.
Human ileum samples from at risk patients were examined and also exhibited abnormal
Paneth cell morphology.198 It is noteworthy at this point to mention that genome wide
association studies for ulcerative colitis did not identify either of these autophagy genes,
nor others. This suggests that Atg16L and IRMG are specific for the physiopathology of
Crohn’s disease, not inflammatory bowel diseases generally.
Muscle atrophy
Muscle atrophy is a symptom of a multitude of pathological states including but
not limited to fasting conditions, denervation, inactivity, cancer, cardiac failure, and
diabetes. Autophagy has been shown to be active in muscular atrophy and other
myopathies however due to the nature of the methods used it cannot be said with
certainty whether autophagy is promoting atrophy or is activated as a cytoprotective
mechanism and coincides with pathology.
In a mouse tissue-specific mouse model generated to investigate the effect of
superoxide dismutase 1 (SOD1) ablation on skeletal muscle, it was found that mutants
developed muscle atrophy, reduction in contractile force and abnormal mitochondria.
Significant upregulation of the mitophagy (specific and selective form of autophagy
wherein mitochondria are preferentially enveloped and degraded) gene Bnip3, as well
as, autophagosome marker LC3 were detected by RT-PCR, most likely as a result of
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activation of transcription factor FoxO3. Oxidant accumulation in SOD1-/- mice resulted
in muscular atrophy through autophagy; this phenotype was rescued by depletion of
LC3 by siRNA knockdown suggesting that autophagy was the driving pathway of
atrophy. These findings imply that autophagy inhibition is a potential therapeutic target
for acute and chronic muscular atrophy.278
Muscle-specific Atg7 conditional knockout mice were autophagy incompetent
and morphologically diverged from wild type control littermates beginning at 40 days of
age. Muscles of the knockout mice exhibited degenerative changes and a decrease in
myofiber size; these abnormal changes were concurrent with the loss of muscle
contractile force which further decreased with increasing age. Even more telling may be
the ultrastructural changes associated with loss of autophagy in the muscles,
abnormally large mitochondria, centrally located nuclei and dilated sarcoplasmic
reticulum all observed via electron microscopy.279
As discussed previously, a muscle-specific Atg5 knockout mouse was generated
and bred onto a glycogen-degrading enzyme acid-alpha glucosidase knockout
background (GAA-KO) to interrogate the nature autophagic degradation of glycogen in
the pathogenesis of Pompe disease. This study provided additional evidence that
autophagy functioned to prevent muscular wasting. Muscle-specific GAA-/-; Atg5-/- mice
developed progressive muscular weakness and eventual paralysis beginning earlier (2-3
months of age) and progressing more rapidly than autophagy-competent GAA KO mice.
Ubiquitin-positive structures accumulated in both GAA KO and GAA-/-; Atg5-/- mice with a
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differing distribution. In GAA KO myocytes, autophagic vesicles built up in the cell and
ubiquitin-positive structures associated with the autophagosome. In GAA-/-; Atg5 -/myocytes, ubiquitin-positive structures were distributed throughout the cell and
appeared to associate with lysosomes, though were not membrane bound. These data
indicated that the disruption of functional autophagy and accumulation of toxic
ubiquitin-positive structures promoted muscular myopathy.280
Stroke
Cerebral ischemia is achieved in mice most often by surgical intervention and
results in global, restricted, or cerebral directed ischemia depending on the method
selected. Furthermore in some models ischemia is reversed, allowing reperfusion of the
cerebral tissue. Autophagy is induced by hypoxia/ischemia events; however it is unclear
whether autophagy is protective or maladaptive in stroke models. Responsibility of
much of the dissenting opinions may be attributed to the variety of techniques used to
induce ischemia events, these have been reviewed at length by Hossmann, see
reference.281 Neonatal mice subjected to hypoxic/ischemic (H/I) brain injury responded
with a robust autophagic response in neurons and hippocampal neuron death. Atg7-/neonates, which are autophagy incompetent, were protected from hippocampal neuron
death when subjected to identical (H/I) brain injury as control mice, indicating a
neurotoxic role for autophagy induction.282 Conversely, in when wild type mice were
subjected to H/I brain injury and reperfusion, damage was mitigated by intraperitoneal
injection of NAD+. NAD+ administration inhibited autophagy induction. In the NAD+
treated group, a reduction of autophagy was correlated with a decrease in neuronal
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damage. To further investigate this link, researchers subjected mice to H/I injury and
treated them with 3- methyladenine (3-MA), an autophagy inhibitor, and an
amelioration of neuronal damage was observed. These data indicated that in adults, H/I
brain injury followed by reperfusion autophagy was maladaptive; furthermore,
inhibition of autophagy at the time of reperfusion was neuroprotective 283. Moreover, in
a rat ischemia model, inhibition of autophagy by Becn1- directed shRNA or 3-MA
treatment led to a reduction in damage and neuronal loss in the ipsilateral thalamus.
This study supported the hypothesis that autophagy induction increased damage when
activated following an ischemia/reperfusion event.284 The variance amongst the model
systems could account for much of the disparity seen in outcomes. The age of the
individual, duration of ischemic event, and presence or absence of reperfusion is all
potential modulators autophagic response.
Type 2 diabetes
Type 2 diabetes (T2D) is a complex disease that manifests in tissues, especially
adipose, muscles, and liver, becoming resistant to insulin signaling and causing
hyperglycemia. Pancreatic β–cells initially respond by increasing their production of
insulin, but prolonged insulin resistance results in atresia of β–cells and a marked
reduction in insulin production. Due to the high metabolic demands placed on β–cells it
follows that autophagy would be play an important role in the pathophysiology of this
chronic disease. In wild type C57BL/6 mice β–cells, unlike most organs, autophagosomes
are sparingly observed after a period of starvation. However, when mice were fed high
fat diets for 12 weeks, autophagosomes were readily observed. These results were
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confirmed in vitro by treating INS-1 β–cells with free fatty acid (FFA), glucose, or
tolbutamide. Cells treated with FFA had increased LC3II levels and observable
autophagosomes while cells treated with glucose or tolbutamide (a drug regularly
prescribed for T2D) did not show any significant change in LC3 conversion or
autophagosome formation. To further investigate the link between autophagy and β–
cells, a β–cell specific Atg7-/- mutant mice was generated (Atg7fl/fl; Rip-Cre). As early as 4
weeks, and degenerating in an age-dependent manner, enlarged cells with pale staining
cytoplasm were identified near the periphery of Atg7fl/fl; Rip-Cre islets. Inclusion bodies
were observed at a high frequency in the enlarged cells the presence of inclusion bodies
increased with age, and deformed mitochondria were also observed in these enlarged
cells. Resting blood glucose levels were higher and insulin secretion was reduced in
Atg7fl/fl; Rip-Cre mice when compared to control Atg7fl/fl mice: these differences were
amplified when control and Atg7fl/fl; Rip-Cre mice were fed high fat diets.285 In a related
model, Marsh et al generated β–cells with a defective secretory pathway in Rab3A-/mice. Although increased intracellular insulin levels were expected, this was not
observed. Increased autophagy of the peptide hormone maintained the levels of insulin
and prevented accumulation of potentially toxic cellular substrates.82 These
experiments together suggested that β–cells depended on autophagy to clear damaged
organelles and toxic intracellular protein aggregates.
Reproductive infertility
The role of autophagy during folliculogenesis is a comparatively new topic of
study. In rats, LC3II expression was characterized in follicles of varying developmental
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stages. Primordial follicles exhibited only weak expression, but antral follicles exhibited
robust expression restricted to granulosa cells. Staining was not observed in the oocyte
proper or theca cells in any stage follicle.286 In mice, expression studies also indicate a
role for autophagy during folliculogenesis. An expression profile of Becn1 mRNA
revealed significantly higher expression in primordial follicles than in other stages.
Immunohistochemistry for BECN1 confirmed this result and consistent staining of
granulose cells, theca cells and oocyte cytoplasm was seen in all follicular stages
examined.287 Interestingly, when Becn1 or Atg7 is ablated specifically in the female
germline (MMTV-CreA; Becn1fl/fl) or globally (Atg7-/-), fewer primordial follicles were
present in the perinatal ovary. These results indicated that autophagy may be vital for
survival of the primordial follicle pool, and be active during folliculogenesis and follicular
atresia. In males it is well accepted that autophagy is responsible for post fertilization
paternal mitochondrial clearance to prevent paternal mitochondrial DNA transmission;
however, the role of autophagy during spermatogenesis is a field in its nascence. It has
been shown in Arabidopsis that Becn1 was essential for pollen development.288 Also,
autophagy induction in stallion sperm, as measured by LC3I to LC3II conversation, was
important for the survival of sperm post ejaculation.289

Conclusion
A variety of mouse models have been established and interrogated to
understand the implications of autophagy in human disease. These genetic-based
models are primarily either reliant upon: 1) the generation of an autophagy-defective
mouse to characterize a given disease state, or 2) the characterization of autophagy
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within a pre-established murine model. As this review has shown, conditional knockout
models have been extremely useful in disease profiling. The next wave of studies will
invariably utilize inducible-based systems for conditional knockouts, genetic-based
rescue experiments of disease models, or pharmaceutical-based modification of
autophagy. A prevailing theme in the field is that autophagy can either be beneficial or
deleterious depending on the disease and its progression state, a theme which must be
addressed in designing and implementing appropriate treatment regimes.
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Chapter Three: Post-pubertal mammary gland development: morphology and
mechanisms
Introduction
This chapter has been published and is included here for completeness of the
dissertation.290
Interest in the mammary gland, the defining characteristic of the class Mammalia,
has stretched across centuries. The primary function of the mammary gland across
mammals is the nourishment of young; however additional functions, such as the
transmission of immune factors to infants, are important in many species. It has been
postulated that mammary glands arose evolutionarily from modified apocrine glands
recently in evolutionary history, approximately 125-190 million years ago.291 Obtaining
evidence for these theories has been technically challenging, since the soft tissue of
mammary glands is not well preserved in the fossil record. However, we can gain insight
from Monotremata, an order of ancient egg laying mammals that represents an
interesting link to the reptilian past. The platypus and echidna are extant egg laying
species that have functional mammary glands that undergo a true lactation phase. This
lends support to the postulation that early apocrine secretions served some beneficial
role to protect and/or nourish eggs via semi-permeable shells, thus selecting for the
retention of these glands.291 While the evolutionary origin of the mammary gland is still
being investigated and debated, developmental and molecular biologists have made
astounding progress in elucidating the mechanisms controlling the development of the
mammary gland in its current incarnation.
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The mature mammary gland is an arboreal structure with ductal branches extending
from a nipple area, colonizing a mammary fat pad, and finally branching and terminating
into alveolar units. Mammary gland development is divided into four stages that align
with the overall growth, sexual maturation and reproductive-associated changes of
mammals, which are: embryonic, pre-pubertal, pubertal, and post-pubertal. The
initiation of mammary development in embryos occurs during gestation with the
establishment of the anlagen; however, the majority of development occurs in the adult
animal. Branching and elongation of the ductal epithelium ensues at the time of
puberty, with the expansion of the alveolar epithelium proceeding in response to
pregnancy. However, terminal differentiation is not achieved until lactation. This
periodic developmental profile is unique amongst tissues and lends the mammary gland
as an excellent model to study branching morphogenesis and other developmental
paradigms in an adult animal. Furthermore, the accessory nature of the mammary gland
is ideal since it allows researchers to make otherwise deleterious mutations in this
relatively large, and easily accessible tissue. Classically, post-pubertal development has
been separated into four main stages: virgin, pregnant, lactation, and involution
(schematically represented in Figure 3.1 and whole mounts in Figure 3.2). These stages
will be discussed individually following a description of embryonic and pre-pubertal
development.

Fetal Development and Pre-Pubertal Development
Although the focus of this chapter is post-pubertal development, it would be
incomplete without a brief overview of embryonic and pre-pubertal mammary
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development. In the interest of continuity, the mouse will be the primary focus of this
chapter and only major developmental discrepancies will be addressed. In most studied
mammalian species mammary lines, ridges of multi-layer ectoderm become visible on
the ventral surface of the embryo running parallel to the anterior-posterior axis of the
embryo between the limbs. The mammary lines, as anatomically evident structures, are
controversial in the mouse; however, specific gene expression patterning corresponding
to proposed mammary line location has been observed. Wnt10b can be detected in a
restricted pattern and Wnt6 in a broader area just antecedent to the anatomical
detection of anlagen presence.292 Histological analysis revealed a change in epithelia colocalizing with the Wnt10b expression, specifically a change to multi-layered cuboidal
epithelia from the surrounding squamous epithelia. In addition, the mammary line also
has a characteristic dense dermis below it.292 In the mouse, the first visible surface
feature of mammary development is five symmetrical pairs of mammary placodes at
E11.5. Interestingly, unlike other models, the mouse placodes do not follow an anteriorposterior developmental pattern. Instead, they proceed pairwise in the order,
numbered anterior-posterior: 3, 4, 1 and 5, then 2. Mammary placodes retain their
expression of Wnt10b, Wnt6, fibroblast growth factor (Fgf10), and Lymphoid enhancer
binding factor 1 (Lef1), a WNT pathway effector. Lef1-/- embryos fail to develop placodes
by E13.5, a phenotype shared by overexpression of Dkk1, a WNT pathway inhibitor.293,
294

Studies on placode development by Mailleux et al revealed distinct signaling

dependence. The thoracic placodes (1, 2, and 3) and the number 5 inguinal placode are
dependent on FGF10/FGFR2b while placode 4 is independent of these signals.295 Of late,
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bone morphogenic protein 4 (Bmp4) and T-box protein 3 (Tbx3) have also been shown
to work synergistically to determine positioning of the mammary buds. For a more
detailed review of signaling pathways involved in morphogenesis and associated
mutants see references.296, 297
After the buds become visible at E13.5, there is a brief resting phase during which
very few cells are mitotically active. Beginning again at approximately E15.5 and
persisting through gestation, each bud extends a small sprout and invades the
mammary fat pad precursor. The sprouts are completed by the formation of a lumen
and by E18.5 each duct has undergone branching and resembles a small ductal tree. The
interaction of parathyroid hormone related peptide (PTHrP) and its receptor PTHR1
drives the rudimentary ductal tree to branch. At the time of parturition, the immature
mammary gland is comprised of approximately 10-15 small branches near the nipple.

Puberty
Mammary gland growth is isometric with the individual from approximately E18.5
until puberty, wherein the development will resume under the control of hormones.
The ductal tree is primarily established during puberty under the control of circulating
hormones. These circulating hormones bind to receptors located in the pituitary gland
and throughout the female reproductive system to initiate changes in gene expression.
Estrogen receptor (EsR) and progesterone receptor (PR) are instrumental during this
period and will be discussed in depth in sections that follow.
At approximately 3-4 weeks of age the ducts become capped with mitotically active,
club-shaped structures termed terminal end buds (TEBs). TEBs are composed of inner
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“body” cells and outer, undifferentiated “cap” cells. The body cells differentiate into
mammary epithelial cells. The cap cells ultimately differentiate into myoepithelial cells.
The innermost layer of body cells undergoes apoptosis to form the hollow lumen. The
programmed cell death rate in the presumed lumen is very high, with a rate far greater
than that detected during involution when the entire gland undergoes remodeling.298
TEB formation is dependent on the paracrine production of IGF-1 by stromal cells which
respond to growth hormone, reviewed in reference.299 The TEBs vary both among
glands within an animal and between animals at the same time point. The number 2 and
3 glands have larger number and size of TEBs when compared to the number 4 inguinal
mammary gland. The size difference of the TEBs is attributed to a larger number of cap
cells rather than cell hypertrophy.300 Circulating estrogen (E2) stimulates allometric
ductal elongation via TEB proliferation which terminates when the TEBs reaches the
limit of the fat pad. Concomitantly, secondary ductal branches are formed off of the
primary ducts by TEB division. After expansion of the ductal tree during puberty, TEBs
are permanently replaced by terminal end ducts (TEDs) which are not mitotically active.
TEDs are then surrounded by stroma with the center cells undergoing apoptosis. The
resultant structure is a single layer of epithelia cells resting on a basement membrane.
The gland remains in this mature virgin state until stimulation by pregnancy.

Pregnancy and Lactation
Pregnancy hormones stimulate further branching of the ductal tree, the
development of the lobuloalveolar compartment, and the terminal differentiation of the
secretory epithelia. The ducts are composed of three major layers; the most apical is a
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single layer of cuboidal epithelial surrounding a hollow lumen, this layer is referred to as
“luminal epithelia.” Basal to the luminal epithelia, specialized myoepithelial cell layer
encircles the luminal epithelia; these cells contain smooth muscle actin and assist with
ductal contraction and movement of milk during lactation. Beyond the myoepithelial
cells, a tough laminin-enriched basement membrane separates the epithelia and the
surrounding connective tissue with a layer of extracellular matrix (ECM) proteins
including proteoglycans and glycoproteins.
The epithelium of the alveoli is a single layer of squamous epithelium which is
discontinuously surrounded by myoepithelial cells then finally a basement membrane.
As pregnancy progresses, the myoepithelia becomes more discontinuous and the
alveolar epithelium may contact the basement membrane directly. During late
pregnancy, approximately pregnancy day 18.5, the alveolar epithelial cells produce milk
proteins and lipids which are retained in the cells, causing them to appear more
cuboidal or pyramidal due to the increased cytoplasmic volume. After the initiation of
lactation, milk proteins and lipids are released into the alveolar lumen and the cells once
again appear morphologically flattened. This is achieved in part by the contraction of
the myoepithelial cells lining the alveoli in response to oxytocin. At this point, large milk
fat droplets can be seen in the lumens. The alveoli continue to expand throughout
lactation until the gland is completely filled. During the height of lactation, very few
adipocytes can be visualized and the ratio of parenchyma to stroma is heavily weighted
toward the parenchyma. The lactation phase will continue until the pups are weaned or
gradually taper off as the pups begin to gain nourishment from other sources.301 The
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pregnancy associated changes: ductal branching, lobuloalveolar development,
proliferation, and differentiation are highly regulated processed. The signaling cascades
responsible will be discussed at length in later sections.

Involution
Cessation of suckling, due to natural or acute weaning and milk stasis, results in the
mammary gland remodeling to again resemble a resting, “virgin-like” state. Involution
proceeds in two stages: the reversible stage and irreversible stage. The early, reversible
stage is characterized by waves of apoptosis-mediated cell death. Transcriptional
profiling studies have detected changes within hours of involution.302-304 Histologically,
secretory epithelia cells are sloughed and seen in alveoli in greater numbers during early
involution than in any other stage. Many of these cells are terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) positive, a marker for apoptosis that detects
DNA fragmentation.305 It is estimated that during involution 80% of epithelial cells will
die via apoptosis, a catastrophic event unparalleled in normal adult tissues. Many
induced mutant mouse models generated exhibit involution phenotypes, see Radisky
and Hartmann for review and references.306
The second phase of involution is initiated approximately 72 hours post-lactation
and is more drastic in nature. Once the gland has entered this phase, lactation cannot
be re-initiated even if the pups are returned to the dam. The superfluous secretory
alveoli collapse, the ECM is remodeled, and adipocytes increase in number. The
irreversible phase is characterized by and dependent upon on a temporal increase in
matrix metalloproteinase activity (MMPs) to stimulate ECM remodeling. Invasion of
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immune cells, primarily phagocytic cells such as macrophages, helps to clear cellular
debris.
Autophagy most likely plays a role during mammary involution though at present
this is poorly described in murine models. Autophagy, Greek for “self-eating,” is a highlyconserved catabolic process initiated in response to cellular stress. In bovine, autophagy
is observed morphologically and detected with molecular methods during involution.
Additionally, pro-autophagic protein BECLIN1 has been shown to play an important role
in mediating involution. It is clear that more work needs to be done to elucidate the role
of autophagy during this stage in murine models.307-309

Signaling Pathways
Msx Family
The class II homeobox, msh-like (Msx) genes, Msx1, Msx2 and Msx3, are common to
vertebrates and often define mesenchymal-epithelia interaction sites. Msx3 expression
is restricted to the dorsal neural tube310, while Msx1 and Msx2 are more broadly
expressed during embryogenesis. Msx1 and Msx2, but not Msx3, are expressed at
varying levels during every stage of mammary development except for pregnancy.
During embryonic development Msx2 expression is detectable both in the epithelia and
the mesenchymal cells, while after parturition expression is restricted to the
mesenchymal cells in close proximity to mammary ducts. Msx2 expression is dependent
on reciprocal interactions with epithelial cells. In cleared fat pads Msx2 is undetectable,
indicating an essential epithelia interaction compartment for normal expression. Msx2
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expression, but not Msx1, is regulated by E2 and progesterone (P4), indirectly via the PR
and directly as a transcriptional target respectively.311
Msx2 is implicated in the regulation of branching, as the in vitro overexpression of
Msx2 is sufficient to drive branching. In addition, in vivo approximately one third of
Msx2 null mice have arrested embryonic mammary gland development with failed
ductal branching.312 Msx1 null neonates do not exhibit a mammary defect, which is not
surprising since homeobox genes typically exhibit high levels of functional
redundancy.313 However, double knockout Msx1/2 mice fail to form mammary anlagen
with a complete penetrance of the phenotype.312 Mice that misexpress Msx1 in the
mammary gland exhibit a reduction in pregnancy-induced differentiation and an
increase of Cyclin D1 (Ccnd1) expression, and an increase in cell proliferation. This model
supports in vitro experiments with Msx-1 overexpressing HC11 mammary epithelial cells
which upregulate Ccnd1 expression and are unable to undergo functional differentiation
in response to lactogenic hormones. The authors propose that Msx1 prevents exit from
the cell cycle, which drives an upregulation of Ccnd1 expression; ultimately, this
proliferative cell fate prevents the terminal differentiation of the epithelial cells.314
Although Ccnd1 is the only verified target of Msx1 in the mammary gland identified to
date, it can also be induced by Msx2 most likely in response to hormonal signaling by E2
and P4. Interestingly, expression profiles of Bmp2 and Bmp4 closely resemble the
profiles of Msx1 and Msx2, respectively. It has been suggested that this indicates a
regulatory relationship, though the nature of this relationship is yet to be determined
owing to the early embryonic lethality of Bmp2 and Bmp4 null mice.315
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Lef1
Lef1 is a nuclear target of the Wnt signaling pathway. In the presence of Wnt
signaling, dephosphorylated β-catenin enters the nucleus and engages Lef1 to act as a
transcriptional activator. Therefore, in the absence of Wnt signaling, Lef1 is a
transcriptional repressor. Lef1 null neonates lack teeth, whiskers, and hair in addition to
lacking mammary glands. Closer inspection of E13.5 embryos revealed a reduced
number of mammary buds, indicating that the mammary rudiment develops
improperly, arrests, and then regresses by the time of parturition. Since other visceral
organs were unaffected, the defect seems to be specific to organs requiring epithelia of
ectodermal origin to interact with surrounding mesenchyme.293

Hormones
Through both endocrine ablation studies and targeted mouse transgenic models it
has been elucidated that E2, P4, and prolactin (PRL) drive the pregnancy-induced growth
and differentiation of the mature mammary gland. P4 is an ovarian hormone secreted
by a temporary endocrine structure within the ovary, the corpus luteum. PRL is a
peptide hormone that signals through PRL receptors (two isoforms, PRLRA and PRLRB).
Together, these hormones are responsible for initiating complex, and sometimes
intersecting, gene pathways responsible for branching and alveologenesis during
pregnancy. Transgenic mouse models have illuminated many of the signaling pathways
that will be discussed in this chapter. For reference, a table has been included with a
synopsis of the models discussed, see Table 3.1.

91

E2/EsR
E2 is a steroid hormone with two characterized receptors, EsRα and EsRβ, which are
members of the nuclear receptor superfamily. The canonical method of activation is: 1)
ligand binding, 2) conformational change of receptor, 3) co-activator recruitment, and 4)
dimerization and binding of receptor to estrogen responsive elements (EREs) in gene
regulatory regions. Several ligand-independent, non-canonical pathways of EsR
activation have been described but are beyond the scope of this chapter. The expression
patterns of the two EsRs are distinct but overlapping, and EsRα is the dominant receptor
type expressed in the mammary gland. Three knockout mouse models have been
generated to study the importance of EsR in the overall growth and development of the
organism. EsRαKO, EsRβKO, and EsRα/EsRβ double knockout (EsRαEsRβKO) mouse
models are all viable and progress to adulthood without defects.316-318 EsRαKO, EsRβKO,
and double knockout (EsRαEsRβKO) do not show defects in embryonic or pre-pubertal
mammary gland development, but after puberty females exhibit ovulation failure
resulting in infertility or subfertility (EsRβ). EsRαKO mice do not undergo the expected
ductal elongation and expansion during puberty. The ductal tree remains sparse with no
lobuloalveolar development occurring.319 Transplantation experiments of EsRαKO
epithelia into wild-type cleared fat pads developed without defect to puberty as
expected, but failed to undergo any development in response to pregnancy. This effect
is epithelia intrinsic since the converse experiment; EsRαKO fat pad grafted into a wildtype host with wild-type mammary epithelial cells grows normally and responds to
pregnancy hormones.320
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EsRβKO females are sub-fertile, yet develop normal mammary glands and are able to
undergo a normal lactation phase.317 EsRαEsRβKO mammary glands phenocopy EsRαKO
mammary glands, further underscoring the importance of EsRα in this tissue. EsR
ablation causes defects in many reproductive tissues beyond the mammary gland and
ovary, see reference for review.321
The detection of residual expression from the EsRαKO necessitated the generation
of a true null allele. To address this, the Cre-LoxP system was used to generate an EsRα
floxed model for tissue-specific deletion strategies. Initially, a global Cre-mediated
deletion was analyzed and the results phenocopied the EsRαKO model.322 An EsRβ
conditional knockout based on the Cre-LoxP system has also been generated using a
similar targeting strategy as was used to generate the conditional EsRαKO allele. LoxP
sites were inserted flanking exon three of the EsRβ gene.323 Exon three was chosen to
ensure a true null allele and effectually reconcile conflicting reports of phenotypes of
the EsRβKO mice due to varying generation and housing conditions. In the context of
the mammary gland, these models will be important to define the temporal
requirement, if any, of EsR in pregnancy-induced mammary gland development. Using
any one of the current mammary directed Cre transgenic models, EsR could be
effectively attenuated at any point in the pregnancy cycle.
As a supplement to many of the previously mentioned loss-of-function models, an
inducible, EsRα model has also been generated using the tetracycline system. In this
MMTV-tTA/tet-op-mEsRα model overexpressed EsRα, and administration of doxycycline
turns off expression of EsRα.324 These recent models, will be invaluable in further
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characterizing the role of EsR in reproductive development and in oncogenesis when
used combination with current cancer models.
P4/PR
P4 is a steroid hormone produced primarily in the ovary and adrenal gland of
females. Its activity oscillates with the estrous cycle and is required for the
establishment and maintenance of pregnancy. P4 is a ligand for the PR, a nuclear
receptor superfamily member. Once the ligand is bound the ligand/receptor complex
translocates to the nucleus and affects transcriptional activity of target genes either
directly or indirectly. The PR has two receptor isoforms, PR alpha and beta (PRA/PRB),
which are splice variants of the gene Pgr.325, 326 The two receptors are structurally
similar with the exception of an amino terminal extension of PRB.326, 327
Since PR is under control of E2, a targeted approach to sort out the function of P4
independent of E2 was needed. The PR knockout mouse (PRKO) is viable and shows no
overt defects through embryogenesis or adulthood. As expected, female mice are
infertile, due to the well characterized role of P4 in establishment and maintenance of
pregnancy. However, a surprising role for P4 in the mammary gland was revealed. PRKO
females produced a rudimentary ductal structure, indicating the P4 was not essential for
ductal elongation, but failed to proliferate and undergo normal lobuloalveolar
development and ductal side-branching in response to hormonal stimulation.328 This
original characterization established a role for PR in normal mammary development and
during pregnancy, but was insufficient to distinguish between systemic and local effects.
To this end, several approaches have been taken to dissect the effect of PR in the
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mammary gland. Transplantation experiments wherein mammary epithelia from PRKO
mice were transplanted into wild-type recipients and vice versa revealed that intrinsic
PR expression was essential in the epithelia for ductal outgrowth in response to
circulating hormones and for lobuloalveolar development during pregnancy.329-332 A PRLacZ reporter helped to clarify the PR expression in both spatial and developmental
contexts. During development, the activity is restricted to the epithelia; however, at
puberty the activity is high in the body cells of the TEBs and ductal luminal cells. The
localization pattern changed in the adult where the activity is clustered around the
terminal ductal side branches, and all activity is reduced toward the end of pregnancy at
the time of terminal differentiation.333 Interestingly, in the juvenile PR expression is
uniform, but in the mature gland only sub-populations of mammary epithelial cells are
PR positive, confirming earlier studies.334
Isoform specific function was addressed elegantly with the generation of PRA and
PRB-specific knockout alleles (PRAKO, PRKOB). The PRAKO did not show abnormal
effects in the mammary gland, indicating that PRB was of greater importance in this
tissue.335 This was confirmed with the PRBKO model that exhibited reduced ductal side
branching and lobuloalveolar development during pregnancy.336 Importantly, this study
also revealed an isoform specific activation of receptor activator of nuclear factor κβ
ligand (RANKL) by PRB, the importance of RANKL in mammary morphogenesis will be
addressed in another section focusing on receptor activator of nuclear factor κβ (RANK)
signaling.
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Two Cre-LoxP-based conditional PR knockout models have been produced allowing
for greater spatial and temporal control of PR ablation. The models differ by targeting
strategy, either exon 1 or exon 2 is flanked by LoxP sites, yet both produce homozygous
null animals that phenocopy the original PRKO.337, 338 Additionally, a knock-in of the
reverse tetracycline-dependent transactivator (rtTA) at the PR locus (driven by the
endogenous PR promoter) has been helpful in identifying target genes of PR signaling.339
These mice (PRrtTA/rtTA) phenocopy the PRKO model, and when treated with doxycycline
PR promoter driven rtTA can induce expression of PR target genes in P4 responsive cells.
This model combined with a reporter transgene allowed for the precise identification of
PR responsive cells. In concordance with earlier studies, this model has confirmed the
non-uniform pattern of PR expression in mature mammary epithelial cells, and has
importantly clarified the role of RANKL as an effector of PR dependent side branching
and alveologenesis.334, 339, 340 These models will be useful in separating tissue intrinsic
functions from systemic effects of PR deficiency and are applicable to many studies of
reproductive biology beyond the mammary gland.
RANKL/RANK
RANK is present on mammary epithelial cells and when activated by its ligand,
RANKL, is a mammary PR effector which is essential for mammary proliferation and
morphogenesis during pregnancy.341 In wild-type animals, RANKL is upregulated in
response to P4 only in PR-positive cells, and PR-positive/RANKL cells cause proliferation
in a paracrine fashion. This regulation was tested in vivo in a PRKO background with a
conditional induction of RANKL targeted only to cells that would normally express EsR,
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PR, and RANKL. With induction of RANKL by drug administration, the mammary defect
observed in PRKO mice can be partially rescued.340 This study highlighted the
importance of the spatial organization of PR positive cells and showed that when RANKL
was induced in PR-negative and PR-positive cells, the ductal outgrowth and alveolar
development was disorganized. RANKL/RANK leads to nuclear factor κB (NFκB)
dependent transcriptional activation of Ccnd1, and disruption of RANKL or the
components of this pathway result in a defect in alveolar proliferation.342 These studies
are supported by the Ccnd1 knockout mouse which has reduced lobuloalveolar
development during pregnancy and fails to lactate.343
Recent evidence has revealed that RANKL serves as an intersection point between
P4 and PRL signaling. Srivastava et al. suggest that RANKL is induced by both P4 and PRL
signaling and is dependent on Janus kinase 2 (JAK2)/ signal transducers and activators of
transcription 5a (STAT5a) signaling.344 Other points of intersection of P4 and PRL
signaling and their potential consequences are reviewed in reference.345 RANKL
regulates CCAAT-enhancer binding protein (C/EBP), to which we will now turn our
attention.
C/EBP
Of the six C/EBP transcription factor family members, C/EBPβ’s three protein
isoforms seem to be the most important for mammary gland development, though
other family members are expressed.346 C/EBPβ is expressed throughout mammary
gland development but is lowest in the virgin, increases during pregnancy, is reduced
modestly during lactation, and then is increased again during the reversible phase of
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involution.347 Ablation of C/EBPβ causes defects in ductal outgrowth manifested by
enlarged ducts and decreased branching.348, 349 During pregnancy (transplantation or
hormone supplementation experiments were required due to infertility of C/EBPβ -/mice), ductal outgrowth occurred but lobuloalveolar development is negatively affected.
Another family member, C/EBPδ, has an important function in involution. The
C/EBPδ knockout mice exhibit a delayed involution phase characterized by a delay in the
appearance of apoptotic cells, indicating a role in early involution, a time when C/EBPδ
expression is highest in wild-type glands. Expression analysis revealed a reduction in the
levels of pro-apoptotic BAX and BAK, and an increase in anti-apoptotic Bcl2l1. STAT3 is
responsible for activating C/EBPδ at the initiation of involution. These results position
C/EBPδ as a regulator of involution-induced cell death.350
Cytokine Signaling, Stat6, and Alveolar Commitment
STAT6 is unique amongst STATs in the mammary gland as it is important early in
gestation and is not directly downstream of PRL signaling (discussed below). Classically,
Stat6 has been characterized as a vital signaling molecule in the T helper (Th) cell
lineage, specifically in the differentiation of Th2 cells. In this context, interleukin (IL) IL4/IL-13 binds its cognate receptor leading to activation of JAK1 and TYK2 which in turn
facilitate recruitment and activation of STAT6. STAT6 forms homodimers which
translocate to the nucleus activating or repressing IL-4/IL-13 target genes including
GATA binding protein, 3 (GATA3), a transcription factor, reviewed in references.296, 351
More recently, however, a new role for Stat6 regulating mammary alveolar cell fate has
emerged. In two transgenic models interrogating this pathway, concomitant IL-4/IL-13
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knockout or Stat6 knockout, resulted in curtailed alveolar development when compared
to controls. Furthermore, in glands lacking SOCS5, a STAT6 inhibitor, accelerated
development of the alveoli is observed.352
Further support for this pathway’s importance in mammary gland proliferation and
differentiation is provided by two studies centering on GATA3, a transcription factor and
target of IL-4/IL-13/STAT6 signaling. In mice with a conditional deletion of GATA3 before
the onset of puberty and continuously thereafter (MMTV-Cre; Gata3fl/fl), TEBs fail to
develop punctually and the ductal epithelia does not invade the fat pad. At 8 weeks of
age, a few TEBs are observed but these are unable to invade the fat pad. Additionally,
the ducts that are present show a myriad of defects including structural defects and
irregular ductal epithelia. Due to clonal expansion of GATA3-positive cells, the authors
generated an acute, drug inducible Gata3 model wherein the rtTA-Cre is driven by the
whey acidic protein (WAP) promoter (WAP-rtTA-Cre; Gata3fl/fl). These mice were
administered doxycycline at 12 weeks of age and the drug was given for 14 days. By the
fifth day of drug administration, defects in luminal epithelia were observed, reminiscent
of those observed in the MMTV-Cre; Gata3fl/fl model. Importantly, in the GATA3deficient glands, luminal epithelia cells lost markers of differentiation and proliferated at
a higher rate. Longer term deficiency led to cell death and defective lactation.353 A
second study also reports similar phenotypes for GATA3 loss in the pre-pubertal gland.
Two additional models are included in this study, a model of GATA3 deficiency in the
mammary primordia (keratin14-Cre; Gata3 fl/fl), and one that causes loss GATA3 during
gestation (WAP-Cre; Gata3 fl/fl). Embryonic loss of GATA3 in the mammary primordia
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results in absent mammary placodes (one or more) and ablation of Lef1 expression in
the expected areas of placode formation, though any placodes formed in the mutant
animals also expressed Lef1. Loss of GATA3 during gestation results in defective
lobuloalveolar development and lactation.354 These studies have indicated a clear role
for GATA3 in formation of the mammary placodes in the embryo, ductal morphogenesis,
maintenance of luminal cell differentiation in mature glands, pregnancy-stimulated
lobuloalveolar development, and lactation. Based on these studies, the importance of
the Th2 producing signaling pathway is important for mammary development, and adds
more complexity to the tightly regulated PRL and P4 cell signaling that has been
previously characterized.
PRL and JAK/STAT Signaling
PRL is a small peptide hormone produced primarily in the anterior pituitary, but may
also be produced in other peripheral tissues. PRL historically has been characterized as a
factor necessary for pregnancy-induced mammary alveolar development and lactation,
for historical references see reference.355 PRL binds to the PRLR to initiate JAK/STAT
signaling. PRLR dimerization causes activation of JAK2. JAK2 phosphorylates three target
STATs depending on the stage of mammary gland development: STAT1, STAT3 and
STAT5. Canonically, phosphorylated STAT forms dimers and then translocates to the
nucleus. Dimers bind conserved, palindromic sequences (TTCNNNGAA) termed γinterferon activation sites (GAS), in gene promoter/regulatory regions to regulate the
initiation of target gene activity.
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PRL knockout mice (Prl-/-) are viable, but females are infertile and mammary gland
development is defective, manifesting with a fully developed ductal tree devoid of
lobuloalveolar units. Since the females are infertile, stages beyond the mature virgin
gland were not analyzed.356 PRLR knockout mice fail to lactate and the glands appear
poorly developed with few branches at maturity. Interestingly, multiparous females that
are hemizygous for the PRLR knockout allele (Prlr+/-) regain mammary function,
indicating a response to repeated hormone stimulation.357, 358 The next component in
the cascade, JAK2, also has pleiotropic roles in both embryonic and post-natal
development.
Since the traditional Jak2 knockout mice (Jak2 -/-) die during embryogenesis due to
defective hematopoiesis leading to severe anemia, a conditional knockout approach to
study Jak2 in the post-pubertal mammary gland was warranted.359, 360 Wagner and
colleagues developed a conditional deletion Jak2 model (Jak2fl/fl), and using two Cre
transgenic strains (MMTV-Cre and WAP-Cre) showed that JAK2 signaling is necessary for
both development of alveolar progenitor cells in mature virgin glands, as well as
maintenance and survival of the secretory epithelium in pregnant mice.361 These
functions are non-redundant and data indicates that STAT5 is activated only in a JAK2dependent fashion.
The transcription factor STAT5 is produced by both Stat5a and Stat5b, two highly
related genes derived from a recent gene duplication event.362 In mammary tissue,
Stat5a is the more abundant and is responsible for 70% of STAT5 present.363 During late
pregnancy and lactation, phosphorylated STAT5 increases precipitously, most likely due
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to its activation of β-casein and WAP, genes that increase dramatically in preparation for
lactation. Knockout studies have revealed independent and overlapping roles of Stat5a
and Stat5b. Mammary glands from Stat5a knockout females (Stat5a -/-) fail to develop
characteristic lobuloalveolar structure and exhibit a complete lactation failure during
the first pregnancy.364 It is important to note that even though Stat5a and Stat5b share
96% similarity, Stat5b does not compensate, indicating either an independent function
or independent regulation.363 After multiple rounds of pregnancy, lactation phase is
sustained, which may be attributed to a late compensatory increase in Stat5b.365 Stat5b
knockout mice are viable and fertile, the mammary glands appear normal, and the
primary reported defects are ablation of sexually dimorphic growth differences and
liver-specific gene expression.366 Stat5a/b double knockout mice are infertile due
ovarian dysfunction, specifically defective corpus luteum formation. Owing to the
aforementioned infertility phenotype, Teglund et al. were unable to study the effects on
mammary gland development but were able to conclude that either individually or
cooperatively Stat5a and Stat5b mediate essentially all PRL and growth hormone
dependent development.367 In effort to investigate Stat5a/b null mammary
development, Stat5a/b null glands were transplanted into wild-type recipients. These
glands developed a ductal tree but did not undergo alveolar morphogenesis, indicating
that STAT5 is necessary for the proliferation and differentiation of mammary alveoli.368
The role of STAT3 in the mammary gland is best characterized as a harbinger of
death, as phosphorylated STAT3 increases dramatically at the onset of involution (within
12 hours) and precedes the wave of post lactation apoptosis and alveolar collapse.369, 370
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The involution-associated cell death is dependent only on local factors such as
mechanical stress due to milk stasis.370 STAT3 activation is dependent on several
secreted factors, namely leukemia inhibitory factor (LIF)371, 372, serotonin 373 and TGFβ3.374 Stat3 null animals die during early embryogenesis (E7.5), with the lethality
attributed to a defect in visceral endoderm function.375 Conditional deletion of Stat3 in
the mammary gland, driven by either WAP-Cre or β-lactoglobulin- Cre (BLG-Cre), both
result in delayed involution and an extension of the reversible phase.376, 377
Of late, the mechanism of cell death during early involution is being revisited due to
the observed delay in TUNEL positivity of shed cells, and cell morphology that does not
align with classical apoptotic condensation, fragmentation, and membrane blebbing.
Recent work from the lab of Christine Watson suggests that the cell death is a STAT3driven, cathepsin-dependent and executioner caspase-independent, lysosomalmediated programmed cells death.378, 379 This study necessitates re-evaluation of
foundational literature and warrants further and more directed attention.
The level of STAT1 remains constant throughout the pregnancy cycle; however,
active STAT1 is detected in the virgin gland and in the late involution gland. This pattern
of pSTAT1 is a unique amongst STATs and the inverse of the pSTAT5 profile.370, 377 No
clear role has been defined for Stat1 in mammary development, and Stat1-/- mice are
viable showing no overt developmental or mammary gland defects.380

Cell Death Signaling
It is currently thought that of the cells that die during involution, the vast majority
die by the classical apoptotic pathway. Apoptosis is a highly regulated, well described
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process wherein a cascade of intracellular signaling is initiated in response to an
extrinsic or intrinsic signal. It is thought that a balance of pro-apoptotic and antiapoptotic factors determines cell fate. The Bcl2 protein family namesake, anti-apoptotic
Bcl2, is not expressed during lactation or early involution, but its expression increases in
late (>10 days) involution. Based on this expression profile it is not surprising that Bcl2
knockout mice do not exhibit a gross mammary defect. Global ablation of Bcl2 (Bcl2-/-) is
not lethal, resulting in small, hypopigmented mice with polycystic kidney disease.381
Overexpression of Bcl2 driven by the WAP promoter results in a delayed involution.382
Studies have revealed that Bcl2l1 is expressed at higher levels than Bcl2 in many tissues
during development and in the adult, including the mammary gland.383, 384 The
traditional knockout (Bcl2l1-/-) is not viable and dies embryonically due to excessive
apoptosis of immature erythroid cells in the fetal liver.385 This model provided valuable
information regarding the role of Bcl2l1 during development, but the embryonic
lethality was prohibitive to study the role of Bcl2l1 in mature tissues. As a result two
conditional, mammary specific Bcl2l1 knockout mouse models (WAP-Cre; Bcl2l1fl/fl,
MMTV-Cre; Bcl2l1fl/fl) were generated. Bcl2l1 deficient mammary epithelia tissue
exhibited an accelerated involution, a phenotype characterized by an increase in
apoptosis, indicating that Bcl2l1 is necessary for cell survival during early involution.386
Pro-apoptotic factors include Bcl2 family members Bax, Bad, and Bak among others.
Bax mRNA is highest at the lactation to involution transition and three splicing products
are produced, however the protein level is unchanged.387 Bax deficient mice intuitively
exhibit hyperplasia in some cell lineages (e.g. B cells, thymocytes); however,
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counterintuitively males are infertile due to the absence of mature sperm and abnormal
mammary development has also been reported.388, 389 Loss of Bax delays involution,
while overexpression of BAX in the mammary secretory epithelia in a WAP-Bax model
results in a lactation defect as well as forced involution based on an increase in
apoptotic cells and precocious Stat3 activation.387, 390 Bak and Bad are present
throughout pregnancy and remain expressed highly through involution. It is
hypothesized that the mammary gland is persistently poised to trigger involution and it
is the balance of pro-apoptotic and anti-apoptotic factors determines lactation to
involution transition.387, 391
The nature of cell death signaling that occurs throughout the developmental cycle of
the mature mammary gland is complex. In many cases canonical functions of proteins
are observed, but many surprising roles have been elucidated using transgenic
technologies.

Conclusion
The mammary gland is a dynamic organ that is reliant upon hormones, growth
factors, and epithelial-stromal interactions to regulate well-established cell signaling
pathways that orchestrate highly regulated developmental programs. These events span
from mid-gestation into adolescence and through adulthood, when terminal
differentiation occurs within a cyclical pattern of growth and regression that is linked to
reproduction. Due to the accessory nature of the gland, ease of accessibility, and
transplantation potential, the mammary gland is a powerful model to characterize the
genetics behind organ development and cell differentiation. In addition to its relevance
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in modeling normal development, the mammary gland is also essential in profiling
breast cancer, neonate immunity, ageing and stem-cell based regeneration. The
blossoming of mouse transgenic technologies over the past twenty years has led to
breakthroughs in the understanding of the underlying mechanisms controlling
mammary gland development. The early endocrine ablation studies that revealed the
pituitary and ovarian control of mammary gland development eventually led to
genetics-based approaches to further characterize these processes. Genetic engineering
has advanced from gain-of-function studies to knockout strategies, giving way to the
current state of conditional (Cre-LoxP, Flp-FRT) and inducible (tet-on, tet-off) models.
This increased specificity for inducing mutations has allowed researchers to investigate
gene and signaling pathway contributions at restricted developmental stages. Although
the genetic tools will continue to expand and increase the array if potential applications,
technology is but a tool to address the basic biological questions that remain in the field.
What is the nature of the crosstalk between the hormonal receptors? Which, if any, of
the other immune cell lineage pathways are relevant for mammary cell lineage
commitment? What are the specific regulatory mechanisms at work regulating the
upregulation of target genes controlled by multiple transcription factors? How do
microRNAs regulate the developmental program of the mammary gland? How do
apoptosis and autophagy interact to promote regression during involution? How does
the methylation state of DNA and histones impact development? These questions and
many others will continue to propel this field in the coming years.
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Figure 3.1 Schematic overview of mouse mammary gland development and major
influencing factors. Mammary gland development is typically divided into embryonic,
perinatal, puberty and adult stages. After sexual maturity pregnancy induced changes
drive the terminal differentiation of the gland. These stages are pictured; pregnancy,
lactation and involution. Many of the influential molecules discussed in this chapter are
included in the figure above the developmental stage/process to which they are
integral. Major developmental stages are depicted schematically; stage labels are below
mammary glands and process labels are below arrows.
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Figure 3.2 Anatomic overview of mouse mammary gland development at four stages.
Whole-mounts were taken of mouse mammary glands at four distinct developmental
stages: A) virgin 5-week-old glands; B) pregnancy day 14; C) lactation day 1; and D)
involution. Epithelial cells stain with the dye carmine alum, whereas the surrounding fat
pad is cleared. Notice in the virgin gland the formation of the ductal tree, as the
epithelia migrate into the surrounding fat pad. Representative terminal end buds (TEBs)
are shown with arrows. Lymph nodes (LN) are shown for orientation in all figures.
Images were taken on an Olympus SZ-PT using 6.7X magnification and the imaging
software QCapture Pro 6.0.
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Table 3.1 Transgenic mouse models and mammary phenotypes observed
Embryo
Lef1
Dkk1

Msx1
Msx2

Msx1/Msx2
Puberty
Esr1

Genotype

Mammary phenotype

Reference

lef1 -/K5-rtTA/tetODkk1
(overexpression)
msx1-/msx2-/-

No placode formation
No placode formation

293
294

No phenotype
1/3 of embryos arrest
mammary development
before ductal
branching/perinatal
lethality
Anlagen fail to form

313
312

No ductal side-branching
or lobuloalveolar
development
No data
Toolbox/kinetics study

316, 319

No phenotype
No phenotype
same as EsRα-/Enlarged ducts/decreased
side-branching

319,317
323
318
348,349

Reduction in
differentiation/increase in
proliferation
No ductal side-branching
or lobuloalveolar
development in response to
hormonal stimulation
No phenotype
Reduced ductal sidebranching and
lobuloalveolar
development
Same as PR-/Same as PR-/Reduced lobuloalveolar
development in response to
hormonal stimulation

314

msx1/msx2-/EsRα-/-

Esr1/ Esr2
Cebpb (C/EBPβ)

deleter-Cre; EsRαf/f
MMTV-tTA/tetop-mEsRα
EsRβ-/CMV-Cre; EsRβf/f
EsRα-/-; EsRβ-/cebpb-/-

Pregnancy/Lactation
Msx1

(overexpression)

Pgr

PR-/-

Esr2

PRA-/PRB-/-

Cebpb (C/EBPβ)

ZP3-Cre;PRf/f
EIIa-Cre; PRf/f
cebpb-/-

109

312

322
324

328

335
336

337
338
348, 349

Table 3.1 Continued

Ccnd1 (Cyclin D1)

Genotype
ccnd1-/-

Stat5a

stat5a-/-

Stat5b
Stat5a/Stat5b

stat5b-/stat5a-/-;stat5a-/-

Stat1
Involution
Stat3

stat1-/-

Mammary phenotype
Reduced lobuloalveolar
development/ lactation
failure
Reduced lobuloalveolar
development
Reduced lobuloalveolar
development
Perinatal lethality/ in
survivors TEBs do not
form on-time/ductal
epithelia does not invade
the fat pad/irregular ductal
epithelia
Similar to MMTV-Cre;
gataf/f/ increased
proliferation/cell death/
failure of lactation
Embryonic death, absent
placodes in survivors
Reduced lobuloalveolar
development/ defective
lactation
Reduced lobuloalveolar
development
Reduced ductal sidebranching /lactation failure
No data -Embryonic lethal
Defect in establishment of
alveolar progenitor cells
Reduced survival of
secretory epithelia
Defective lobuloalveolar
development/lactation
failure
No phenotype
Transplant studies reveal
failure of alveolar
morphogenesis
No phenotype

Stat6

stat6-/-

Il4/Il13 (IL-4/IL-14)

IL-4-/-;IL-14-/-

Gata3

MMTV-Cre;
gataf/f

stat3-/WAP-Cre;stat3 f/f
BLG-Cre;stat3 f/f

No data -Embryonic lethal
Delayed involution
Delayed involution

WAP-rtTA-Cre;
gata f/f

Keratin14Cre;gataf/f
WAP-Cre; gataf/f

Prl

PRL-/-

Prlr

PRLR-/-

Jak2

jak2-/MMTV-Cre;jak2 f/f
WAP-Cre;jak2 f/f
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Reference
343

375
376
377

352
352
354

353

354
354

356
357,358
359,360
361
361
364

366
367, 368

380

Table 3.1 Continued

Bcl2

Bcl2l1

Bax

Genotype
bcl2-/WAP- bcl2
(overexpression)
Bcl2l1-/WAP-Cre; bcl2l1f/f
MMTV-Cre;
bcl2l1f/f
bax-/WAP- bax
(overexpression)

Mammary phenotype
No phenotype
Delayed involution

Reference
381
382

No data -Embryonic lethal
Accelerated involution
Accelerated involution

385
386
386

Delayed involution
Lactation defect/forced
involution

388
390
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Chapter Four: Forced Involution of the Functionally Differentiated Mammary Gland by
Overexpression of the Pro-Apoptotic Protein BAX
Introduction
This chapter has been published and is included here for completeness of the
dissertation.390
Mammary gland development is classically compartmentalized into four distinct
phases: virgin, pregnancy, lactation, and involution. The contributions of hormones,
signaling pathways, and genes that give rise to the mammary gland, from the
progression of the rudimentary anlagen during embryonic development through the
post-natal stages described above, has been intensely studied.392 Although estrogen and
progesterone are the predominant hormones responsible for development of the gland
in the virgin and early pregnancy phases, prolactin directs the proliferation and
differentiation of the epithelia during mid-pregnancy through the prolactin receptor
PRL-R/JAK2/STAT5 signaling pathway. JAK2-STAT5 signaling is persistent through the
lactation phase for transcriptional activation of milk protein genes, and drops at the
lactation-involution transition phase. Involution proceeds through: (1) an initial
reversible phase marked by programmed cell death of secretory epithelium without
remodeling of the lobuloalveolar structure, followed by (2) an irreversible phase
characterized by remodeling of the gland by proteases (e.g., matrix metalloproteinases,
MMPs) and macrophages.393
Forced involution, initiated at lactation day 10, triggers apoptosis in response to
milk stasis within the alveolar lumen and the precipitous drop in lactogenic hormones
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(e.g., prolactin).394 The lactation–involution transition is regulated, in part, by the
contrasting activation of STAT5 and STAT3. STAT5 phosphorylation is maintained
through lactation but drops precipitously at the onset of involution, while STAT3
phosphorylation is initiated as the gland enters involution.369, 395, 396 Conditional deletion
of Stat5 results in the loss of mammary epithelium during mid-pregnancy and lactation,
suggesting that this transcription factor is required for cell survival. In contrast,
transgenic overexpression of Stat5 or gene ablation of Stat3 delays the involution
process.377, 397 Similarly, loss of Socs3, a negative regulator of the JAK-STAT pathway,
leads to an increased rate of involution via increased STAT3 activity.398 In addition to the
JAK-STAT pathway, genetic modifications within the IGF and AKT1 signaling pathways
reveal their importance. Transgenic IGF-1 or IGF-2 mice have delayed involution, while
IGFBP5 overexpressors have increased apoptosis.399-401 Downstream in the IGF signaling
pathway, overexpression of PTEN or Akt1 in transgenic models displayed accelerated or
delayed involution phases, respectively.402-404 Recently, STAT5 has been demonstrated
to transcriptionally regulate Akt1, and conditional expression of Stat5 leads to persistent
Akt1 activation and delayed involution.405 In addition, PTEN ablation increased the
survival of alveolar cells similar to the Akt1 overexpression. 406
Programmed cell death (PCD), an important physiological process that is
necessary for development, is classified either as either: Type I (apoptosis), Type II
(autophagy), or Type III (non-lysosomal vesiculate degradation). Apoptosis can be
generally stratified into a three-tiered molecular cascade system consisting of ‘‘elicitor’’
death receptors (e.g., TNFR1, TNFR2, FAS)407, 408, Bcl2 family member ‘‘mediators’’ (e.g.,
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BCL2, BCL2L1L, BCL2L1S, BAX, BCL2L2)409-411, and the caspase ‘‘executioners.’’412-414 The
mammary gland is an advantageous organ to profile the stages of involution, as a forced
involution allows for the synchronization of the biochemical processes. In the context of
cell death programs, the involution phase exhibits one of the most dramatic
physiological responses, with around 80% of the mammary epithelial cells undergoing
programmed cell death.415 The cohort of signaling pathways and cell death genes
necessary for this transitional period has been reviewed extensively.416-418 Although
microarray and proteome analyses have revealed a predicted cast of proteins and
highlighted biochemical pathways involved in involution, the most revealing studies
have stemmed from mouse models. 303, 304
Bcl2 family members are considered the gatekeepers of the mitochondrialmediated apoptosis, with the fate of the cell dependent upon the relative levels of the
individual proteins. Bcl2-like proteins can be subdivided into two distinct groups, those
that are pro-apoptotic (e.g., BAX, BCL2L1S, BID, and BAD) and anti-apoptotic (e.g., BCL2,
BCL2L1L, and BCL2L2). BCL2L1L and BAX are the two most prominent Bcl2 family
members expressed in mammary tissue. Bcl2l1L mRNA levels are low in virgin mammary
tissue, but increase during pregnancy in parallel with STAT5 activation and cell
differentiation. Bcl2l1L mRNA levels decrease during lactation, but increase again sharply
within 48 h of involution. Similarly, Bax mRNA levels increase with the onset of
involution.389 Within the Bcl2 family, several models highlight their influence on the
maintenance of the secretory epithelium. We have shown previously that the mammary
gland-specific deletion of Bcl2l1L resulted in an increase in apoptosis and hastened
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involution.386 In the Bax-deficient mammary gland, involution is initially delayed but
resembles the wild-type gland at involution day 10 after remodeling is completed.391
Although Bax-deficient mammary glands have a delayed early involution, the loss of Bax
does not rescue the accelerated cell death in Bcl2l1L -null mammary epithelium in our
conditional knockout of Bcl2l1L.386 These studies show a cell- and developmentalspecific dependence on BAX-mediated apoptosis. Ablation of Bax or enforced
expression of Bcl2 (WAP-Bcl2 transgenic) delays but does not prevent involution, and
promotes mammary tumor development.382, 419 387, 420
To date, it has not been addressed whether upregulation of a single proapoptotic factor is sufficient to initiate involution and remodeling of the functionally
differentiated mammary epithelium. To address this issue, we generated transgenic
mice that express Bax under a mammary gland-specific promoter that is upregulated
during secretory differentiation. WAP-Bax transgenic females display a lactation defect
due to an increase in cell death and premature involution from ectopic STAT3 activation.
This suggests that upregulation of BAX can override the pro-survival signaling functions
of STAT5 and AKT1 in the lactating mammary gland.

Results
WAP-Bax Transgenic Mice Exhibit Impaired Alveologenesis
Co-injection of the WAP-Bax transgene (Figure 4.1A) and a F1 K14-agouti
construct gave five independent founder lines out of 72 progeny as determined by PCR
analysis (Figure 4.1B). Previous characterization of co-injected transgenes with the K-14
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agouti demonstrated 95% co-integration, which allowed for visual determination of
transgene inheritance.421 All WAP-Bax lines also carried the K-14 agouti transgene,
making it possible to distinguish bi-transgenic mice by a phaeomelanin (yellow) coat
color (Figure 4.1C, D). Q-PCR was performed to establish copy number of the WAP-Bax
transgenic lines, with a range of 1–3 copies of the transgene per line. Upon establishing
germline transmission of the WAP-Bax transgene, F1 females were mated with control
C57 males to determine effects on mammary gland development. Out of the five lines,
two lines that demonstrated protein expression (IR5, IR15) could not support litters at
lactation day 1 (L1). Neonates from WAP-Bax dams did not have milk ‘‘spots,’’ but could
be fostered onto control lactating females (Figure 4.1E, F). Therefore, the defect was
not a suckling defect with the neonates but the transgenic dams. Whole mount analysis
showed that control mammary glands at lactation day 1 predominantly consisted of
secretory epithelia (Figure 4.2A). In addition, there was a distinct ‘‘rounded’’
morphology to the alveoli. In contrast, WAP-Bax mammary glands demonstrated a
reduced epithelial compartment and altered ‘‘star-shaped’’ alveoli (Figure 4.2B, C).
Hematoxylin-eosin staining of paraffin-embedded mammary glands showed normal,
uniform secretory epithelia in the control glands, but reduced epithelia with altered
morphology in the postpartum WAP-Bax transgenic glands (Figure4.3). Epithelia in the
mutant glands displayed increased signs of apoptosis; condensed cells had pyknotic
nuclei with many being released into the lumen (Figure 4.3D).
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Activation of an Apoptotic Program in Response to Expression of BAX
To determine the activation of the apoptotic program, a series of
immunohistochemistry (IHC) experiments were performed. For these experiments, the
IR15 line, which showed the highest expression and greatest loss of epithelia, was used.
At lactation day 1, expression of BAX was confined to the epithelial compartment of
WAP-Bax mammary glands, but not detected in the controls (Figure 4.4). Upon BAXmediated permeabilization of the mitochondria outer membrane, it was expected that
cytochrome C is released, culminating in the activation of Caspase 3 downstream of the
apoptosome. Using IHC, we detected cytochrome C, ApaF1 localization, and active
Caspase 3 within the cytosol of mammary epithelial cells of WAP-Bax transgenic females
(Figure 4.5). This clearly suggests that overexpression of BAX is sufficient to elicits a
classical mitochondria-mediated apoptotic program of functionally differentiated
mammary epithelial cells.
Secretory Mammary Epithelial Cells in WAP-Bax Females are Lost due to
Apoptosis
Upregulation of BAX normally coincides with the first phase of involution, which
precedes the actual remodeling process 2–3 days later.389, 391 To confirm that
continuous expression of exogenous BAX is sufficient to induce the second and terminal
stage of apoptosis, we performed TUNEL staining (Figure 4.6). As expected, mammary
glands of postpartum control females did not reveal apoptotic cells. In contrast,
mammary glands of WAP-Bax transgenic mice had high levels of TUNEL-positive cells in
the epithelial compartment. Transgenic lines IR62 (Figure 4.6B) and IR32 (Figure 4.6F)
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which expressed less BAX had also fewer TUNEL-positive cells compared to lines IR5 and
IR15 (Figure 4.6C–E).
Clusterin is a glycoprotein that is found to be expressed at high levels during
pregnancy and involution, but is suppressed during lactation.422 Because of its
expression profile, it is a marker for the lactation-involution transition. Clusterin was
found by IHC in the WAP-Bax mammary glands and not in the control glands (Figure
4.7). More importantly, nuclear pSTAT3 was not present in control glands but was found
in transgenic glands (Figure 4.8). pSTAT5 was expressed in control and transgenic glands
as well. In line IR15, where most of the epithelia was already lost, pSTAT3 and pSTAT5
was not detected. Overall, these data suggest that the lactation defect in WAP-Bax
females is due to a ‘‘forced involution’’ process and loss of the secretory epithelia due to
classical pSTAT3-mediated apoptosis.

Discussion
Programmed cell death (PCD) is a requisite cellular mechanism for development and
homeostasis. Apoptosis, Type I PCD, can proceed via extrinsic or intrinsic pathways.
Extrinsic pathways rely on apoptosis initiation by receptors at the cell surface, while
intrinsic pathways from internal signals such as cellular damage.423 Both pathways can
converge on the mitochondria to mediate the cell death program. BAX, a pro-apoptotic
protein from the Bcl2 protein family, can induce pore formation in the mitochondria
that ultimately leads to mitochondria outer membrane permeabilization (MOMP). Once
MOMP occurs, cytochrome C is released from the damaged mitochondria, thus
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triggering apoptosome formation, caspase activation, and DNA degradation.
Alternatively, release of additional mitochondrial proteins (e.g., AIF, OMI, and EndoG)
can lead to necrosis through caspase-independent events.423, 424
Other genetic studies from mouse models have revealed roles for BAX in
regulating apoptosis in reproductive tissues. Bax-null mice have phenotypes within the
testis and ovary. Males are sterile from the developmental failure of primary
spermatocytes to mature into secondary spermatocytes, thus prompting a wave of
apoptosis in the adolescent testis.388 Females are endowed with three times the
population of primordial follicles compared to wild-type females. In addition, the
reproductive lifespan of Bax-/- females is longer due to reduced atresia.425 BAX is also
involved with primordial germ cell (PGC) development in the fetus. BAX ensures the
apoptotic death of ectopic PGCs that fail to arrive at the indifferent gonad.426 Moreover,
once PGCs colonize the fetal gonads, we have shown that BAX and BCL2L1L regulate the
survival of the germ cells.427 Reduction of BCL2L1L in PGCs leads to a sterile ‘‘Sertoli cell
only’’ phenotype in the male, and a 30-fold reduction in primordial follicle in the male.
The loss of germ cell populations is restored by the concomitant loss of BAX in PGCs.
Previously we have shown that the secretory epithelia of the mammary gland are also
impacted by the loss of BAX or BCL2L1L. These studies show a cell- and developmentalspecific dependence on BAX-mediated apoptosis.
Our WAP-Bax transgenic model demonstrated a ‘‘forced involution’’ and
premature cessation of lactation at parturition. The cell death we find is due to a
Caspase-dependent induction of apoptosis, as determined by active Caspase-3 IHC and
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TUNEL assay. Although STAT5 and AKT1 promote cell survival in the mammary gland
during pregnancy and lactation, the ectopic overexpression of BAX overcomes these
signals. BAX is regulated by AKT1 phosphorylation at Ser184, which serves to maintain
the cytosolic localization of BAX and prevent its mitochondrial targeting.428 Since AKT1,
BCL2, and BCL2L1L are all cleaved by Caspases, initial Caspase-3 activation would provide
a positive feedback loop to inhibit these pro-survival proteins.429-432 It is unclear as to
the mechanism of pSTAT3 activation, although either induction of C-Src or Caspasemediated degradation of SOCS3 could lead to premature STAT3 phosphorylation. An
additional cell survival mechanism that the mammary gland would utilize is autophagy.
Autophagy is active in the L1 murine mammary glands, which normally would serve to
sequester damaged mitochondria into autophagosomes for turnover (unpublished
observations EBR, ANH).433 Apparently, the 2 transgenic WAP-Bax lines with lactation
defects have overcome the normal capacity of autophagy as a survival pathway within
the epithelia. Interestingly, PUMA-dependent activation of BAX has been shown to
concurrently induce autophagy of mitochondria (mitophagy) and a pro-apoptotic
response.434 Thus, our WAP-Bax model may not only have an increase in BAX mediated
apoptosis but also BAX-dependent autophagy. Quantitation of autophagosomes in the
WAP-Bax model with the transgenic GFP-LC3 autophagy reporter line would establish
whether both of these processes are coordinately activated.164 Some cells could be lost
from autophagic cell death, although the abundance of pyknotic nuclei and TUNELpositive cells argue for apoptosis as the central programmed cell death mechanism.
There are two classical stages of mammary gland involution: the programmed cell
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death-driven reversible phase and the remodeling irreversible phase. However, gene
expression studies of the early phase has demarcated seven signature profiles: (1) a 12h peak, (2) a 24- h peak, (3) a 24-h increase with persistent expression, (4) a 24-h peak
with a slow decrease, (5) a 72- to 96-h peak, (6) a delayed expression for 48 h, and (7) a
delayed expression with peak after 96 h.416 Bax mRNA is found in the fourth group with
a 24-h peak and slow decrease. As previously stated, this is the developmental window
when BAX has an effect on involution. From our study, BAX also has a dramatic effect on
the survival of the secretory epithelia around parturition. This highlights the dynamic
plasticity of the mammary gland; epithelia poised with the requisite proteome to carry
out programmed cell death given the proper internal signal or environmental cue. In
summary, overexpression of the pro-apoptotic protein BAX initiates programmed cell
death of functionally differentiated mammary epithelial cells in vivo.
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Figure 4.1 Generation of WAP-Bax transgenic lines. WAP-Bax transgenic mice were
produced by pronuclear injection of the WAP-Bax and K14-agouti constructs. (a)
Schematic of WAP-Bax transgene, showing the Bax cDNA cloned into a WAP promoterbased plasmid. The WAP promoter, portions of Exons 1 and 3, Intron 3, 4, and
downstream sequence are present. (b) Gel electrophoresis of Bax PCR products from
negative control or transgenic WAP-Bax lines IR5, IR15, IR20, IR32, and IR62. Lanes: 1,
100 bp ladder; 2, wild-type control; 3, line IR5; 4, line IR15; 5, line IR20; 6, line IR32; 7,
line IR62. (c) Coat color of bi-transgenic WAP-Bax; K14-agouti mice. (d) Coat color of
non-transgenic littermate. (e) Neonates (Day 1 of lactation) from WAP-Bax IR15 dam,
which have failed to recover milk after suckling. (f) Neonates from WAP-Bax IR15 dam
fostered onto control lactating dam.
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Figure 4.2 Expression of Bax under regulation of the WAP promoter results in reduced
epithelial content in the postpartum mammary gland. Whole mounts from lactation
day 1 control (a) and WAP-Bax transgenic mice (b, c) show reduced epithelial
compartments in the transgenic mice. In addition, the wild-type alveoli have a rounded
morphology compared to patches of collapsed, ‘‘star-shaped’’ alveoli in the transgenic
mice (denoted by arrows). Fp = fat pad. Bar = 0.5 mm.
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Figure 4.3 Presence of apoptotic cells in mammary glands of WAP-Bax transgenic
females at lactation day 1. Hematoxylin-eosin staining of lactation day 1 mammary
glands was performed on control (a) and WAP-Bax mice (b–d). (a) Control glands show
uniform epithelial morphology and large lipid droplets in the lumens. (b) WAP-Bax
glands show reduced epithelia and increased fat pad, and lumens have smaller lipid
droplets. (c) Altered morphology is apparent in the epithelium and at higher
magnification (d). Apoptotic cells are present as characterized by pyknotic nuclei
(arrows). Fp = fat pad. Bar (a–c) = 50 μM. Bar (d) = 25 µM.
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Figure 4.4 Expression of Bax under regulation of the Wap promoter is confined to the
epithelial compartment of the developing mammary gland in postpartum females.
BAX IHC shows localized expression in WAP-Bax but not control lactation day 1
mammary glands. (a) BAX protein is not found to be expressed in the control gland using
IHC; (b) negative control for wild-type gland. (c) and (e) reveal BAX confined to the
epithelial compartment in WAP-Bax glands; (d) and (f) represent negative IHC controls.
Counterstain was performed with nuclear fast red (a–d) or hematoxylin (e, f). Arrows
point to positive cells/alveoli. Fp = fat pad. Bar = 100 μM.
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Figure 4.5 Misexpression of Bax in the secretory mammary epithelium causes
mitochondria-triggered Caspase activation. WAP-Bax glands showed IHC staining for
cytochrome C (b), apaF1 (d), and active Caspase 3 (e, f), whereas control glands did not
show cytochrome C (a) or apaF1 staining (c). (e) WAP-Bax gland revealed active
Caspase-3 IHC staining in the alveoli (denoted with arrow) but not in the duct (du).
Counterstain was performed with nuclear fast red (a, b, f) or hematoxylin (c, d, e).
Arrows point to positive cells/alveoli. Fp = fat pad; du = duct; lu = lumen. Bar (a, b, e, f) =
25 μM. Bar (c, d) = 50 µM.
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Figure 4.6 Premature involution of secretory mammary epithelial cells in postpartum
WAP-Bax transgenic females. WAP-Bax glands showed increased levels of apoptosis
compared to control gland. (a) Wild-type lactation day 1 mammary gland with no
TUNEL-positive cells. (b) WAP-Bax line IR62. (c, d) WAP-Bax line IR15. (e) WAP-Bax line
IR5. (f) WAP-Bax line IR32. Lines IR5 and IR15 (c–e), which have lactation defects, have
increased levels of TUNEL-positive cells compared to lines IR62 and IR32 (b and f).
Counterstain was performed with methyl green. Arrows point to positive cells. Fp = fat
pad; lu = lumen. Bar = 100 μM.
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Figure 4.7 Clusterin expression in the lactating mammary gland. Clusterin expression, a
marker for involution, was not found in the control lactation day 1 gland (a) but was
present in the WAP-Bax gland (b). Counterstain was performed with hematoxylin.
Arrows point to positive cells/alveoli. Fp=fat pad; Lu=lumen. Bar=50 µM.
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Figure 4.8 pSTAT3 and pSTAT5 expression in the WAP-Bax mammary gland. pSTAT3
(a–d) and pSTAT5 (e–h) immunolocalization in wild-type (a, e), IR15 (c, g), and IR20 (d,
h) glands at L1. Negative control (no primary Ab) is shown for pSTAT3 (b) and pSTAT5 (f).
Arrows show nuclear localization of pSTAT5 and pSTAT3. Counterstain was performed
with hematoxylin. Bar=50 μM.
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Chapter Five: An essential, autophagy-dependent role for Beclin1 in murine mammary
gland development
Introduction
Macroautophagy, the process by which cytoplasmic cargo and/or organelles are
enveloped by a double membrane structure and trafficked to the lysosome for fusion,
degradation, and recycling, was once thought to be primarily a type of programmed cell
death; however, it has since been shown to be indispensable for normal development
and cell survival (reviewed in reference 1). Macroautophagy, hereafter referred to
simply as autophagy, proceeds through four main steps: initiation, elongation, fusion,
and degradation. The process is dependent on de novo formation of a double
membrane structure, termed the autophagosome, which fuses with the lysosome to
degrade and recycle cargo to maintain energy homeostasis and prevent cellular
damage. BECN1 is an essential autophagy protein that functions during both the
initiation and fusion steps.435 The traditional Becn1 knockout mice die during fetal
development at embryonic day (E) 7.5 due to a failure to close the pro-amniotic canal,
thus investigating the subsequent contribution of BECN1 to both normal growth and
development as well as under pathologic conditions has been challenging.184, 185 Our lab
has generated a Becn1 conditional knockout model to remedy this rift in our
foundational knowledge.287 We wanted to explore the contribution and necessity of
autophagy in the growth and development of the mammary gland, an organ that is
accessory in nature and undergoes the majority of its development in the postnatal
period. Additionally, since it has been reported that Becn1 is a tumor suppressor, owing
to the observation that Becn1 hemizygous mice are prone to sporadic tumorigenesis
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and that Becn1 is mutated or silenced in a majority of examined human breast cancers,
the mammary gland is an important, clinically-relevant tissue to investigate in this
context.184, 185, 436,437,438
The majority of mammary gland development occurs at puberty and in
association with reproduction. Briefly, at the time of birth the mouse mammary gland
exists as a rudimentary structure and lengthens proportionally to the postnatal
individual (i.e. isometric growth) until the onset of puberty, at approximately three to
four weeks of age. Under the control of circulating hormones, most notably estrogen,
the ducts then begin to lengthen disproportionately to the individual’s growth (i.e.
allometric growth) and the ductal tree invades the fat pad and branches. After
reproductive maturity is attained the gland will remain quiescent unless stimulated by
pregnancy hormones.
During the pregnancy cycle, mammary gland development is divided into four
stages: mature virgin (resting), pregnancy, lactation, and involution. During the
pregnancy to lactation transition, the secretory epithelia must terminally differentiate.
The lobulo-alveolar structures mature and prepare for upregulation of do novo synthesis
of nutrients, both protein and lipid, and the massive secretory burden of lactation.
Terminal differentiation of the secretory epithelia is dependent on pregnancy hormones
(e.g. progesterone and prolactin). Prior to the day of parturition the alveolar lumena
enlarge and the secretory epithelia flatten against the basement membrane. After pups
are weaned, the massive programmed cell death and remodeling that characterize the
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involution stage return the gland to a resting like state. The majority of the programmed
cell death is ascribed to apoptosis; however, some evidence in the literature supports a
role for autophagy in turnover and phagocytosis. Data from bovine studies show that
Becn1 expression and autophagy are upregulated during the dry period (i.e. involution)
and similar results from were found using mammary epithelial cells (MECs).439, 440 In
mice, only Becn1+/- and Atg7-deficient glands have been examined by other groups.
Atg7, important for elongation of the autophagosome, is important for gland
remodeling during involution. Atg7-deficient glands exhibit delayed involution and fail at
mitigating inflammation resulting in persistent inflammation partially due to impaired
efferocytosis.433
In this study, we pursued a Cre-loxP based strategy centering on a Becn1 floxed
model and two discrete mammary gland-specific Cre transgenic models to interrogate
the role of Becn1 in mammary gland development. We report two distinct and novel
roles for Becn1 in mammary gland biology: the regulation of branching morphogenesis
at puberty, and the control of terminal differentiation of the secretory alveoli during
pregnancy and lactation. We show that autophagy is reduced concurrent with
phenotypic differences in Becn1 cKO glands, and that the phenotype can be
recapitulated in vitro using the HC11 cell line. We suggest that Becn1 is important for
properly regulated pubertal development and critical for terminal differentiation of the
mammary gland due to its role in proper secretion of milk fat globules.
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Results
Mammary gland directed Becn1 cKO is specific and efficient
It has been postulated that programmed cell death may be essential for
mammary gland development and lumen formation. We hypothesized that autophagy
was required for proper ductal tree formation. To test this hypothesis, we used our
floxed Becn1 model and a transgenic Cre strain active in the developing mammary
gland, MMTV-CreD.441, 442 Since the description of the MMTV-CreD transgenic did not
include all time points we were interested in collecting, it was imperative to verify
temporal specificity of the recombination. We generated bi-transgenic reporter mice
which express a red fluorescent protein variant, DsRed, in cells that Cre mediated
recombination has occurred to examine the efficiency and localization of Cre expression
in the MMTV-CreD transgenic line.443 Nulliparous bi-transgenic females (MMTV-CreD;
DsRed+) and littermate controls were sacrificed and mammary glands as well as other
selected organs (data not shown) were collected at five and six weeks of age. Glands
were either prepared for fluorescent whole mount analysis or sectioned. The reporter
females indicate high expression was evident in the ducts (Figure 5.1B-D) as well as in
the terminal end buds (TEBs) (Figure 5.1C) but not in the stroma. We identified little
aberrant expression in the mammary gland with exception of the lymph node, which
was previously reported (Figure 5.1E). We concluded that MMTV-CreD transgenic mice
have efficient recombination and specificity in the mammary ducts and TEBs.
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Becn1 cKO mammary glands exhibit hyper-branching phenotype
The MMTV-CreD; Becn1fl/fl mice are viable and fertile, with no evident gross
functional mammary defect. Mutant individuals are able to maintain a typical gestation
length and sustain litters for three or more pregnancy cycles (data not shown). Mutant
females (MMTV-CreD; Becn1fl/fl) were collected and examined at 3, 5, 8, and 10 week
time points. Since whole mounts collected from five week old individuals consistently
appeared to have increased branching (Figure 5.2A, B), we decided to analyze the
branching network of mature nulliparous mice. We reasoned that since some variability
exists in maturing glands between four and six weeks, all glands should be in a mature
state by ten weeks of age. We found that secondary, tertiary, quaternary, and total
branching was significantly increased in mutant glands when compared to sibling
controls (Becn1fl/fl) (Figure 5.2C). Mutants exhibit a 1.71-fold increase in secondary
branching, a 1.98-fold increase in tertiary branching, a 2.06-fold increase in quaternary
branching and 1.94-fold increase in total number of branching (n=5 controls, n=9
mutants). Mutant females were otherwise normal. Females are able to sustain
pregnancy and normal lactation. Aged nulliparous or primiparous females did not show
any sign mammary tumors, females were observed up to 10 months of age.
Becn1 cKO mammary glands have lactation defect
In this series of experiments, we examined the effect of ablating BECN1
expression in the mammary gland persistently from mid-pregnancy forward, specifically
in secretory epithelia cells. This strategy functionally separates the effects of pubertal
development from those of pregnancy related development, a necessity since Becn1
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compromised ductal trees exhibit a hyper-branching phenotype. To examine pregnancy
related development and terminal differentiation, we crossed our Becn1fl/fl model with a
second Cre transgenic line using the Whey-Acidic-Protein promoter to drive Cre
expression, hereafter referred to as WAP-Cre.441 Mammary development was analyzed
from pregnancy day (P) 14.5 until 48 hours post parturition. In order to maximize the
ablation of BECN1 in the mammary gland, we chose to use one germline null allele and
one floxed allele in combination with the Cre transgene (WAP-Cre; Becn1fl/-). This
strategy results in the production of an animal that is globally hemizygous for Becn1 and
the expression from the remaining allele will be recombined by expression of Cre
specifically in the secretory epithelial cells in the mammary gland. The presence of a
null allele does not have a developmental consequence in the mammary gland, as
Becn1+/- females exhibit normal pregnancy and lactation stages. The WAP-Cre transgene
becomes active beginning at P12.5 and continues to increase throughout pregnancy and
remains high for the duration of lactation.441 Effective recombination of the remaining
Becn1 floxed allele is observable by BECN1 immunohistochemistry as early as P14.5,
with further reduction at P16.5 (Figure 5.3A). Reduction in total protein is evidenced by
western blot conducted on whole glands, sans associated lymph nodes, harvested on
the day of parturition (Figure 5.3E). In mutant glands, BECN1 expression is reduced 25fold when compared to control glands. WAP-Cre; Becn1fl/- dams are unable to sustain
litters and all the pups succumb to starvation within 24 hours of parturition. Pups
nursing on mutant dams did not have observable milk spots indicative of failure of
nutrient transfer from the dam. This phenotype is a result of a lactation failure in the
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dam, as the pups exhibit normal suckling response and are competent when fostered by
a wild type dam.
WAP-Cre; Becn1fl/- mammary glands are autophagy impaired and structurally
compromised
Since BECN1 is an essential autophagy protein, we examined autophagy function
relative to control animals using several methods. A chief responsibility of autophagy is
the clearance of poly-ubiquinated protein aggregates that are too large to be degraded
by the proteasome. An ubiquitin binding protein, SQSTM1 (commonly known as p62),
serves as an adaptor molecule for the autophagic engulfment of aggregates.44 SQSTM1
is a useful marker of autophagic function because when autophagy is impaired SQSTM1
tagged aggregates accumulate in the cell. In the Becn1 cKO mutant glands autophagy is
compromised as determined by changes in SQSTM1. SQSTM1 total protein is increased
1.61 fold relative to control on the day of parturition (Figure 5.4C), and SQSTM1
intracellular aggregates can be detected by IHC (Figure 5.4A, B). In addition, TEM
revealed the accumulation of enlarged autophagosomes with altered morphologies,
many with identifiable undigested cargo (Fig 5.4E, F) in the mutants while few are
observed in the control (Figure 5.4D). The loss of normal tissue architecture and
morphology changes is increasingly evident as pregnancy reaches term. On the day of
parturition, morphologic analysis reveals a loss of the functional, secretory unit
organization and a reduction in overall epithelial content and volume. Control animals at
48 hours post parturition have readily identifiable secretory units and lumena full of
milk fat globules (Figure 5.5A), while mutant glands have milk fat globules retained in
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the cytoplasm, epithelial cells are morphologically cuboidal, and have collapsed alveolar
structure (Figure 5.5B). At the ultrastructure level, control glands have an organized
typical secretory structure (Figure 5.5C, D) and mutant females lack organized secretory
units. In the rarely identifiable secretory units, evidence of improper lipid secretion and
enveloping can be seen (Figure 5.5E), as well as atypical lysosome associations with milk
fat globules (Figure 5.5F).
Canonical mammary signaling pathways are intact in Becn1 mutant glands
Classically, JAK/STAT signaling has been viewed as the intrinsic regulator of
mammary function and involution. Stat5a KO, Stat5a/b double KO, and expectedly the
prolactin receptor KO (Prlr -/-) do not undergo a functional lactation stage.357, 358, 364, 367,
368

Despite the lack of direct evidence linking BECN1 or autophagy with JAK/STAT

regulation, we wanted to investigate the possibility that JAK/STAT signaling was altered
in Becn1 mutant glands. Antibodies recognizing phosphorylated STAT5 (pSTAT5) and
Cyclin D1 (CCND1), a transcriptional target of STAT5 and cell cycle regulator, were used
to perform IHC on control and mutant glands. Ccnd1 -/- animals do not lactate and have
reduced lobulo-alveolar development.343 We found that the expression of pSTAT5 and
CCND1 in Becn1 cKO glands was indistinguishable from control glands (Figure 5.6),
indicating that extrinsic (i.e. progesterone-mediated) signaling is unaffected.

140

Autophagy inhibition in vitro results in retained lipid droplets and exocytosis of
autophagosomes
To determine if the lipid accumulation in secretory epithelial cells is autophagy
dependent or strictly Becn1 dependent, we used an in vitro system in parallel with our
mouse model. We chose to model our in vivo system with a mammary epithelial cell
line, HC11, derived from a mid-pregnant BALB/c mouse.444-446 These cells can be coaxed
into a lactogenic state by treatment with dexamethasone, insulin, and prolactin (DIP) via
media supplementation, and are used in the field extensively to model lactation stage
glands. To examine the effect of autophagy inhibition during lactogenic differentiation
and during lactogenic fate, we used the chemical autophagy inhibitor BafilomycinA1
(BafA1). BafA1 inhibits fusion of the autophagosome with the lysosome for cargo
degradation at early time points but also prevents acidification of the lysosome at later
time points (>2 hours of treatment). Since we are examining 24 and 48 hour time points
and using a relatively low treatment dose (200nM), it is important to note that we will
expect an increase in autophagosomes, amphisomes, and autolysosomes containing
undigested cargo to verify autophagy inhibition (Figure 5.7C). We analyzed the
differentiated HC11 cells at the 24 and 48 hour time points, time 0 indicating the
addition of both DIP media and 200nm BafA1. After 48 hours of treatment, TEM analysis
confirmed an inhibition of autophagy, as well as large autolysosomes containing
undigested cargo in the BafA1 treated lactogenic cells. We identified several cases of
direct exocytosis of autophagosome and autolysosomes in BafA1 treated cells (Figure
5.7C). Since our Becn1 cKO model exhibited an increase in retained intracellular lipid
141

droplets we investigated if this was also the case in our autophagy-inhibited,
differentiated HC11 cells. We used BODIPY 493/503 to stain lipid droplets and
counterstained with DAPI. BafA1 treated cells accumulated significantly (p< 3.25E-08)
more lipid droplets than the untreated lactogenic cells, with a mean number of lipid
droplets per cell of 23 (SEM ± 1.3) and 14 (SEM ± 0.81) respectively (Figure 5.7A, B).

Discussion
We investigated the contribution of Becn1 to the formation of the mammary
ductal tree and the terminal differentiation of secretory epithelial cells. The MMTVCreD; Becn1fl/fl mouse is the first in the field to genetically ablate an essential autophagy
protein in the ductal epithelia of the postnatal mouse mammary gland prior to puberty
and was a necessary experiment to answer a long-standing questions of whether
autophagy is necessary for ductal lumen formation. We found that Becn1 is not
essential for lumen formation during ductal outgrowth. We report Becn1 cKO glands
exhibit a significant increase in higher order branching in the mature nulliparous gland.
This effect is likely a result of removal of cell cycle repression by Becn1, as has been
suggested in the literature by others.185 We have also shown that Becn1 is critically
important for mammary gland development and terminal differentiation. Interestingly,
developmental activation of autophagy increases during late pregnancy and lactation in
wild type individuals and is highest during involution, as shown by our lab and others. 433
This confirms several studies that indicate canonical autophagy proteins have high and
dynamic expression during pregnancy, lactation, and involution.440, 447 Our work
indicates that canonical BECN1 function and the autophagic machinery is essential for
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mammary gland development, despite the energy surplus conditions. This finding is
novel and counterintuitive to prevailing opinions. The lactation failure exhibited by
WAP-Cre; Becn1fl/- dams is completely penetrant in primiparous females and intact
JAK/STAT signaling indicates that the glands are receiving extrinsic signaling necessary
for lactation and prevention of involution. Thus the phenotype is distinct from the
previously published work interrogating this pathway.363, 376, 377
SQSTM1 IHC and western blot, as well as ultrastructure analysis by TEM,
independently confirm an impairment of autophagy in the mutant glands; however, we
can only conclude that autophagy reduction is correlated with, but not necessarily
causative, with regard to the phenotype of Becn1 compromised mammary glands. The
increased severity and advanced timing of the Becn1 cKO phenotype when compared to
the Atg7 cKO phenotype also suggests that Becn1 is important for cellular activities
beyond canonical autophagy, or autophagy in the mammary gland during pregnancy
and lactation is ATG7-independent (i.e. non-canonical autophagy). One key difference
between the studies is that in our study one allele is a global null and the other is
recombined in the mammary gland by WAP-Cre (WAP-Cre; Becn1fl/-) while Teplova et al.
uses a WAP-Cre; Atg7fl/fl. This difference may be important since WAP-Cre; Becn1fl/fl
females are able to sustain litters. Since the embryonic lethality of the traditional Becn1
KO mouse is a more severe phenotype than the other autophagy related protein KO
models, our study and the results gleaned from the traditional Becn1 KO together
indicate a higher echelon for Becn1 in the hierarchy of autophagy proteins. The
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possibility remains that the observed phenotypes, may be a result of both autophagydependent and autophagy-independent functions of BECN1.
Our in vitro experiments using BafA1 in lactogenic HC11 cells recapitulate the in
vivo lipid droplet retention phenotype. Lactogenic, BafA1 treated HC11 cells retained
significantly higher numbers of lipid droplets. This result suggests that the lipid droplet
retention is an effect of autophagy inhibition and not an autophagy- independent role of
BECN1. Although the autophagy complex II (BECN1-UVRAG) is important for
autophagosome fusion with the lysosome, other studies have shown that these
autophagy proteins also function in endocytosis and exocytosis pathways.435 TEMs
reveal that BafA1 treated cells contain both large, undigested autophagosomes and deacidified autolysosome remnants. Since direct autophagosome exocytosis has been
shown in several model systems, there is a strong likelihood that autophagic proteins
(including BECN1) are important for lipid droplet secretion in the lactating mammary
gland.448, 449
The implication of autophagy proteins and process associated with lipid
secretion and lipid metabolism has been strengthened by recent work. It has been
recognized for several years that autophagy traffics intracellular lipids to the lysosome
for β-oxidation, termed macrolipophagy. In Atg7 cKO mice, lipids accumulate in large
intracellular lipid droplets in the liver; furthermore, the inhibition of autophagy in other
tissues has yielded similar results leading to the general conclusion that the most tissues
utilize autophagy and/or autophagy proteins to regulate lipid metabolism. 94
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Additionally, acute lipid stimulation can inhibit autophagy, while a chronic increase in
lipid stimulates autophagy, suggesting there are multiple regulatory mechanisms
involved depending on the type and duration of intracellular lipid content. 450 Becn1
expression is upregulated in response to an increase in lipid and cholesterol inclusions in
models of Neimann-Pick C disease, a lipid storage disorder.268, 451, 452 Taken together it is
apparent that the interplay of lipids and Becn1 is of paramount importance in
development and misregulation is antecedent to numerous clinically-relevant
pathologies.
In future studies, our lab will use the tetracycline inducible system to perform
BECN1 ablation and rescue experiments to understand the role of BECN1 during
involution, a strategy developed and described by Creamer et al.453 This strategy will
give us a broader and clearer picture of the roles for BECN1 throughout mammary gland
development.
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Figure 5.1 MMTV-CreD is a specific and effective driver for mammary specific
recombination in nulliparous mice.
(A) Control animals labeled with DAPI do not exhibit any red fluorescence of ducts or
stroma while reporter females (B, C, D) exhibit red fluorescence that is highly restricted
to mammary ducts and TEBs. Fluorescent whole mounts of inguinal mammary glands
from reporter females (E, F) exhibit red fluorescence in primary and secondary ducts as
well as TEBs visible at 5 weeks of age. The lymph node is also targeted by the transgene
for recombination (E). A, B, D (200X magnification), C (100Xmagnification), arrowhead
indicates mammary duct in longitudinal section, arrows indicate TEBs, LN- lymph node.
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Figure 5.2 MMTV-CreD; Becn1fl/fl females exhibit hyper-branching phenotype.
Whole mount analysis of inguinal mammary glands harvested from 5 week old females
revealed signs of hyper-branching in the MMTV-CreD;Becn1fl/fl glands when compared
to control (A), as indicated by arrowheads (B). Quantitative analysis of branching in 10
week old females (C) confirmed these observations indicating a significant increase in
secondary, tertiary, quaternary, and total number of branches, n=5 control and n=9
mutants (*P < 0.05, Student t-test).
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Figure 5.3 WAP-Cre; Becn1fl/- mammary glands have reduced BECN1 expression in the
mammary gland from mid-gestation.
IHC of BECN1 on P14.5 and P16.5 mammary glands (A). Glands harvested on the day of
parturition exhibit a marked loss in total BECN1 protein abundance when compared to
control animals by western blot (B).
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Figure 5.4 WAP-Cre; Becn1fl/- mammary glands have impaired autophagy clearance of
SQSTM1.
SQSTM1 IHC of control (A) and Becn1 cKO (B) inguinal mammary glands on the day of
parturition imaged at 400X magnification. Scale bars are 10µm. SQSTM1 protein is
increased in Becn1 cKO mammary glands when compared to controls and normalized to
GAPDH (C). TEM of control (D) and mutant glands (E, F) 48 hours after parturition, scale
bars as indicated. Arrows indicate SQSTM1 positive aggregates, open arrowheads
indicate autophagosomes
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Figure 5.5 WAP-Cre; Becn1fl/- mammary glands show defects in gland organization and
abnormal milk fat globule processing.
Semi-thin sections of resin-embedded control (A) and WAP-Cre; Becn1fl/- glands (B) 48
hours post parturition. Note the lack of milk fat globules in the lumens of (B). TEM of
control (C, D) and mutant (E, F) glands, scale as indicated. (E) Lipid enveloping and
secretion defects are noted with asterisks and arrowheads highlight lysosome
abnormalities (F).
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Figure 5.6 WAP-Cre; Becn1fl/- mammary glands receive typical extrinsically mediated
signaling and CCND1.
Phospho-STAT5 expression, as measured by IHC, is similar in both control and mutant
glands (A). CCND1 expression is indistinguishable between control and mutant glands
(B). All glands are inguinal mammary glands harvested on the day of parturition.
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Figure 5.7 Lactogenic HC11 cells recapitulate the lipid accumulation observed in
primiparous Becn1 cKO mammary glands.
HC11 cells were kept in growth media, differentiated (DIP), or differentiated and treated
with BafA1 (DIP + BafA1) then all groups were stained with BODIPY 493/503,
counterstained with DAPI and imaged (A). Mean lipid droplets per cell at 24 hours post
treatment time point were calculated for each group (B) (*P < 0.05, Student t-test). TEM
of HC11 cells from DIP (C), and DIP + BafA1 treated group (D) highlight the accumulation
of autolysosomes in the DIP + BafA1 group as well as direct exocytosis of abnormal
autophagosomes with undigested cargo (E). Scales as indicated.
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Chapter Six: TSC1 is a Novel Interacting Partner of Beclin1 and Essential for Terminal
Differentiation of the Mammary Gland
Introduction
Tuberous sclerosis 1 (Tsc1) and Tsc2 produce the gene products TSC1/2, also
known as hamartin and tuberin respectively. The TSC1/2 heterodimer is a well
characterized inhibitor of MTOR signaling. Typically TSC2, when bound to TSC1 for
stability, uses its GTPase activating protein domain (GAP) to inhibit Rheb, a GTPase,
which inhibits mechanistic target of rapamycin 1 (MTORC1) signaling. Tsc1 and Tsc2 are
the causal genes of the disorder tuberous sclerosis complex (TSC), a diverse multisymptomatic autosomal dominant disease characterized by hamartoma formation that
affects ~1 in 6,000 births to varying degrees.454 The Tsc1 knockout (KO) mouse model
dies embryonically between E9 and E13.5 of liver hypoplasia and anemia.176 Notably the
phenotype of the Tsc1 KO was milder than the Tsc2 KO where exencephaly was
reported in addition to other developmental defects.243 Embryonic lethality prompted
generation of the Tsc1 floxed model which has been used to ablate TSC1 in a myriad of
cell types, tissues, and organs.455 For a table of published tissue-specific deletions see
Table 6.1.
Autophagy, an intracellular catabolic process enlisted to envelope and degrade
damaged organelles and long-lived proteins, is essential for organismal vitality, growth,
and development. Productive autophagy is characterized by four steps: initiation,
elongation of a double membrane structure termed the autophagosome around cargo,
fusion of autophagosome with a lysosome, and degradation of cargo by lysosomal
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enzymes for recycling of macromolecules for energetic homeostasis. Canonically,
MTORC inhibits autophagy at the level of the autophagy pre-initiation complex, which is
a regulatory complex upstream of the initiation step, and impaired autophagy has been
reported in several systems that compromise TSC1 function or expression. 63, 456-459
Beclin1 (BECN1) is an essential, pro-autophagic protein that serves as a scaffolding
protein during the initiation stage of autophagy. Interestingly, human BECN1 was
identified as a TSC1 binding partner in 293T cells by a high-throughput affinity capture
experiment.460 This finding creates a link between two tumor suppressor genes, as well
as suggests the potential existence of an uncharacterized regulatory loop with
significant clinical relevance.
Tsc1 and Tsc2 have been studied extensively in the context of inherited
tumorigenic disease, and have been characterized as tumor suppressor genes. Fewer
studies have examined Tsc1 in the mammary gland or in breast cancer. A single
nucleotide polymorphism (SNP) analysis of Tsc1 and Tsc2 identified a single variant that
associated with a significantly later age at diagnosis of estrogen receptor (EsR) positive
ductal carcinoma.461 Additionally, TSC1 and TSC2 expression is reduced in invasive
breast cancer and the TSC1 promoter is heavily methylated in several breast cancer cell
lines and in most breast tumors while is only rarely methylated in normal tissue. This
report also concluded that low expression of TSC1 is correlated with unfavorable clinical
outcomes.462 Inducible Tsc1 deletion in primary mammary tumor cells results in hyperactivation of MTORC, accelerated breast cancer progression, and changes in autophagy
levels.463 Becn1 is a well-characterized tumor suppressor. Becn1 hemizygous mice are
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prone to spontaneous tumors, and, in humans, Becn1 is mutated or silenced in a
majority of breast cancers investigated. 184, 185, 436
In this study we report the interaction of mouse TSC1 and BECN1 in vitro and
examine the in vivo consequences of ablating TSC1 expression in the mouse mammary
gland. We hypothesize that TSC1 and BECN1 interact to complete a regulatory feedback
loop and this interaction affects autophagy function and the MTORC signaling axis, thus
cell growth and differentiation.

Results
TSC1 and BECN1 interact in vitro
Since the initial report that TSC1 and BECN1 are interacting partners used a
human BECN1 expressed at supraphysiological levels it was important to determine if
TSC1 and BECN1 interacted when both are expressed at endogenous levels. We used
protein-protein interaction assay based rolling circle amplification. Briefly, cells were
cultured as recommended then fixed and blocked. Primary antibodies raised in different
species were applied. Secondary antibodies conjugated with oligo probes were applied
and incubated. A ligation reaction and polymerase based amplification make physical
interactions visible as a fluorescent puncta. Analysis is conducted using fluorescent
microscopy (Figure 6.1A). We found that a significant 59.3% of NIH3T3 cells were
positive for the TSC1 and BECN1 interaction (Figure 6.1B, C). On average, across all cells
assayed, 1.14 TSC1-BECN1 associations per cell were counted (Figure 6.1D). Since we
know that levels of TSC1 can affect autophagy dynamically in response to changes in
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nutrient status we wanted to investigate the nature of the TSC1-BECN1 interaction
under serum-starvation conditions. We subjected established cells to a prolonged serum
starvation protocol (Figure 6.1E). Following an eight hour serum starvation the
percentage of positive cells was reduced significantly from 29.6 % with complete media
to 17.7% after serum-starvation (Figure 6.1F), suggesting that the TSC1-BECN1
interaction is also nutrient responsive.
TSC1 is important for mammary gland development
The mammary gland is a highly dynamic organ that undergoes the majority of its
development in the adult animal. During pregnancy, estrogen and other circulating
hormones stimulate the cell proliferation, growth, and branching of an arboreal ductal
structure. Nearing the time of parturition secretory epithelia, positioned at the terminal
points of branches, prepare for secretory activation and lactation. During lactation the
epithelia must produce copious quantities of protein and lipid and secrete these into the
ductal lumens for neonate support. After weaning the gland undergoes a bipartite
involution stage where programmed cell death and efferocytosis remodel the gland into
a resting-like state (Figure 6.2A).
Relatively few studies have been conducted investigating the expression of Tsc1
in the normal developing mammary gland. Studies in bovine have revealed that Tsc1
expression is dynamic across pregnancy and lactation, notably Tsc1 expression increases
significantly during mid-lactation (120 days post parturition in bovine), relative to latepregnancy levels.464 We assayed the expression of TSC1 in mouse mammary glands by
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western blot across five stages of development; virgin, pregnancy (P) 14.5, P18.5, L1,
Involution (I)2. We cannot directly compare our data with the bovine expression data
but we corroborate the dynamic nature of TSC1 at the protein level across
developmental time points. In mice, TSC1 expression is very low at the virgin stage so
we compared protein expression relative to P14.5 (set to 1). TSC1 protein abundance
increases 8.4-fold at P18.5, 6.6-fold at L1, and 4.7-fold at I2 (Figure 6.2B, C). Generally,
expression is low in the resting gland, increases to a peak during late pregnancy, around
the time of secretory activation, and begins to taper off as lactation and involution
ensue.
TSC1 is necessary for secretory activation of the mammary gland and lactation
Since both TSC1 and BECN1 have been implicated in breast cancer and we know
from previous studies that BECN1 is essential for mammary gland terminal
differentiation we wanted to examine the consequences of deleting TSC1 in the
mammary gland during pregnancy. We used a Cre transgenic in which the Whey Acidic
Protein (WAP) promoter is used to drive Cre expression. The WAP-Cre transgenic line in
combination with the Tsc1 floxed model that carries one germline recombined allele
(Tsc1fl/-) resulted in an animal globally hemizygous for Tsc1 and recombination of the
remaining floxed Tsc1 allele in the mammary gland from mid -pregnancy (P12.5)
forward.441, 442
On the day of parturition the Tsc1 cKO females were unable to sustain litters.
Pups did not have milk spots, indicating failure of nutrient transfer, but were
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successfully fostered on control dams. IHC against TSC1 revealed a reduction in
expression levels on the day of parturition in Tsc1 cKO glands when compared to control
levels detected (Figure 6.3 ).
The Tsc1 cKO dams have a lactation defect. Whole mount analysis of inguinal
glands harvested from Tsc1 cKO animals on the day of parturition revealed abnormal
swollen and engorged alveoli (Figure 6.4A- D). Histologically, retained milk fat globules
in secretory epithelial cells and abnormal gland architecture could be observed in Tsc1
cKO glands. Several lysed secretory cells can be identified. Overall reduction in secretory
epithelia is observed. These histological abnormalities indicate a failure of secretory
activation (Figure 6.5A-D).
TSC1 cKO glands have altered MTORC signaling and reduced autophagy
As discussed above, TSC1 is a known MTOR inhibitor and we investigated the
implication of TSC1 ablation on the MTOR signaling pathway in the mammary gland. We
found that total MTOR is increased 3.6-fold in Tsc1 cKO glands as compared to controls
and normalized to GAPDH, as expected (Figure 6.6A). Downstream MTOR effector
p4EBP1 expression was increased 1.7-fold in Tsc1 cKO glands as compared to controls
and normalized to GAPDH (Figure 6.6B). Since autophagy is inhibited by MTOR we
decided to examine autophagy by looking at Sequestosome 1 (SQSTM1/p62) expression.
SQSTM1 is selectively metabolized by the autophagic pathway and, when autophagy is
inhibited or impaired SQSTM1, intracellular levels increase. Tsc1 cKO glands have a 2fold increase in SQSTM1 over control glands and normalized to GAPDH, indicating a
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reduction in autophagy (Figure 6.6C). We did not detect any significant difference in cell
proliferation rates as measured by phospho-histone H3 (pH3) staining (data not shown).
TSC1 and BECN1 expression in breast cancer
To examine the changes that occur during tumorigenesis we used a tumor tissue
microarray to examine TSC1 expression in a variety of breast cancers. Each tissue core
was scored 0-4, zero being no expression and 4 being the highest level of expression. In
normal human breast tissue TSC1 is evenly distributed in the epithelia (Figure 6.7A). We
found that 100% of scored breast cancer samples expressed TSC1 to some degree
(n=34) and 41.2% had low TSC1 expression (Figure 6.7C, D). The remaining cores, 58.8%,
had high expression (rated 3 or 4) (Figure 6.7B). Typically epithelia stained more
dramatically for TSC1 than stromal tissue which stained to varying degrees. TSC1 protein
was localized to the cytoplasm in a diffuse pattern and spread throughout positively
staining cells, even in the case of polarized secretory cells (Figure 6.7E, F). Amongst a
group of breast ductal adenocarcinomas the level of TSC1 staining was similar to the
level BECN1 staining in 81.3% of samples assayed (n=32), though in some cases the
distribution was different. In this ductal adenocarcinoma pictured BECN1 staining is
punctate and basally located in polarized cells while TSC1 is diffuse in the cytoplasm
(Figure 6.7G, H). BECN1 staining is also more prevalent in the non-luminal cells.

Discussion
Using both in vitro and in vivo approaches we were able to investigate a novel
protein-protein interaction and its implications in the development of an organ. We
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report the novel interaction of murine TSC1 and BECN1 in vitro at endogenous
expression levels. Furthermore, we show that the interaction is dependent upon
nutrient condition. After serum-starvation the observed TSC1-BECN1 interactions were
reduced, indicating that the interaction is nutrient-responsive. In vivo, mammary glands
of Tsc1 cKO mice exhibit failed lactation, impaired secretory activation characterized by
abnormal morphology at the organ level and the histological level. Engorged and
expended alveoli are easily identified in Tsc1 cKO glands indicating retained lipids. At the
histologic level, lipid droplets can be seen centrally located in the secretory epithelia
cells and many cells have an uncharacteristic cuboidal appearance. As expected, MTOR
expression was increased in the Tsc1 cKO mammary glands and autophagy was
compromised.
This work begins to unravel the complex and likely ephemeral interaction
between two tumor suppressor proteins; TSC1 and BECN1. Both traditional KO models
are embryonic lethal very early in development and both have been studied intensively
as tumor suppressors. We report here that ablation of Tsc1 in the developing mammary
gland results in a lactation defect similar to Becn1 cKO mammary glands. It is interesting
to note that others have reported that in Tsc1 cKO cells and Tsc1 cKO mammary tumor
cells amino acid-starvation induced autophagy is decreased, as expected since MTORC is
hyperactive, but in TSC1 cKO mammary tumor cells glucose-starvation induced
autophagy is surprisingly increased.463 This differential response is important since
autophagy has long been characterized as a “double edged sword” in cancer.
Autophagic response is typically cytoprotective, allowing cells to survive stress and
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protect cells from misfolded proteins or cytotoxic protein aggregates; however, after a
tumor is established activation of autophagy can be permissive for tumor
progression.465 Another tumor suppressor, RB1-inducible coiled-coil 1 (RB1CC1), has
been reported to interact with TSC1 and is a known member of the autophagy preinitiation complex.466 The ULK1/2-ATG13- ATG101-RB1CC1 autophagy pre-initiation
complex is directly downstream of MTOR, subject to its regulation, and upstream of the
BECN1 anchored autophagy initiation complex.61 The interaction between RB1CC1 and
TSC1 has been shown to regulate cell size, but not proliferation.466, 467 The regulation of
these players, involved in nutrient responsive pathways as well as tumorigenesis, is
more complex than has previously been appreciated. Thus, what we are proposing is a
nutrient-sensitive, regulatory feedback loop that encompasses TSC1/2 complex
inhibition of MTOR and regulation of autophagy and has consequence for normal
development and possibly tumor initiation. This work lays the foundation for a specific
and directed interrogation of the role of TSC1 in mammary tumor establishment and
progression.
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Table 6.1 Tsc1ckO produced and corresponding phenotypes
Central Nervous System
Genotype
Tissue
Emx1-Cre;
Embryonic neural
fl/fl
Tsc1
progenitors

Phenotype
Defective cortical lamination;
enlarged abnormal astrocytes;
decreased myelination
Olfactory nodules; abnormal
neuronal infiltration

Reference
468

Nestin-CreEsRT2;
Tsc1fl/fl
(tamoxifen
induced)
Gbx2-CreEsR;
Tsc1fl/fl

Neuronal
precursors and
astrocytes
Thalamus

Enlarged thalamic neurons,
disorganized circuitry; seizures;
compulsive grooming behavior

470

Pomc-Cre;
Tsc1fl/fl
CaMKIIα-Cre;
Tsc1fl/fl

Pomc neurons of
hypothalamus
Neurons within
the cortex and
hippocampus
Post mitotic
neurons

dysregulation of Pomc neurons
and hyperphagic obesity
Seizure activity; increased
mortality; impaired autophagy;

471

Seizures;
abnormal/enlarged/ectopic
neurons; myelination delay
Increased excitability and a proepileptogenic circuit
Seizures; increased astrocyte
number; disorganized
hippocampal neurons
Impaired astrocytic gap junction
coupling and potassium buffering
Elevated glutamate levels in
hippocampi; increased neuronal
death in hippocampus and
neocortex; impaired learning and
memory
Seizures; epileptogenesis

472

SynI-Cre; Tsc1fl/fl

Synapsin1-Cre;
Tsc1fl/fl
GFAP-Cre;
Tsc1fl/fl

Neurons

GFAP-Cre;
Tsc1fl/fl
GFAP-Cre;
Tsc1fl/fl

Glia

Cag-CreERT1;
Tsc1fl/fl or CagCreERT1; Tsc1fl/(tamoxifen
induced)

Global

Glia

Glia
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469

211

473
455

474
475

476

Table 6.1 Continued
Peripheral Organs
Genotype
Tissue
Fabp4Lung(pulmonary
Cre;Tsc1fl/fl
epithelial cells),
heart, skin and
kidney, and in
liver and brain at a
lower level
T2
SPC-Cre-EsR ;
Lung alveolar
Tsc1fl/fl
epithelial cells
(tamoxifen
induced)
SM22-Cre;
Cardiovascular
Tsc1fl/fl
tissue
fl/fl
Alb-Cre; Tsc1
Liver
fl/fl
Alb-Cre;Tsc1
Liver
Rip2-Cre;
Tsc1fl/fl

Tie2-Cre;Tsc1fl/fl

β-cells of
pancreas,
hypothalamus
β-cells of
pancreas,
hypothalamus
Distal convoluted
tubule
Subset of renal
tubular cells
Vasculature

K14-Cre; Tsc1fl/fl

Epithelia

Rip2-Cre;
Tsc1fl/fl
Emx1-Cre;
Tsc1fl/fl
Nse-Cre; Tsc1fl/fl

Phenotype
Smaller; lung hemorrhages;
reduced levels of surfactant
proteins A and B

Reference
477

No data, only recombination
efficiency reported

478

Cardiac hypertrophy; reduced left
ventricular end-diastolic diameter
Hepatocellular carcinomas
Protection from hepatic steatosis;
defect in SREBP1c activation
Improved glycemic control;
obesity (off target effect)

479
480
481
482

hyperphagia and obesity; enlarged 471
neuron cell size in a number of
hypothalamic populations
Cystogenesis; elongated primary
483
cilia
polycystic kidney disease
457
Embryonic lethality;
484
cardiovascular defect;
disorganization and failed
sprouting of vasculature; defective
mitochondrial and endoplasmic
reticular morphology
Accelerated wound healing
485
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Table 6.1 Continued
Reproductive System
Genotype
Tissue
fl/fl
PR-Cre; Tsc1
Uterus:
epithelium,
stroma and
myometrium
Amhr2-Cre;
Tsc1fl/fl
Amhr2-Cre;
Tsc1fl/fl
Cyp19-Cre;
Tsc1fl/fl
PB-Cre4; Tsc1fl/fl

Phenotype
Infertility; oviductal hyperplasia;
retention of embryos in the
oviduct; implantation failure;
epithelial hyperplasia; embryo
development was disrupted
As above with exception: embryo
development was unaffected
Poor oocyte quality, compromised
implantation, infertility

Reference
486

Hyperfertility; accumulation of
corpus lutea
Neoplasia of prostatic epithelia
progressing to more advanced
lesions with increased age

488

Phenotype
Loss of quiescence; reduced
number of T-cells
partial block in B-cell maturation;
reduction in the marginal zone
population; defective immune
response
Increased mitochondrial
biogenesis; increased ROS;
reduced hematopoiesis; reduced
self-renewal

Reference
490

Hematopoietic
stem cells

Premature aging of HSCs

493

Global
(hematopoietic
organs)

Polycystic kidney disease; failure
to thrive; reduced HSCs; loss of
quiescence; reduced self-renewal

494

Uterus: stroma
and myometrium
Granulosa cells of
ovary; stroma of
oviduct and uterus
Granulosa cells of
ovary
Prostate
epithelium

Hematopoietic System
Genotype
Tissue
fl/fl
Lck-Cre; Tsc1
T-Cells
CD4-Cre; Tsc1fl/fl
CD19-Cre;
B-cells
fl/fl
Tsc1

MX-1-Cre;
Tsc1fl/fl
(polyinosinepolycytidine
induced)
MX-1-Cre;
Tsc1fl/fl
(polyinosinepolycytidine
induced)
Rosa26CreEsRT2; Tsc1fl/fl
(tamoxifen
induced)

Hematopoietic
stem cells
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487

489

491

492
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Figure 6.1 BECN1 and TSC1 interact in vitro.
BECN1 and TSC1 are identified as interacting partners. (A) Schematic representation of
protein-protein interaction assay depicts two primary and secondary antibodies binding
to targets, ligation of conjugated oligos, and rolling circle amplification for visualization.
(B) The control has very few interaction puncta while the BECN1-TSC1 panel has many
puncta, cells are counterstained with DAPI. Overall 59.3% of cell are positive for the
interaction (C), and on average, cells have 1.14 interactions each (D). When cell are
subjected to a prolonged serum-starvation protocol (E), the number of interactionpositive cells decreases significantly (F). *= statistically significant and refers to a pvalue<.05

169

Figure 6.2 TSC1 is expressed during normal pregnancy, lactation, and involution.
Schematic representation of a pregnancy cycle is depicted (A). The mammary gland
progresses through four phases: mature virgin (resting) which is quiescent, pregnancy,
lactation, and involution. The depictions are stylized ductal structures and
representative growth of the secretory epithelia as pregnancy and lactation progress.
TSC1 is expressed at very low levels in the mature virgin gland and increases to a peak in
late pregnancy. Expression remains high during lactation and during the early involution
phases (B, C).
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Figure 6.3 TSC1 protein is reduced in Tsc1 cKO glands at L1.
Glands harvested from L1 controls have strong TSC1 staining in the secretory epithelia
(A, E) as detected by IHC. In Tsc1 cKO glands (B, C, D, F) overall staining in the secretory
epithelia is reduced. A-D 400X magnification; E, F 600X magnification; bar=25μm
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Figure 6.4 Tsc1 cKO whole mount mammary glands are less dense and have abnormal
secretory alveoli.
Mammary glands collected on the day of parturition typically appear dense and
differentiated as the control gland (A). Mutant glands (B-D) appear less dense and
present with less secretory alveoli. In many cases secretory alveoli appear engorged and
abnormal alveoli can be seen budding off of branches (open arrowheads). Bar= 1mm
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Figure 6.5 Histologic analyses of Tsc1 cKO mammary glands.
Control mammary glands collected on the day of parturition have undergone secretory
activation and epithelia appear squamous, lipid droplets are secreted into large lumena
(A). Mutant glands (B-D) contain secretory epithelia that appear cuboidal and many lipid
droplets can be observed retained in the cytoplasm (asterisks). In many cases secretory
epithelia has been lysed (asterisks).Bar=25nm

174

Figure 6.6 Tsc1 cKO mammary glands have increase MTOR pathway signaling and
decreased autophagy.
Total MTOR abundance in increased 3.6-fold in Tsc1CKO mammary glands (A) and
downstream target p4EBP1 is increased 1.7-fold (B). SQSTM1 is increased 2-fold in Tsc1
cKO mammary glands indicating that autophagy is reduced (C).
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Figure 6.7 TSC1 expression in breast cancer is variable and typically trends with BECN1
expression.
In normal breast tissue TSC1 is expressed in a majority of cells’ cytoplasm (A). A panel of
breast cancer cores was examined. In a breast ductal adenocarcinoma high expression
can be seen in epithelia (B), and in similarly graded core expression is overall reduced
(C-D). TSC1 exhibits high expression (E-F) in a restricted patter and BECN1 also exhibits
a high expression level but has a slightly different pattern of localization (G-H). A, B, C, E,
G 200X Bar=25nm; inset images A, B, C, E, G 100X; D, F, H 400X, Bar=50nm
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Chapter Seven: Conclusions and Future Directions
Introduction
Through these studies we have explored the contribution of apoptosis and
autophagy to mammary gland development and differentiation. Combined, they have
focused our attention on the importance of balance and timing during dynamic
remodeling and shifts in tissue function and physiologic demand. Perturbation of this
system highlights the fragility of establishing and maintaining lactation. The WAP-Bax
mice showed that overexpression of a single pro-apoptotic protein at an improper time
leads to forced involution and lactation failure. Ablation of Becn1, viewed primarily as a
cell survival protein, during pregnancy causes a similar gross outcome; lactation failure.
Reconciliation of the delicate balance of pro-apoptotic and pro-survival signals is central
to further our understanding of normal mammary development as well identifying and
predicting pathologies, including cancer, which arise in this dynamic tissue.
Furthermore, TSC1, an MTOR regulator and tumor suppressor never before examined in
the mammary gland, also proved to be essential for lactation. Our continued exploration
of the function of Tsc1 in vitro has revealed a novel protein-protein interaction between
TSC1 and BECN1. This work has left us with many observations that push the boundaries
of our knowledge regarding the regulation and function of autophagy pathway related
proteins and the regulation of mammary gland development.
Since I have spent considerable time discussing the status of the field and our
research findings, I intend to use this space for discussion, speculation, and to expound
on experiments to further this line of thinking.
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BECN1- More than an autophagy protein
Much has been published regarding the canonical function of Becn1, that is to
say, the autophagy-promoting, initiation complex I-centric function. The studies
described in this compilation push against this presumption and highlight alternative
and non-canonical functions of BECN1, on which I wish to elaborate here.
By TEM, an accumulation of autophagosomes, both completed and incompletely
closed, was identified in the Becn1 cKO model. This finding suggests that the engrained
notion of BECN1 acting primarily in the autophagosome initiation complex is too
simplistic. After Becn1 ablation we do not see an effect on autophagosome production,
but we can identify a defect in functional autophagy, so three possibilities are feasible:
1) the residual BECN1 is sufficient for autophagosome formation, 2) in the mammary
gland non-canonical BECN1-independent autophagy is most common, or 3) BECN1 is
unnecessary for autophagosome formation in this model system.
We cannot completely discount the first possibility since there is no information
regarding the stability of BECN1 in vivo; however we have shown that we significantly
reduced BECN1 protein levels by both IHC and western blot. Since we are able to detect
that functional autophagy is reduced by SQSTM1 accumulation, it is likely that
autophagy in the mammary gland is impacted by BECN1 reduction and leads me to
discount the second possibility. The third possibility holds water since we observe
failure of autophagosomes to productively fuse with the lysosome. This supports an
important and less-studied function of BECN1, its inclusion in “complex II” which
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mediates fusion of the autophagosome with the lysosome. Interestingly, our lab as well
as a collaborator’s lab, have identified similar accumulation of autophagosomes in at
least two additional tissues (personal communication Rucker, Gawriluk, Wang)
suggesting that this phenomenon is not restricted to the mammary gland. This working
model is depicted schematically in Figure 7.1A.

BECN1 and Lipid Droplets
My data also illuminate a novel role for BECN1 in regulating lipid trafficking and
secretion. In vivo, lipid retention in the secretory epithelia is easily identified by
histologic analysis in late pregnancy and early lactation phases. We then moved to an in
vitro system to evaluate lipid retention in lactogenic mammary epithelial cells and found
that when cells were treated with the autophagy inhibitor BafA1, an inhibitor that
targets autophagosome-lysosome fusion and prevents lysosomal re-acidification, lipid
droplets were, again, retained. Tellingly, when I repeated this experiment with the
inhibitor wortmannin, which inhibits autophagy specifically at the level of the initiation
complex (complex I), I found no significant difference in lipid droplet accumulation in
the treated vs. untreated cells (Figure 7.2). This difference is important as it also
supports the hypothesis that BECN1, in a complex that mediates membrane fusion
(complex II), is important for lipid trafficking and/or secretion. At this time I am
proposing a working model in which BECN1 participates in at least two distinct
complexes, and some complex components are shared between the roles of
autophagosome-lysosome fusion, and lipid droplet regulation.
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The idea that autophagy proteins are important for lipid droplet synthesis,
fusion, and trafficking is supported by studies in other model systems. Mammalian Atg2
homologs, ATG2A and ATG2B, are important for lipid droplet size regulation and
distribution. Additionally, silencing of Atg2A and Atg2B together results in a block in
autophagic flux and accumulation of unclosed autophagic structures.495 In hepatocytes
and cardiac myocytes LC3-II localizes to the surface of lipid droplets as well as
autophagosomes under starvation conditions, and in Atg7-deficient livers lipid droplets
were reduced and overall reduced in sized compared to controls.496 This work laid the
foundation for the involvement of the ATG7 conjugation system in lipid droplet
formation, and in further studies, LC3 was directly associated with lipid droplet
formation.497 It seems that many of the classic autophagy related proteins have roles
outside of autophagy and there is significant overlap with lipid droplet formation,
regulation, and trafficking.
Similarities can also be pulled from studies focusing on lipid droplet formation
and secretion in the mammary gland. The lipid droplet is thought to be formed at the ER
and gain membrane material from many sources, similar to the autophagosome, before
it is secreted (Figure 7.1D, II-IV). Droplets often fuse together in the cytoplasm with
other lipid droplets and sometimes secretory vesicles before secretion (Figure 7.1D, III).
The process of two distinct organelles fusing in the cytoplasm without any known
control mechanisms or higher regulation is reminiscent of the fusion of
autophagosomes and lysosomes, for which we have shown Becn1 is important.
Interestingly, xanthine oxidase is a constitutive component of the milk lipid globule
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membrane and in mice the knockout has a similar phenotype to the Becn1 cKO with
regard to lipid retention and lactation failure.498 It would be interesting to look at
potential BECN1 localization at sites of inception or fusion of lipid droplets. This
technically challenging experiment would be best conducted using live imaging of cells
to track a likely short and dynamic association.
Together these studies indicate that much of the machinery that has been
classically describe as autophagy machinery is essential for lipid droplet formation and
size regulation. Furthermore the nature of formation, elongation, and fusion are in
many ways parallel between lipid droplet formation and secretion and autophagy. It is
therefore reasonable that BECN1 is a member of a complex, potentially complex II with
UVRAG or other fusion proteins, which functions in lipid droplet formation, size
regulation, trafficking, and fusion in addition to autophagic initiation and fusion.

What About Unconventional Protein Secretion?
There have been many reports of autophagy related proteins being important
for unconventional protein secretion, defined as a method for secretion that bypasses
the ER-Golgi route and instead leaves the ER and may use a vesicular structure to be
exocytosed. A simplistic schematic is depicted in Figure 7.1D, I. In yeast, Acyl coenzyme
A (CoA)–binding protein (Acb1) is secreted in an unconventional process that is
autophagosome and Atg11 dependent.499, 500 In mammalian cells, pro-inflammatory
cytokine IL-1β depends on ATG5 and LC3 co-localizes in the cytoplasm, implicating an
autophagic vesicle is required for its transport.501
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While my data yield no indication that protein secretion is impaired in Becn1 cKO
mammary glands, as casein can readily be seen in any identifiable lumena, we did not
specifically measure levels of secreted protein, thus cannot be certain. In our work we
used total mammary gland for analysis, removing only the lymph node. A milk protein
analysis from whole gland lysate did not reveal any difference between control and cKO
mice across pregnancy time points (Figure 7.3). The caveat is that any proteins retained
within the cells and not secreted would still contribute to the milk protein abundance
represented on the gel. For studies focusing on the potential role of BECN1 in
unconventional protein secretion, milk protein will need to be analyzed separate from
the stromal and epithelial compartments of the mammary gland.
In sparse and old reports, a marrying of unconventional protein secretion and
lipid secretion has been described.502 In short, secretory vesicles leaving the Golgi
surround a lipid droplet in the cytoplasm and form a syncytial layer around the droplet
(Figure 7.1D, IV). The outer membrane, which is now composed of secretory vesicles
and cargo, fuses with the plasma membrane and is exocytosed to the lumen. I have
identified some of these structures in control animals on the day of parturition by TEM
(Figure 7.4 A, B), one of only a handful of reported examples of this phenomenon.
When lipid droplets are enveloped with plasma membrane (Figure 7.1D, III) and
secreted, chunks of plasma membrane sometimes remain associated with the globule in
the lumen (7.4C, D). These enveloping defects occur in the first 24 hours of lactation in
controls and are very rarely observed at later time points.

183

When examining Becn1 ckO glands on the day of parturition, defining phenotypic
differences based on errors in fusion and secretion can be ambiguous since control
glands are also likely to make errors at this time. Many sections and individuals must be
included in such a study. Preliminary, qualitative results gathered from Becn1 cKO
glands harvested on the day of parturition are discussed here. In Becn1 cKO glands
globules are readily identified in lumena. Incidences of secretory vesicles surrounding
and depressing lipid droplets are seen (Figure 7.5A, B). In some cases it appears that
membrane integrity has been compromised (Figure 7.5 C, D). These results are brief but
further investigation is needed. Quantification of lipid droplet size would be valuable
but would require at least six animals of each genotype for comparison. This is a
fascinating, understudied, and technically challenging area; as a result, much of the
basic biology of lipid droplet secretion and mammary milk fat globules is still unknown.

BECN1 During Involution
When we initially embarked on this journey we were interested in answering the
open question of whether or not autophagy is important during mammary gland
involution. Since the WAP-Cre; Becn1fl/- mice exhibit a lactation defect and precocious
involution, a proper investigation of the role of Becn1 during involution was prohibited.
Future studies using the MMTV-CreD; Becn1fl/fl model would be valuable to better
examine this process. Involution would be forced at L10 by removal of the litter in
mutant and control animals. Tissue would be assayed for proliferation index, apoptosis
index, and examined for morphologic differences. Clusterin and pSTAT3 would be used
as markers for involution stage by IHC and western blot.
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BECN1, Tumor Suppressor?
Since Becn1 is purported to be a tumor suppressor gene, and our studies to date
have not identified tumors in mammary-specific cKO animals, we have designed a study
to more directly address the role of Becn1 in breast cancer. We are using the established
MMTV-neu transgenic mouse model in combination with our mammary-specific Becn1
cKO with WAP-Cre mediated deletion. This project necessitates backcrossing onto the
tumor permissive FVB background (6 generations). Focal mammary tumors arise in
MMTV-neu female mice beginning at 4 months with a median incidence of 205 days. In
this model we can ablate Becn1 expression in primiparous mice and compare median
tumor incidence to transgenic primiparous controls with full Becn1 compliment. This
targeted experiment, conducted on a tumor-permissive background will support either
1) the widely regarded notion that Becn1 is a tumor suppressor, or 2) the model that
tumors are addicted to autophagy and ablation of Becn1 will delay tumor onset and/or
retard growth. If Becn1 is a tumor suppressor we will expect that tumors arise earlier in
the Becn1-deficient animals. This scenario would be quantified by a shorter median
incidence or that tumors arise with similar incidence but grow at a more rapid rate.
Conversely, if autophagy promotes tumor incidence and growth by allowing them to
survive sub-optimal nutrient and hypoxic conditions, we would expect that the Becn1
cKO animals present with a longer median incidence and/or tumors that arise do not
grow as rapidly as control animals. In essence, either outcome will be important to the
research community and clarify the role of BECN1 in tumorigenesis.
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High Energy, High Autophagy?
Physiologically it is interesting that both Becn1 and Tsc1 are important for proper
function of the mammary gland since cell survival pathways including MTOR and AKT,
which inhibit autophagy and TSC1/2 complex respectively, have been shown to be
active during this time. It has been proposed by others that in certain cell types which
are either undergoing senescence, or highly metabolically active (e.g. podocytes), it is
beneficial for autophagy (i.e. catabolic process) and protein synthesis (i.e. anabolic
process) to be concomitantly operating and spatially linked. The authors propose that in
cells under high demand to produce bulk synthesis of secretory products that the
catabolic and anabolic machinery are spatially coupled for efficiency.503 The finding by
our lab of yet another example of this and another level of interconnectedness between
the MTOR pathway and the autophagic pathway in metabolically active and highly
secretory cells beseeches more experiments be conducted teasing out this mechanism.
A thorough understanding of the interplay between TSC1, BECN1, and MTOR is
paramount.

TSC1-BECN1 Interaction
The interaction between BECN1 and TSC1 complicates the idea of MTOR
pathway regulation, and reinforces the importance of multiple nutrient-sensitive
regulatory levels. It has been well characterized that TSC1 is necessary for the stability
of its binding partner TSC2, and in Tsc1 cKO animals TSC2 levels are undetectable at the
protein level due to rapid degradation by the proteasome. The TSC1-BECN1 interaction
could mediate the pool of BECN1 in the cytoplasm that is available for rapid response to
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cellular insult (Figure 7.1B). Under this model the stability of BECN1 in the Tsc1 cKO
would be compromised, thus BECN1 would be less available to perform its cellular roles
leading to a similar, though milder phenotype, to the Becn1 cKO (Figure 7.1C). This is
precisely the results we have observed. Moving forward it is important to characterize
the domains involved in this interaction, though it is probable that since both proteins
contain a coiled-coil domain that this is the point of interaction. Protein-protein
interaction assays (e.g. Duo-Link or co-immunoprecipitation) using constructs with
targeted domain deletions and truncations will be useful for making this determination.

Summary
In closing, with the experiments that have been described as a foundation, the
perceptions and boundaries of at least two fields have been challenged. It is clear that
BECN1 is far more that an autophagy protein and the extent of its importance during
development is still being revealed. Our conditional Becn1 model will be a fruit-bearing
asset to the autophagy community for many years. We have shown two new proteins
that are essential for terminal differentiation in the mammary gland and proposed a
mechanism based on a murine protein-protein interaction detected for the first time. In
this chapter I have put forth ideas which are a result of an amalgamation of published
literature and our findings. We have challenged the long-held characterization of BECN1
as a tumor suppressor and will continue to directly address this question in the future.
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Figure 7.1 BECN1 Working Model
BECN1 is a member of two distinct complexes, complex I, which acts at the initiation
stage and complex II, which functions at the autophagosome-lysosome fusion step. The
two roles, depicted schematically in (A), have mutually exclusive binding partners and
may include uncharacterized components. TSC1-BECN1 interaction stabilizes the
available pool of BECN1 in cytoplasm and protects BECN1 from degradation (B), when
the association is disrupted (C) either by knockout of Tsc1 or endogenous mutation,
BECN1 is left unprotected and destabilized resulting in impairment of BECN1-dependent
functions. In (D), autophagosome-dependent unconventional protein secretion (I) and
several mechanisms of lipid secretion in the mammary gland (II, III, and IV) are depicted.
Autophagosomes are pictured as orange vesicles; Lysosomes are pictured as blue
vesicles; Green spheres represent lipid droplets; UPC, unconventional protein cargo; ER,
endoplasmic reticulum; PM, plasma membrane; SV, secretory vesicle
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Figure 7.2 Autophagy inhibition with wortmannin does not affect lipid droplet
retention in vitro.
HC11 cells were driven to lactogenic differentiation by supplementation with DIP (A, B).
The treatment group (B) was concomitantly treated with wortmannin (100 nM). Both
groups were stained with BODIPY 493/503 after 24 hours of treatment and cellular lipid
droplets counted. The experiment was conducted in triplicate. No significant difference
in lipid content was detected between groups by student’s t-test (C), p-value=.985.
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Figure 7.3 Milk protein abundance is unchanged in Becn1 cKO mice
Secretory activation in the mammary gland precedes milk production. Total protein was
extracted from whole mammary glands of control and mutant primiparous females,
from which the lymph nodes were removed. Coomassie brilliant blue stain was used to
visualize the characteristic milk protein banding patterns. No difference in total protein
abundance was detected between control and Becn1 cKO mice. WAP, whey acidic
protein; CSNα, casein alpha; CSNβ, casein beta; CSNγ, casein gamma.
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Figure 7.4 Secretory vesicles surround and plasma membrane envelopes lipid droplets
in control mammary glands on the day of parturition.
In control glands, units of secretory vesicles surrounding milk fat globules can be seen in
the lumen on the day of parturition (A, B). Asterisks indicate the area around the milk
fat globule (secreted lipid droplet) that is encapsulated by secretory vesicles. Note that
not every globule is affected. In (C), and at higher magnification in (D), there is plasma
membrane and one secretory vesicle surrounding the globule. Errors in enveloping, the
most common method of droplet secretion, are common in controls in the first 24 hours
of lactation but are rare after lactation is established. Open arrowheads indicate areas
where large amounts of plasma membrane remain on secreted lipid droplets. Scale bars
and magnification are as shown below each panel.
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Figure 7.5 Becn1 cKO glands may have difficulty fusing membranes
Becn1 cKO glands were harvested on the day of parturition and examined by TEM.
Secretory vesicles, probably containing casein, can be seen surrounding lipid droplets (A,
B). In some areas with secretory vesicle-lipid droplet contact the droplet appears
distorted. Instances of secretory vesicle membrane fusion failure can also be identified
(C, D). Open arrowheads point to areas of potential fusion failures. Scale bars and
magnification are as shown below each panel.
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Chapter Eight: Materials and Methods
Generation of WAP-Bax Transgenic Mice
The WAP-Bax construct was digested with NotI and gel purified with the Qiagen Gel
Extraction Kit. The keratin 14 (K14)-agouti transgene 421 was digested with ClaI and also
gel purified. Transgenes were co- injected at a final concentration of 2 μg/ml-1 into
pronuclear-staged FVB embryos. Pups (3 weeks old) were genotyped for the Wap-Bax
transgene with the following PCR primers and reaction conditions: forward (5’-TAG AGC
TGT GCC AGC CTC TTC-3’); reverse (5’-GAC ACA GTC GAC TCA GAA CAT CTT CTT CCA G3’); cycling conditions of 94°C for 5 min (1 cycle), 94°C for 30 s, 58°C for 30 s, 72°C for 1
min (32 cycles), and a final step of 72°C for 5 min. The product of 650 base pairs was
resolved on a 1.5% agarose gel. Founders were backcrossed with C57/BL6 mice for five
generations. WAP-Bax transgene copy number was determined using exon 3 and 4
specific primers paired with an exon 3-specific TaqMan probe (5’-6FAM ATG CGT CCA
AGA AGC TGA GCG TAMRA-3’ at 200 nM final) with cycling conditions of 50°C for 2 min
(one cycle), 95°C for 10 min, 95°C 15 s, 60°C for 1 min (40 cycles) on an ABI Prism 7700
thermocycler. Copy number was normalized to the endogenous Bcl2l1 gene (two
copies).

Gene targeting and generation of Becn1 cKO mouse
For the targeting vector, a three loxP plasmid vector (ploxP3–NeoTK) with
phosphoglycerol kinase (PGK)-neomycin and PGK–thymidine kinase cassettes for
positive–negative selection was used. Genomic DNA isolated from 129SvEv mice was
used to amplify three regions of homology for the targeting arms: a 2.7 kb Becn1 arm #1
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(Becn1 promoter sequence), a 3.0 kb Becn1 arm #2 (promoter, exon 1, intron 1, exon 2,
and a portion of intron 2), and a 2.0 kb Becn1 arm #3 (intron 2 sequence). For the
amplification, the AccuPrime Pfx was used according to manufacturer's directions to
generate blunt PCR fragments that were gel purified (Gel extraction kit, Qiagen) and
cloned into pBlunt vector (Invitrogen). For the electroporations, 25 μg NotI-linearized
DNA was resuspended in 25 μl electroporation buffer (Chemicon, Billerica, MA, USA) and
electroporated into 1×107 129SvEv ES cells using the GenePulser II (250 V and 500 μFd;
Bio-Rad) with 0.4 cm cuvettes. G418 selection (200 μg/ml) was started on day 1 after
electroporation and continued thereafter; ganciclovir selection (2 μM) was performed
on days 4–7 after electroporation. On day 12, 3× 96-well plates were picked and
expanded for cell stocks and DNA isolation. Clones were initially screened by pooled
PCRs using LaTaq (Takara) with a 5′-flanking reverse primer (5′-CCC TAG CTG GCC TGG
AAC TCA GAA ATC T-3′) and neomycin-specific reverse primer (5′-TAC CGG TGG ATG TGG
AAT GTG TGC GA-3′) set. The presence of the third loxP site was confirmed using
flanking PCR primers (forward: 5′-CAG GAG AAG TGC CAT GGT GCA TCC TCT T-3′;
reverse: 5′-CAA AGC CAA GGT TTC CAT GCT AAT GCC-3′). Individual clones were
subjected to PCR confirmation from positive pools. Positive clones were confirmed by
Southern blot diagnostics with an external 5′ probe. Targeted mouse embryonic stem
(ES) cells were expanded and used for blastocyst injections at the Transgenic Animal
Core facility at Texas A&M University (College Station, Texas).
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Generation of mammary gland specific Becn1 cKO mice
Becn1fl/+ mice were generated by gene targeting in 129SvEv ES cells as described in
previous section. A germline transmissible Becn1 null allele (Becn1-) was generated by
breeding hemizygous Becn1fl/+ with MMTV-CreA mice. Presence of the null allele was
confirmed by PCR analysis (sense: 5’-ATG GAA GGA AGG AAG GTT AG-3’; antisense: 5’CAA AGC CAA GGT TTC CAT GCT AAT GCC-3’). Mice carrying homozygous floxed alleles
and neomycin cassettes were confirmed by PCR of tail-snipped DNA. True floxed alleles
were generated by crossing Becn1flneo/+ and Ella-Cre mice. Deletion of the neo cassette
and production of “true floxed” allele was confirmed by PCR analysis (sense: 5’-ATG GAA
GGA AGG AAG GTT AG-3’; antisense: 5’-GGT TGC ATG TTA AGT CTT TGT CGA-3’). WAPCre; Becn1fl/- mice were generated by crossing WAP-Cre; Becn1fl/- males with Becn1fl/fl
females. Presence of the WAP-Cre transgene was confirmed using PCR (sense: 5’- CAG
ACA CTC AGA CAG CCA TCA GTC-3’; antisense: 5’- CCA TGA GTG AAC GAA CCT GGT CG3’) All animal work was conducted using protocols approved by the Institutional Animal
Care and Use Committee at the University of Kentucky.

Generation of mammary gland specific Tsc1 cKO mice
Tsc1fl/+ mice (Tsc1tm1Djk/J) were crossed with Vasa-Cre transgenic line (FVB-Tg(Ddx4cre)1Dcas/J) to produce a germline transmissible Tsc1 null allele (Tsc1-). Presence of the
null allele was confirmed by PCR analysis (sense: 5’- AGG AGG CCT CTT CTG CTA CC-3’;
antisense1: 5’- CAG CTC CGA CCA TGA AGT G-3’; antisense2: 5’- AGC CGG CTA ACG TTA
ACA AC-3’). Presence of the floxed allele was confirmed by PCR analysis (sense: 5’-GTC
ACG ACC GTA GGA GAA GC-3’; antisense: 5’-GAA TCA ACC CCA CAG AGC AT-3’). WAP198

Cre; Tsc1fl/- mice were generated by crossing WAP-Cre; Tsc1fl/- males with Tsc1fl/fl
females. Presence of the WAP-Cre transgene was confirmed using PCR (sense: 5’- CAG
ACA CTC AGA CAG CCA TCA GTC-3’; antisense: 5’- CCA TGA GTG AAC GAA CCT GGT CG3’). All animal work was conducted using protocols approved by the Institutional Animal
Care and Use Committee at the University of Kentucky.

Mammary gland collections
Mutant and control animals were sacrificed at designated time points according to the
experimental design. An incision at the midline, but not piercing the peritoneum of the
abdominal cavity, is carried to the distal rib. A second incision is made to separate the
fourth and fifth mammary glands, parallel to the femoral artery. The number four
mammary gland is removed carefully and used for whole mount and histological
analysis. RNA and protein samples are taken from the contralateral inguinal mammary
gland, but exclude the inguinal lymph node. In some cases a thoracic gland is also
removed in a similar manner, but never used for RNA or protein analysis due to its
skeletal muscle component.

Histology and Immunohistochemistry
Inguinal mammary glands were fixed in 4% (w/v) paraformaldehyde or 10% neutral
buffered formalin solution (WAP-Bax experiments) at 4° C overnight, then placed in 70%
ethanol and stored at 4° C. Paraffin embedding was performed at the Histology
Laboratory of the University of Kentucky Imaging Facility. Processed glands were
sectioned (5-7 μm) and mounted on charged glass slides. Slides were then
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deparaffinized and hydrated for immunohistochemistry (IHC) or deparaffinized and
hydrated, stained with methyl green, nuclear fast red, hematoxylin, and/or eosin, and
dehydrated and mounted. For slides undergoing IHC, antigen unmasking was
performed in citrate antigen unmasking buffer (Vector H-3300) followed by endogenous
peroxidase quenching with 3% H2O2 diluted in methanol. Slides were blocked in 2.5%
normal horse serum (Vector S-2012) for 20 minutes at room temperature. Primary
antibodies against Bax (1:200; B.D. PharMingen 13686E), BECN1 (1:100, Santa Cruz
Biotechnology sc-11427), Active Caspase-3 (1:50, B.D. PharMingen 559565), Caspase-3
(1:50, Santa Cruz 556425), Cytochrome C (1:50, B.D. Phar- Mingen SC7159), SQSTM1
(1:250, Sigma-Aldrich, P0067), TSC1 (1:100, Novus Biologicals, NB 100-80855),
antibodies were diluted to indicated titers and incubated overnight at 4°C. ImmPRESS
Reagent Kit-Anti-Rabbit IgG (Vector Labs, MP-7401) and ImmPACT DAB (Vector Labs, SK4105) were used according to manufacturer’s directions. Sections were counterstained
with Hematoxylin QS (Vector Labs, H-3404) or eosin (Fisher Scientific, E-511) and
visualized using an Olympus IX71 microscope (Olympus Corporation of the Americas).
pSTAT5 and CCND1 IHC was performed at Epply Institute for Cancer and Allied Diseases,
Omaha, Nebraska by our collaborators Dr. Kay-Uwe Wagner and Dr. Kazuhito Sakamoto.

Tissue Array
Tissue microarray slides were obtained from the Cooperative Human Tissue Network
and the Tissue Array Research Program (TARP) of the National Cancer Institute, National
Institutes of Health, Bethesda, MD, USA. The array analyzed in this study is the T-MTA6A.
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Measurement of Apoptosis in WAP-Bax Mammary Gland Epithelial Cells
For quantitation of apoptotic cells, the TUNEL-based Apoptag assay was performed
according to the manufacturer on paraffin-embedded sections (Intergen). Briefly
described, mammary gland tissue sections were deparaffinized, quenched in 3%
hydrogen peroxidase and incubated with terminal transferase. After applying the antidigoxigenin conjugate, the color was developed in DAB peroxidase substrate for 6 min.
Samples were counterstained with methyl green (Vector Labs).

Mammary Gland Whole Mounts
Inguinal mammary glands (#4) or thoracic (#3) mammary glands were removed and
spread on a charged glass microscope slide. Glands were fixed with Carnoy’s fixative
overnight (6 parts 100 % EtOH, 3 parts CHCl3, 1 part glacial acetic acid). Glands were
washed in 70% ethanol for one hour then gradually hydrated. Glands were stained with
Carmine Alum, prepared by placing 1 g carmine (Sigma C1022) and 2.5 g aluminum
potassium sulfate (Sigma A7167) in 500 ml distilled water and boiling for 20 min. The
final volume was adjusted to 500 ml with ddH2O and filtered before use, and kept at 4°
C overnight or until a desirable stain was attained. Glands were then dehydrated with a
series of graded ethanol and transferred to xylenes to clear. Glands were left in xylene
until sufficiently cleared then mounted with Permount (Fisher Scientific SP15-500). The
protocol is described at
http://mammary.nih.gov/tools/histological/Histology/index.html. The processed glands
were imaged using an Olympus SZ-PT dissecting microscope. Fluorescent Whole Mounts

201

were prepared as described in Landua et al. (Method 1, Protocol B).504 They were
visualized using an Olympus IX71 microscope (Olympus Corporation of the Americas).

Immunoblotting
Tissues were lysed in RIPA and protease inhibitors (Santa Cruz Biotechnology sc-24948).
An equal amount of protein from each cell lysate was resolved on a SDS-polyacrylamide
gel and transferred to nitrocellulose membranes (Bio-Rad 162-0094). Nonspecific
binding was blocked with 5% nonfat dry milk powder in TBST for 60 min. The blots were
incubated overnight at 4°C with primary antibody followed by washing with TBST and
incubation with anti-rabbit-HRP secondary antibody in 5% nonfat dry milk powder in
TBST for 2 hours. After washing in TBST, the immunoblots were developed with
enhanced chemiluminescence detection system (Amersham RPN-2108) as per the
manufacturer’s instructions. GAPDH was used as loading control. Primary antibodies
used: BECN1 (Santa Cruz Biotechnology, sc-11427), MTOR (Cell Signaling Technologies,
2983P), p4EBP1 (Cell Signaling Technologies, 2855P) SQSTM1 (Sigma-Aldrich, P0067),
and TSC1 (Novus Biologicals, NB 100-80855).

HC11 cell culture
HC11 cells (a generous gift from Dr. Kay-Uwe Wagner, University of Nebraska) were
cultured on coverslips in growth media ( RPMI, 10% FBS, 5 µg/mL insulin, 10 ng/mL EGF,
50 µg/mL gentamycin, 100 U/mL pen/strep) until confluent (at least 6 days). Induction
media (RPMI, 10% FBS, 5 µg/mL insulin, 5 µg/mL prolactin, 0.1 µM dexamethasone, 50
µg/mL gentamycin, 100 U/mL pen/strep) was added and the cells were maintained for
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24 or 48 hours. At appropriate time points cells were prepared for light and fluorescent
imaging as follows. Cells were washed three times with PBS, cells were fixed with 4%
paraformaldehyde for 15 minutes, and then washed three times with ice cold PBS. To
permeabilize cells, samples were incubated in PBS containing 0.25% Triton X-100 for 10
minutes. Cells were washed three times with PBS, five minutes per wash. Coverslip were
mounted onto microscope slides using VectaShield mounting medium for fluorescence
with DAPI (Vector Laboratories Inc., H-1200). Slides were viewed using an Olympus IX71
microscope (Olympus Corporation of the Americas)

NIH3T3 Cell culture and Protein-Protein Interaction Assay
NIH3T3 cells were cultured on coverslips or using chamber slides (Nunc, 154526) in
growth media (DMEM supplemented with 10% bovine calf serum, and 100 U/ml
penicillin and streptomycin) in a 5% CO2 incubator until confluent. Serum-free medium
lacks the bovine calf serum. At designated time points, as dictated by experimental
design, cells were prepared for protein-protein interaction assay according to
manufacturer’s directions, using recommended protocol and wash buffers (Omega
Bioscience, DUO-LINK II). TSC1 (Novus Biologicals, NB 100-80855) and BECN1 (Santa Cruz
Biotechnology, sc-48381) antibodies were employed. Coverslip were mounted onto
microscope slides using VectaShield mounting medium for fluorescence with DAPI
(Vector Laboratories Inc., H-1200). Slides were viewed using an Olympus IX71
microscope (Olympus Corporation of the Americas).
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Transmission Electron Microscopy (TEM)
All TEM experiments were conducted under the supervision of the University of
Kentucky Imaging Core. Briefly, mammary glands were harvested and minced into 1mm 2
pieces in cold fixative (3.5% glutaraldehyde in 0.1M cacodylate buffer, pH 7.4) for 1.5
hours at 4°C. Glands were washed in 0.1M cacodylate buffer with 5% sucrose (4 times,
15 minutes each). Samples were post fixed with 1% osmium tetroxide for 1.5 hours at
4°C then washed in cacodylate buffer. Tissues were dehydrated in graded ethanol, 10
minutes each and transferred to propylene oxide (2 changes, 15 minutes each). Tissues
were infiltrated overnight with resin/propylene oxide overnight then put in 100% resin
(2 changes, 1 hour each). Tissue was embedded in resin for 48 hours at 60°C, thin
sectioned using Reichert Ultracut E, and imaged using a Philips Tecnai Biotwin 12
transmission electron microscope.
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Appendix: Abbreviations

3-MA, 3-methyladenine; ATG, autophagy related; BafA1;bafilomycin A1; Bmp, bone
morphogenic protein; BH3, Bcl2 homology domain; cKO, conditional knockout; DAPI, 4',
6-Diamidino-2-Phenylindole, Dihydrochloride; DC, dendritic cell; DISC, death-inducing
signaling complex; E, embryo(nic); E2, estrogen; ECM, extracellular matrix; EDD,
endothelium-dependent dilatation; EM, electron microscopy; ER, endoplasmic
reticulum; ERE, estrogen responsive element; ESCRTI/ESCRTIII, endosomal sorting
complex required for transport complex I and III; EsR, estrogen receptor; FFA, free fatty
acids; FGF, fibroblast growth factor; GAS, γ- interferon activation sites; GD, glucose
deprivation; GFP, green fluorescent protein; H/I, hypoxic/ischemic; HOPS, homotypic
vacuole fusion protein sorting complex; HSC, hematopoietic stem cell; IL, interleukin;
ITPR, Inositol trisphosphate receptor; JAK, Janus kinase; KO, knockout; LD, lipid droplet;
LIF, leukemia inhibitory factor; MEC, mammary epithelial cell; MEF, murine embryonic
fibroblast; MMP, metalloproteinase; MOMP, mitochondria outer membrane
permeabilization; Msx, homeobox, msh-like; MVB, multivesicular body; NBD-PS, 7-nitro2-1,3-benzoxadiazol-4-yl-phosphoserine; OMM, outer mitochondrial membrane, P,
pregnancy; P4, progesterone; PCD, programmed cell death; PE,
phosphatidylethanolamine; PGC, primordial germ cell; PM, plasma membrane; PR,
progesterone receptor; PRL, prolactin; PRLR, prolactin receptor; PtdIns3Pphosphatidylinositol 3-phosphate; PThrP, parathyroid hormone related peptide; RANK,
receptor activator of nuclear factor κβ; RANKL, RANK ligand ROS- reactive oxygen
species; SCN, suprachiasmatic nucleus; SNARES, Soluble NSF attachment protein
205

receptors; SNP, single nucleotide polymorphism; STAT, signal transducers and activators
of transcription; T2D, type 2 diabetes; Tbx, T-box protein; TEB, Terminal End Bud; TED,
terminal end duct; TEM, transmission electron microscopy; Th, T helper; TUNEL,
Terminal deoxynucleotidyl transferase dUTP nick end labeling; UPR, unfolded protein
response; UPS, ubiquitin proteasome system; WAP, Whey acidic protein; XeB/XeC,
xestospongin B/C
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